

## **BRIEF CURRICULUM VITAE, ALBERTO ORTIZ**

January 20, 2024

### **Summary**

Prof Alberto Ortiz, MD, PhD, Chief of Nephrology and Hypertension at Health Research Institute of the Jiménez Díaz Foundation (IIS-FJD); Professor (Catedrático) of Medicine at Autonomous University of Madrid (UAM); Councillor and Chair of the Registry (European Renal Association, ERA), European Renal Best Practice (ERBP, the ERA clinical guidelines body) member; core member of European Uremic Toxins (EUTox), Chair of the Fabry Registry European Board, national coordinator of the Spanish Renal Research Network (RETIC REDINREN, 2013-2022; RICORS2040 2022-2024) and SpaCKDc (Spain CKD cause) precision medicine consortium nationally, 2020 ERA-EDTA Award for Research Excellence, Editor-in-Chief for Clinical Kidney Journal (Q1, IF 5.9) up to May 2022, editorial board member for JASN (top nephrology journal), J Nephrol and Nefrologia, among others, Scientific Program Chair for the 2019 ERA Congress and Management committee member in 2 ongoing COST actions, WHO expert on long COVID-19 (topic: nephrology), co-chair of the KDIGO controversies conference on chronic kidney disease (CKD) prevention (Rome, November 2023)..

Prof. Ortiz studied Medicine at the UAM, specialized in Nephrology at the IIS-FJD, was postdoctoral research fellow at U. Pennsylvania, PA, USA (1992–1994) before returning to IIS-FJD as Senior Researcher (National program to repatriate PhDs working abroad) and later as Staff Nephrologist. A physician-scientist: his research career started in 1985 as a 5th year medical student awarded a basic research CSIC grant and was a full-time basic researcher for 5 years (2 in USA and 3 in Spain).

Research interests: epidemiology, pathogenesis, and treatment of kidney disease and vascular injury in kidney disease. From 2006 to 2017 he was a recipient of a Research Activity Intensification grant of the ISCIII. He has been PI for 11 Spain National Research Plan projects, including non-commercial clinical trials, 3 EU research project (a clinical trial: PRIORITY, prevention of CKD: PREVENTCKD, and green nephrology: KitNewCare), 5 Community of Madrid research projects and 3 nationwide research networks, including REDINREN and RICORS2040. Has been director/mentor of 11 public competitive research contracts: 4 post-specialty research contracts for nephrologists (Rio Hortega), 3 Sara Borrell early-stage post-doctoral contract, 3 Miguel Servet senior post-doctoral contracts and 2 physician-scientist Joan Rodes contract. He directed multiple PhD grantees funded by private and public competitive sources, resulting in 35 successfully defended PhD dissertations and 9 ongoing PhD theses. He was Secretary of the European REnal and CArdiovascular Medicine (EURECA-m) working group of the ERA, ERA Scientific Advisory Board (SAB) member, Vice Dean for research at the School of Medicine UAM, Spanish representative in the European Cost Action EUOKUP, international coordinator for the gevokizumab phase II RCT in diabetic nephropathy and EMA expert on nephrotoxicity biomarkers, contributor to ERBP clinical guidelines on Fabry and autosomal dominant polycystic kidney disease (ADPKD) and to Spanish guidelines on ADPKD and advanced CKD management, associate editor at NDT 2015-2017 and ERA Councillor 2015-2017. Participated in KDIGO Controversies Conferences on Fabry disease, Rare Disease and CKD and co-chaired one on Prevention of CKD. Invited to write reviews/editorial comments to Lancet, Lancet Endocrinology, Nat Rev Nephrol, JASN, Kidney Int, J Pathol, NDT and others. Reviewer for >60 journals, including NEJM, Lancet and for National funding bodies in 10 European countries.

AO has published >1000 papers in peer-reviewed journals, 40 “Highly Cited in Field” (WOS). h-index 96 (WOS)/121 (Google Scholar-GS 1IKOVx0AAAAJ, i10 index 688). Citations: 89 818 WOS/140500 GS.

According to the Expertscape website (<https://expertscape.com/ex/kidney>), based on the publications record of the past 10 years, AO is ranked #1 in Spain and #4 in the world in the topic Kidney.

## **1. PERSONAL DATA**

DOB: 20-07-1963, Place of birth: Madrid, Spain, Nationality: Spanish

Address: Unidad de Diálisis, Fundación Jiménez Díaz, Av Reyes Católicos 2, 28040 Madrid, Spain

Phone: (34)915504940, FAX: (34)915494764

Email: [aortiz@fjd.es](mailto:aortiz@fjd.es) ; [alberto.ortiz@uam.es](mailto:alberto.ortiz@uam.es)

### **Current position**

1. **Chief, Department of Nephrology and Hypertension**, University Hospital and Research Institute Fundación Jiménez Díaz (2010-)
2. **Professor (Catedrático) of Medicine, School of Medicine**. Universidad Autónoma de Madrid, Spain (2020-)
3. **Editorial Board Member J Am Soc Nephrol (from Jan 1, 2020), Perit Dial Int (2004-), Turkish Journal of Nephrology (2017-), Portuguese Journal of Nephrology and Hypertension (2016-)**
4. **Corresponding member, Spanish Royal National Academy of Medicine**
5. **Coordinator, Spanish Renal Research Network (RETIC REDINREN 2012-2022, RICORS2040 2022-24)**
6. **Global Burden of Disease (GBD) expert on CKD from 2013**
7. **Coordinator, MOOC on kidney pathophysiology (<https://www.edx.org/course/fisiopatologia-renal-y-enigmas-de-la-uamx-renal701x-2>), Universidad Autonoma de Madrid, EDX**
8. **Chair, ERA Registry**
9. **Member, European Renal Best Practice (ERBP, guideline development body of the ERA-EDTA), 2018-**
10. **Chair of the European Fabry Registry Advisory Board (2020- )**
11. **Member of the International Fabry Registry Advisory Board (2020-)**

### **Clinical expertise.**

Chronic kidney disease: CKD progression, CKD-MBD

Glomerular disease and podocyte injury

Diabetic and Fabry kidney disease

Polycystic kidney disease

Peritoneal dialysis

Vascular disease in CKD

## **2. STUDIES AND EXPERIENCE**

1. **Licenciado (MD) in Medicine and Surgery**, Universidad Autónoma de Madrid, Spain 1987. **Extraordinary Licenciatura award**
2. **Fellowship in Nephrology**, Fundación Jiménez Díaz, Madrid, Spain, 1988-91
3. **Doctor in Medicine (PhD)**, Universidad Autónoma de Madrid, 1992. **Extraordinary Doctorate award.**
4. **Fellowship in Molecular Nephrology**, University of Pennsylvania, PA, USA 1992-1994. Assistant Professor of Medicine, 1993-4
5. **Staff Researcher** Fundación Jiménez Díaz, 1994-1996
6. **Staff Nephrologist**, Fundación Jiménez Díaz, 1996-2001
7. **Associate Chief of Nephrology**, Fundación Jiménez Díaz, 2001-2010
8. **Coordinator, Dialysis and CKD unit**, Fundación Jiménez Díaz, 2009-
9. **Chief of the Peritoneal Dialysis program** at Fundación Jiménez Díaz 1994-2010
10. **Director** of 35 PhD dissertations
11. **Chief Mentor of Nephrology fellows** Fundación Jiménez Díaz 1997-2002; 2008-10
12. **Honorary Professor of Medicine, School of Medicine**. Universidad Autónoma de Madrid, Spain, 2000-2007
13. **Assistant Professor of Medicine, School of Medicine**. Universidad Autónoma de Madrid, Spain, 2000-2012
14. **Associate Professor of Medicine, School of Medicine**. Universidad Autónoma de Madrid, Spain, 2012-2020
15. **Adjunct Professor of Medical Sciences. School of Medicine. Universidad San Pablo-CEU, Madrid, 2004-2009**
16. **Vice-Dean for Research, School of Medicine, Universidad Autonoma de Madrid (2014-2015)**
17. **Associate Editor Nephrol Dial Transplant (2014-2017)**
18. **Coordinator, Iberoamerican chronic kidney disease Research Network (CYTED network IBERERC)(2013-2016)**
19. **Ordinary council member European Renal Association (ERA-EDTA) (2014-2017)**
20. **Secretary, EUropean RENal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) 2013-2018**

21. **Chair of the Scientific Committee, 2019 ERA-EDTA Congress Budapest**
22. **Scientific Advisory Board (SAB) member, ERA-EDTA 2014-2018**
23. **Editor-in-Chief, Clinical Kidney Journal (2014-2022)**
24. **Coordinator of Research, Spanish Society of Nephrology (2015-2020)**
25. **Coordinator of Innovation, IIS-Fundacion Jimenez Diaz UAM (2014-2020)**
26. **Member, International Scientific Advisory Board (ISAB) of the Dutch Kidney Foundation (DKF), 2017-23**

### **3. HONORS**

1. **FERA 2013**
2. **Past Member of the Editorial Board.** Frontiers in Bioscience (2004-), J Nephrol (2015-2020), Nefrología (2007-2014). J Am Soc Nephrol (2010-2017)
3. **Reviewer for** over 100 different journals, including New Engl J Med and Lancet and for research grant awarding bodies in multiple European countries (e.g. Deutsche Forschungsgemeinschaft (German Research Foundation), Swiss National Science Foundation (SNSF), Romanian National Council for Scientific Research, Research Foundation - Flanders (Fonds Wetenschappelijk Onderzoek - Vlaanderen, FWO), Israel Research Agency, Kidney Research UK, Polish Research Fund, Austrian Research Fund), Wellcome trust India, South African research fund and Canada.
4. **Member of the Research Commission** of the Spanish Society of Nephrology (2000-2003 and 2009-), Research Commission Fundacion Jiménez Diaz (2004-2011) and Research Commission Fundacion Jiménez Diaz (2012-).
5. **Member of the Hereditary Renal Disease Working Group in the Spanish Society of Nephrology and of the ERA/EDTA**
6. **Member of Glomerular Disease Working Group (GLOSEN) and Diabetic Nephropathy Working Group (GEENDIAB), Spanish Society of Nephrology**
7. **Research awards: Several** Spanish Research awards, among them, the award of the Fundación Renal Iñigo Alvarez de Toledo (4 times), Research awards from the Spanish Society of Nephrology (7) and awards to the Best Editorial published in the Nefrología journal (2), **Ortho Biotech Merit Award 2001**
8. **Core member, REDINREN (Spanish renal research network) steering committee (2008-2012)**
9. **Member. WGIKD (Working Group on Inherited Kidney Disorders) of the ERA/EDTA**
10. **Member. Diabetesity (Working Group on Diabetes and Obesity) of the ERA/EDTA**
11. **Auditor, EURECA-m within European renal association (ERA/EDTA), 2010-2012**
12. **Member. EuTox, 2011-**
13. **2020 ERA-EDTA Award for Research Excellence**
14. **2023 Miembro de Honor (Honorary Member) de la Sociedad Española de Nefrología**
15. **2023 Honorary International Member** of the Japanese Society of Nephrology
16. **2023 Best Spanish Nephrologist, Merco - Observatorio de Salud (OdS) award, based on reputation among colleagues**

### **4. RESEARCH INTERESTS**

Pathogenesis and treatment of renal injury with emphasis on acute kidney injury

Glomerular disease, podocyte injury, diabetic kidney disease

Genetic kidney diseases (Fabry disease, polycystic kidney disease, Participant in ERBP, KDIGO and SENEPRO guidelines, controversies and guidance documents)

Pathogenesis and treatment of chronic kidney disease complications, including cardiovascular disease

Phosphate and aging, phosphate binders, CKD-MBD

Dietary potassium and microbiota

### **5. RESEARCH PROJECTS (Annex 1)**

Principal Investigator for National and European Union Competitive Research Projects since 1998

### **5. PATENTS AND PATENT APPLICATIONS (Annex 2)**

6 on new approaches to therapy of kidney diseases

### **7. PUBLICATIONS**

#### **7.1. Journals:**

##### **7.1.1. h-index**

- **101** in ISI-WOK, citations: 89 818

- 121 in Google Scholar, i10-index 688, citations 158 513
  - <https://scholar.google.com/citations?user=1IKOVx0AAAAJ>

**7.1.2. Ranked 4 out of >200,000 Kidney experts by Expertscape (January 2024)**

**7.1.3. Publications in peer-reviewed journals: 921 in English (Annex 3), 102 in Spanish**

## **8. SERVICE TO ERA-EDTA**

1. Clinical Nephrology Governance Chair/Chair of the Registry (2021-25)
2. ERA-EDTA Congress
  - a. Abstract Reviewing or Paper Selection Committee 2014-24
  - b. Scientific Committee 2015-2025
  - c. Chair of the Scientific Committee 2019 (Budapest)
3. Fellow of the ERA 2013
4. Ordinary Council Member 2014-2017
5. Working Group EURECA-m Auditor 2010-2012, Secretary 2012-2018, Board Member 2019-2021
6. Website Committee Chair 2015-2017
7. Clinical Kidney Journal CKJ Editor-in-Chief 2013-2017, 2017-2022
8. Scientific advisory board (SAB) Member 2014-2018
9. Nephrology Dialysis Transplantation Associate Editor 2014-2017
10. Press Validation Committee 2015-2017
11. Green Nephrology Committee 2018-2019
12. European Renal Best Practice 2018-
13. Several ERA-EDTA Mentorships for basic research and clinical grant awardees

## **RESEARCH PROJECTS (Annex 1)**

### **A. National**

1. Associated researcher. Ayuda 91/162 del Fondo de Investigaciones Sanitarias de la Seguridad Social. "Estudio de la participación de las células mesangiales y epiteliales glomerulares y de los mediadores de la inflamación en el daño renal".
2. Associated researcher. Ayuda 92/0042 del Ministerio de Educación y Ciencia, Dirección General de Investigaciones Científicas y Técnicas. "Estudio del metabolismo de proteínas de matriz extracelular y de los mecanismos de esclerosis en las glomerulonefritis evolutivas "
3. Associated researcher. Ayuda 94/0370 del Fondo de Investigaciones Sanitarias de la Seguridad Social. "Papel de la fibronectina y de la apoptosis en la remodelación o progresión del daño renal. Abordajes terapéuticos".
4. Principal investigator. Ayuda de investigación en Nefrología de la Sociedad Española de Diálisis y Transplante, 1994: "La participación de la muerte celular por apoptosis y de los genes que la regulan en el mantenimiento y resolución del daño glomerular".
5. Beneficiario. Subvención para la incorporación de Doctores y Tecnólogos a grupos de investigación en España en el marco del Programa Nacional de Formación del Personal Investigador del Plan Nacional de Investigación Científica y Desarrollo Tecnológico. Ministerio de Educación y Ciencia, 1994-1996
6. Associated researcher. Ayuda 95/0093 del Ministerio de Educación y Ciencia, Dirección General de Investigaciones Científicas y Técnicas. "Mecanismos moleculares de la atrofia y fibrosis renal: regulación de la apoptosis renal por Fas y matriz extracelular", 1997-1999
7. Principal investigator dedicacion parcial. Ayuda 97/0071 de la Dirección General de Investigaciones Científicas y Técnicas. Apoptosis y nefrotoxicidad: mecanismos moleculares, 1997-1999
8. Principal investigator dedicacion parcial. Ayuda FIS 98/0637. Bases moleculares de la apoptosis en las complicaciones de la diálisis peritoneal. 1998-2000
9. Asesor. Ayuda FIS 99/0557. Efectos de la disrupción de las uniones adherentes intercelulares sobre la biología celular y molecular de las células endoteliales en cultivo: papel del factor de crecimiento del endotelio vascular. 1999-2001
10. Principal investigator Proyectos de investigación en ciencias de la salud, enfermedades cardiovasculares y su terapéutica de la Comunidad de Madrid. Enero a diciembre de 2000. Ref: 08.4/0007/1999 1. Alteraciones genéticas de las células de ratas hipertensas durante el desarrollo de la hipertensión.
11. Principal investigator. Ayuda de investigación de la Fundación Mapfre Medicina. 2000. La apoptosis de las células de músculo liso vascular como mecanismo responsable de las alteraciones estructurales de los vasos durante la hipertensión arterial. Estudio de la implicación del factor de transcripción NF- $\kappa$ B.
12. Principal investigator Comunidad de Madrid. 2001-2002. Ref: 08.2/0030/2000 Nuevos mecanismos moleculares de la nefrotoxicidad y hepatotoxicidad
13. Principal investigator Sociedad Española de Nefrología. 2001-2002. Nuevos mecanismos moleculares de la nefrotoxicidad
14. Principal investigator dedicacion?. Ayuda FIS 01/0199. Participación de proteínas proapoptóticas en el fracaso renal agudo y la insuficiencia renal crónica asociada al envejecimiento. 2002-2004
15. Associated researcher Ayuda FIS 02/0292. Estudios de las acciones ejercidas por el 17-nbeta-estradiol y el raloxifeno sobre el equilibrio OPGL/RANKL y sobre los factores implicados en la apoptosis de las células óseas en osteoblastos humanos en cultivo
16. Principal investigator Comunidad de Madrid. 2003-04. Ref: 08.2/0007/2003 1. Modulación de la apoptosis como nuevo objetivo terapéutico en la defensa antibacteriana
17. Principal investigator SAF 2003-00884 del Ministerio de Educación y Ciencia. Regulación de la supervivencia del podocito glomerular. 2004-2006
18. Principal investigator Ayuda A La Investigación En Nefrología – 2005, Sociedad Española de Nefrología. 2006-2007. TWEAK: un nuevo mediador de la lesión renal,
19. Principal investigator Ayuda FIS 06/0046. TWEAK como objetivo terapéutico. 149435 €, 2007-2009
20. Principal investigator en FJD. EC07/90532. Proyectos de Investigación clínica independiente del FIS. Estudio multicentrico prospectivo, abierto, controlado con placebo, aleatorizado, de grupos paralelos para evaluar la eficacia y seguridad del tratamiento con eritropoyetina recombinante humana en la prevención de la nefrotoxicidad asociada a la utilización de contrastes iodados, 2008-2009
21. Principal investigator Influence of PD solutions on new mediators of peritoneal defense and angiogenesis. Principal investigator: Alberto Ortiz. 2007. Baxter Healthcare.
22. Principal investigator Globotriaosilfingosina (liso-GB3) en la enfermedad de Fabry: Consecuencias terapéuticas.

- Principal investigator: Alberto Ortiz. 2009. FEEL: Fundación Española de enfermedades lisosomales.
23. Código de Protocolo: SEQ-ALO-2007-01. N° EUDRACT: 2007-006994-10. Titulado: “Evaluación de la utilidad del alopurinol en la prevención de la morbimortalidad cardiovascular de los pacientes con enfermedad renal crónica (ERC) e hiperuricemia” 2008-2010
24. Principal investigador Ortiz Proyecto Intrasalud FIS PS09/00447. Caracterización de nuevos mediadores y marcadores de daño renal identificados mediante transcriptómica. 2010-2013.
25. Principal investigador Caracterización de nuevos mediadores y marcadores de daño renal identificados mediante transcriptómica. Ayuda a la investigación en nefrología SEN, año 2009
26. Vitamina D, globotriaosilesfingosina (liso-GB3) y nefropatía de la enfermedad de Fabry. Principal investigador: Alberto Ortiz. 2010. FEEL: Fundación Española de enfermedades lisosomales.
27. Associated researcher del aliskiren sobre el remodelado vascular, inflamación y estrés oxidativo asociado a la hipertensión arterial.
28. Coordinadores: Jesús Egido, Jorge Rojas-Rivera, Alberto Ortiz, Emilio González Parra, José Luño, Manuel Praga. Efecto del Paricalcitol sobre la Albuminuria, La Inflamación y la Fibrosis en Pacientes con Enfermedad Renal Proteinúrica Crónica (estudio PALIFE): ensayo controlado randomizado. Ensayo clínico en fase IV-III, con especialidades farmacéuticas comercializadas. N° EudraCT: 2011-002877-46. Promotor: Fundación Renal Iñigo Álvarez de Toledo. Fuente de Financiación: ABBOTT. Fecha prevista de comienzo: 2012
29. PI de grupo, proyectos integrados de excelencia en institutos de investigación sanitaria acreditados de la convocatoria 2013 de la acción estratégica en salud 2013-2016. Financiables Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz, PI: Jesus Egido, PIE13/00051 DiabetesCancerConnect:Targeting common inflammatory markers and signaling pathways in diabetes mellitus and cancer.
30. PI: Alberto Ortiz, PI13/00047 FIS ISCIII Implicaciones terapéuticas de nuevos mediadores del daño renal identificados mediante transcriptómica y proteómica 2014-2016
31. Becas de Investigación Fundación Genzyme en Enfermedades de depósito Lisosomal de este año 2013, “Identificación por transcriptómica de mediadores moleculares de la fibrosis en la enfermedad de Fabry” Principal investigador: Dr. Alberto Ortiz Arduan.
32. PI: Alberto Ortiz, Proyecto FIS PI16/02057, ISCIII. Caracterización de nuevos factores nefroprotectores y aplicaciones terapéuticas. 2017-2019
33. Expediente/ Código:00-00002299-16. Nuevo dispositivo para el tratamiento de aneurisma de aorta abdominal. Fundación para la innovación y la prospectiva en salud en España (FIPSE) 2016. Convocatoria de ayudas para financiación de estudios de viabilidad de innovaciones en salud. PI: Ciro Baeza Bermejillo. I Asociados: Alberto Ortiz, María Dolores Sánchez Niño. 24/01/2017-30/09/2017
34. Title: Kidney disease treatment with small molecules. PI: Maria D Sanchez-Niño. Funding: FIPSE (Foundation for innovation and foresight in health in Spain), 2018.. N° expediente: 3273-17.
35. Ayuda de la Fundación Madrileña de Nefrología 2018 al proyecto “Identificación de un panel biomarcador de respuesta nefroprotectora a vaptanes mediante biología de sistemas”.
36. DTS18/00032; DTS18 - Proyectos de Investigación en Salud (AES 2018). January 2019- December 2020. Reposicionamiento de nuevas formulaciones de 3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1Hpurine-2,6-diona para retrasar el envejecimiento. PI Alberto Ortiz
37. PI19/00815. New approaches to tissue protection in kidney disease. 2020-2022. PI Alberto Ortiz
38. PI22/00050 (ISCIII) Promoviendo las defensas endógenas frente a la enfermedad renal. 2023-2025 PI Alberto Ortiz

## **B. Research networks**

1. Investigador asociado del Grupo 6 (Patología Vasculardel, Jefe del Grupo: Jesús Egido), del Nodo 10 (Universidad Autónoma de Madrid) de la red temática de investigación cooperativa (Red de Centros) del Área Cardiovascular
2. RETICS 2006: RedinREN RD06/0016 2007-2012. Investigador principal del grupo
3. Investigador principal Ayudas para la realización de Programas de Actividades de I+D entre Grupos de Investigación de la Comunidad de Madrid en Biociencias. CAM: S-BIO-0283-2006 Fracaso renal-CM. 2007-2010 Investigador principal del grupo.
4. Investigador principal programas de actividades de I + D entre grupos de investigación de la Comunidad de Madrid en Biomedicina S2010/BMD-2378. Utilización de modelos animales y celulares para caracterizar el fracaso renal agudo y multiorgánico. CIFRA. 2012-2015.
5. IP: Alberto Ortiz. Programas de actividades de I + D entre grupos de investigación de la Comunidad de Madrid en Biomedicina B2017/BMD-3686 CIFRA2-CM, Consorcio para el estudio del fracaso renal agudo: fisiopatología, nuevas terapias, biomarcadores y modelos experimentales. 2018-2021

- 6.RD12/0021/0001. Coordinador de la Red Nacional de Investigación en Enfermedades renales (RETIC REDINREN) del Fondo de Investigación Sanitaria 2013-2016
- 7.RD16/0009/0001. Coordinador de la Red Nacional de Investigación en Enfermedades renales (RETIC REDINREN) del Fondo de Investigación Sanitaria 2017-2022
- 8.Coordinador de IBERERC (Iberoamérica enfermedad renal crónica), Red Temática de grupos de investigación del Programa Iberoamericano De Ciencia Y Tecnología Para El Desarrollo (CYTED), con participación de Argentina, Ecuador, El Salvador, España, México, Perú, Portugal y Venezuela 2013-2016,
- 9.IP. Alberto Ortiz Plataforma de Innovación en Tecnologías Médicas y Sanitarias (ITEMAS) (PT13/0006 y PT17/0005/0016)
10. IP. Alberto Ortiz Instituto de Salud Carlos III (ISCIII) Medicina Precisión programa PMP21/00109 Spain CKD cause (SPACKDc) 2022-2025
- 11.IP: Alberto Ortiz. Comunidad de Madrid en Biomedicina P2022/BMD-7223, CIFRA\_COR-CM2023-2025

### C. International

- 1.Associate Researcher.Meeting EU Concerted Action Grant, BMM-4-CT98-3631 (DG12-SSMI) Chronic Inflammation leading to scarring the Major Mechanism for kidney failure. 2000-2002
- 2.Principal investigator. Apoptotic pathway in PD. Research agreement with Fresenius Medical Care Deutschland GmbH. 2002-2003
- 3.Associate Researcher EU project QLG1-CT-2002-01215. Common molecular pathways in progression of kidney disease (CHRONIC KIDNEY DISEASE). 2003-2005
- 4.Associate Researcher con el rango de “deputy”: co-director del grupo. EU project. Paradigm shift from kidney biopsies to advanced molecular diagnostics from patient urine. European sixth framework program grant LSHBCT-2004-6 (ADDNET). 2004-2006
- 5.Principal investigator. Role of apoptosis in peritoneal pathophysiology during PD. Research agreement with Fresenius Medical Care Deutschland GmbH. 2005-2006
- 6.Associate Researcher. Proyecto Europeo LSHB-CT-2007-036644. “Development of Innovative Assays and Locally acting therapies aiming at critical Kinases in hepatic and renal fibrosis DIALOK”. 2007-2009. Comienzo en Marzo de 2007. Coordinado por Dr P van der Hoeven Netherlands. Principal investigator: Marta Ruiz-Ortega
- 7.Principal investigator. Beyond the peritoneum: exploring systemic effects of PD solutions. Research agreement with Fresenius Medical Care Deutschland GmbH. 2007-2010,
- 8.Spanish representative in the Management Committee of the COST Action BM0702, Urine and Kidney Proteomics, EUROKUP. Co-operation in the field of Scientific and Technical Research - IP: Antonia Vlahou. 19-5-2008 a 19-5-2012
- 9.Associate Researcher. Proyecto Europeo LSHB-CT-2007-200647. Fighting aneurismal disease: FAD”. 2008-2012. Coordinado por Dr Jean Baptiste Michel, Francia. Principal investigator: Jesus Egido
- 10.Principal investigator alberto Ortiz. PRIORITY (FP7 Collaborative Project): Proteomic prediction and Raas Inhibition prevention Of early diabetic nephropathy In TYPe 2 diabetic patients with normoalbuminuria. FP7-HEALTH.2011.2.4.3-1 PRIORITY Project number 279277. Coordinador: Peter Rossing (Copenhagen) 1-enero-2012 a 31 diciembre 2018
- 11.Lasertherapy for chronic kidney disease. Research agreement with Ceres GmbH. 2010-2012
- 12.Alberto Ortiz. Associated Partner. FP7-PEOPLE-2013-ITN – 608332. iMODE-CKD (Clinical and system –omics for the identification of the MOlecular DEterminants of established Chronic Kidney Disease) 2013 Marie Curie Initial Training Networks call (ITN 2013). Marta, Gloria, Ana, Loli, Adrian. 01-09-2013 to 2017.
- 13.Alberto Ortiz. Associated Partner. MARIE CURIE ACTIONS. Innovative Training Networks (ITN). Call: H2020-MSCA-ITN-2017. CaReSyAn. Combatting the CardioRenal Syndrome: towards an integrative Analysis to reduce cardiovascular burden in chronic kidney disease. 2018-2021.
- 14.IP: Mezzano S. Fondecyt Chile 1120480. El título : Gremlin: a novel renal pro fibrotic biomarker ? Its role in human and experimental renal pathology. Ortiz es Associate Researcher
- 15.EXPL/DTP-FTO/1792/2013. HivKIomics - novos desenvolvimentos no diagnóstico de lesão tubular e nefrotoxicidade em doentes infectados pelo VIH Fundação do Ministério de Ciência e Tecnologia de Portugal. Ortiz: Associate Researcher. IP: Karina Soto (Lisboa) 2014-2015
- 16.Sociedad Portuguesa de Nefrologia (SPN). HIV-Nephromics. Novos marcadores de nefrotoxicidade produzida por antiretrovirais em doentes HIV+”, Ortiz: Associate Researcher. IP: Karina Soto (Lisboa) 2014-2015
- 17.Associate Researcher. Renal MRI. Magnetic Resonance Imaging Biomarkers for Chronic Kidney Disease [http://www.cost.eu/COST\\_Actions/ca/CA16103](http://www.cost.eu/COST_Actions/ca/CA16103).: 1 april 2017 – 1 april 2021.
- 18.Associate Researcher. Open Multiscale Systems Medicine (OpenMultiMed)

<https://www.cost.eu/actions/CA15120>, 2015-2020

19. Sustituto de representante español en management committee: CA18240 ADHESion GPCR Network: Research and Implementation Set the path for future Exploration. European Union. (2019-2023).

20. Associate Researcher. IP en España: Ana B Sanz. 1st Joint Transnational Call for Proposals (JTC) on "Research projects on personalised medicine – smart combination of pre-clinical and clinical research with data and ICT solutions" within the framework of ERA PerMed. PersTIgAN Personalized Treatment in IgA Nephropathy. 2019-2020 AC18/00071

21. Principal investigator y coordinador europeo del proyecto. 1st Joint Transnational Call for Proposals (JTC) on "Research projects on personalised medicine – smart combination of pre-clinical and clinical research with data and ICT solutions " within the framework of ERA PerMed. Multidimensional stratification for treatment of acute kidney injury (Kidney Attack); 2019-2021

22. PI: Alberto Ortiz. KitNewCare, Project ID: 101137054, Call: HORIZON-HLTH-2023-CARE-04., Programme: HORIZON. DG/Agency: HADEA. Coordinator: Brett Duane. 2024-2027

23. PI Alberto Ortiz. ERA-PerMed-JTC2022 AC22/00027. SPAREKID. Multi-markers risk assessment of kidney sensitivity to injury to personalize prevention of acute kidney injury 2023-2025

24. Management committee. COST action CA21165 - Personalized medicine in chronic kidney disease (PerMediK) 2023-2026

25. PI Alberto Ortiz. PREVENTCKD Consortium Project ID: 101101220 Programme: EU4H DG/Agency: HADEA 2023-2025



## **PATENTS AND PATENT APPLICATIONS (Annex 2)**

1) Pharmaceutical composition and its use for the manufacture of a drug for the treatment of chronic kidney disease and method of selection of compounds

Spanish patent (OEPM)

Inventors: Alberto Ortiz Arduan; Maria Dolores Sanchez Niño

Institution: IDIPAZ and IIS-FJD

Number: P201430081

Country: Spain

Request: 27/01/2014

Concession: 16/08/2016

2) "Pentoxifilina para conservar o aumentar la expresión del gen anti-envejecimiento Klotho"

Spanish patent (OEPM)

Inventors: Alberto Ortiz Arduán, Maria Dolores Sanchez Niño, Navarro González, Juan Francisco, Ana B Sanz.

Institution: IIS-FJD and University Hospital "Nuestra Sra. De Candelaria"

Number: P201530616

Country: Spain,

Request: 06/05/2015

Concession: 22/08/2017

3) "MAP3K14 role in the prevention and treatment of acute renal failure

Spanish patent (OEPM)

Inventors: Alberto Ortiz Arduan, M<sup>a</sup> Dolores Sánchez-Niño, and Manuel Fresno.

Institution: IIS-FJD (90%), UAM (10%)

Number: P201531328

Country: Spain,

Request: 18/09/2015

Concession: 11/05/2018

4) Elaboración de un medicamento para prevenir el envejecimiento prematuro en humanos, composición farmacéutica y método de selección de compuestos basado en el uso de siRNA de NFKbiz

Spanish patent (OEPM)

Inventors: Alberto Ortiz Arduan, M<sup>a</sup> Dolores Sánchez-Niño, Ana Belen Sanz, Jonay Poveda

Institution: IIS-FJD

Number: P201531933

Country: Spain,

Request: 30/12/2015

Concession: 16/04/2018

5) "Derivados del Crotonato para la fabricación de un medicamento para el tratamiento de la enfermedad renal crónica y fracaso renal agudo"

Spanish patent (OEPM)

Inventors: Alberto Ortiz Arduan, M<sup>a</sup> Dolores Sánchez-Niño, Ana Belen Sanz, Olga Ruiz Andres

Institution: IIS-FJD

Number: P201531677

Country: Spain,

Request: 19/11/2015

Concession: 30/08/2018

6) Elaboración de un medicamento para prevenir el envejecimiento prematuro en humanos, composición farmacéutica y uso de la sobreexpresión de Bcl3

Spanish patent (OEPM)

Inventors: Maria Dolores Sánchez Niño; Alberto Ortiz Arduán; Ana Sanz Bartolomé; María Vanessa Pérez Gómez; Beatriz Fernández Fernández

Institution: IIS-FJD

Number: P201631183

Country: Spain,  
Request: 12/09/2016  
Concession: 18/12/2018

7) "GDF15 en orina como biomarcador de daño renal"

Spanish patent (OEPM)

Inventors: Alberto Ortiz Arduan, M<sup>a</sup> Dolores Sánchez-Niño, Ana Belen Sanz, Jonay Poveda

Institution: IIS-FJD

Number: P201830849

Country: Spain,

Request: 28/08/2018

### **PUBLICATIONS, English (Annex 3)**

Retirado uno italiano, uno polaco y 2 español ramn

1. Egado J, Robles A, Ortíz A, Ramirez F, Gonzalez E, Mampaso F, Sanchez Crespo M, Braquet P, Hernando L. Role of platelet activating factor in adriamycin-induced nephropathy in rats. *Eur J Pharmacol* 1987;138:119-123.
2. Egado J, Mampaso F, Gomez-Chiarri M, González E, Ortiz A, Lerma JL, Robles A, Braquet P, Hernando L. Evidence suggesting a role for platelet activating factor (PAF) in experimental nephrotic syndrome. *Int J Tiss Reac* 1990;12:213-220
3. Egado J, Ortiz A, Gomez-Chiarri M, Lerma JL, Robles A, Bustos C, Gomez-Guerrero C, Alonso J, Gonzalez E. Involvement of lipid mediators in the pathogenesis of experimental nephrosis in rats. Its pharmacological modulation. *Renal Failure* 1991;13:95-101
4. Ortiz A, Garrón MP, Navarro A, Rodriguez-Barbero JM, Aguilera B, Caramelo C. Ischaemic hepatic necrosis and intestinal infarction in a haemodialysis patient. *Nephrol Dial Transplant* 1991;6:521-523
5. Ortiz A, Caramelo C, Plaza JJ. Transfusion-associated graft-versus-host disease. *N Engl J Med* 1991;324:128
6. Ortiz-Arduan A, Martín-Llonch N. Supermarket neuropathy. *Muscle & Nerve* 1991;14:785
7. Plaza JJ, Ortiz A, Blum G, Moliz M, Caramelo C. Persistent anemia after successful kidney graft. *Nephron* 1991;59:158-159
8. Ortiz A, Giraldez D, Egado J, Fernandez-Guerrero ML. Salmonella enteritidis empyema complicating lupus pleuritis. *Postgrad Med J* 1991;67:778-779
9. Ortiz A, Martín-Llonch N, Garrón MP, Alberola ML, Caramelo C, Ortiz-Gonzalez A. Cefazolin encephalopathy in uremic individuals. *Rev Infect Dis* 1991;13:772-773 y Ortiz A. Cefazolin-induced neurotoxicity. *Clin Infect Dis* 1992;14:624
10. Ortiz A, Gomez-Chiarri M, Lerma JL, Gonzalez E, Egado J. The role of platelet-activating factor (PAF) in experimental glomerular injury. *Lipids* 1991;26:1310-1315
11. Ortiz A, Plaza JJ, Egado J. Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits. *Nephron* 1992;60:248
12. Plaza JJ, Blum G, Ortiz A, Hernando L, Feijóo E, Sanz J, García R, Ortiz F. Usefulness of serum-soluble interleukin-2 receptor levels in monitoring renal transplantation. *Transplant Proc* 1992;24:64-65
13. Ortiz A, Gonzalez-Parra E, Alvarez G, Egado J. Bladder cancer after cyclophosphamide therapy for lupus nephritis. *Nephron* 1992;60:378-379
14. González-Cabrero J, de Nicolás R, Ortiz A, Mampaso F, Hernando L, Egado E. Presence of circulating antibodies against brush border antigens (F<sub>x</sub>1A) in a patient with membranous nephropathy and bilateral pyeloureteral stenosis. Comparison with idiopathic membranous nephropathy. *Nephrol Dial Transplant* 1992;7:293-299
15. Ortiz A, Caramelo C, Fortes JR, Sarasa JL, Hernando L. Fatal coma and superimposed acute renal failure in a diabetic peritoneal dialysis patient following myelography. *Nephron* 1992;60:381-382
16. García-Fuentes M, Alvarez-Granda JL, Arias A, Ortiz A, Jimenez J, Egado J. Urticaria-associated recurrent glomerulonephritis with a favorable response to indomethacin. *Nephron* 1992;61:483-484
17. Caramelo C, Carreño V, Gonzalez-Parra E, Quiroga JA, Garron MP, Marriott E, Ortiz A, Galera A, Lopez MD, Porres JC. Positive Elisa 2 is pathologically relevant in Elisa-1-negative patients on hemodialysis. *Nephron* 1992;61:474
18. Chahin J, Ortiz A, Mendez L, Gallego E, García-Perez J, García-Castro G, Julian BA, Egado J. Familial IgA nephropathy associated with bilateral sensorineural deafness. *Am J Kidney Dis* 1992;19:592-596
19. Ortiz A, Garrón MP, Rovira A, Moliz M, Banderas M, Crespo M, Sandiumenge J, Hernando L, Caramelo C. Effect of recombinant human growth hormone in a postpediatric hemodialysis patient with delayed growth. *Am J Nephrol* 1992;12:471-473
20. Gomez-Chiarri M, Ortiz A, Seron D, Glez E, Egado J. The intercrine superfamily and renal disease. *Kidney Int* 1993, suppl 39:S81-S85
21. Egado J, Gomez-Chiarri M, Ortiz A, Alonso J, Gomez-Guerrero C, Gomez-Garre D, Bustos C, Lopez-Armada MJ, Plaza JJ, Glez E. The role of tumor necrosis factor alfa in the pathogenesis of glomerular diseases. *Kidney Int* 1993;supl 39:S59-S64
22. Caramelo C, Ortiz A, Aguilera B, Porres JC, Navas S, Marriott E, Alberola ML, Alamo C, Galera C, Garrón MP, Gonzalez-Parra E, Fernandez de Gabriel MV, Oliva H, Carreño V. Liver pathology in hemodialysis patients with antibodies to hepatitis C virus. *Am J Kidney Dis* 1993;22:822-828
23. Gómez-Chiarri M, Ortíz A, Lerma JL, Mampaso F, González E, Egado E. Involvement of tumor necrosis factor and platelet activating factor in the pathogenesis of experimental nephrosis in rats. *Lab Invest* 1994;70:449-459
24. Ortiz A, Gomez-Chiarri M, Alonso J, Bustos C, Gomez-Guerrero C, López-Armada MJ, Gómez-Garre D, Palacios I,

- Ruíz-Ortega M, Gutierrez S, Gonzalez E, Egado J. The potential role of inflammatory mediators and fibrogenic cytokines in the pathogenesis of glomerular diseases. *J Lipid Med* 1994;9:55-74
25. Karp SL, Ortiz A, Li S, Neilson EG. Metanephric mesenchymal cells will differentiate in culture after stimulation with hepatocyte growth factor or embryonic spinal cord. *Proc Natl Acad Sci USA* 1994;91:5286-5290
  26. Ortiz-Arduan A, Neilson EG. Apoptotic cell death in renal disease. *Nefrología* 1994;14:391-407
  27. Ortiz A, Bustos C, Alonso J, Alcazar R, López-Armada MJ, Plaza JJ, Gonzalez E, Egado J. Involvement of tumor necrosis factor alfa in the pathogenesis of experimental and human glomerulonephritis. *Adv Nephrol* 1995;24:53-78
  28. Ortiz A, Egado J. Is there a role for specific anti-TNF strategies in glomerular diseases? *Nephrol Dial Transplant* 1995;10:309-311
  29. Ortiz A, Gonzalez-Cuadrado S, Bustos C, Alonso J, Gómez-Guerrero C, López-Armada MJ, González E, Plaza JJ, Egado J. Tumor necrosis factor and glomerular damage. *J Nephrol* 1995;8:27-34
  30. Ortiz A, Alonso J, Gomez-Chiarri M, Lerma JL, Seron D, Condom E, González E, Egado J. Fibronectin decreases glomerular lesions and synthesis of TNF $\alpha$ , PAF and fibronectin in proliferative glomerulonephritis. *Clin Exp Immunol* 1995;101:334-340
  31. Ruíz Ortega M, Gonzalez S, Serón D, Condom E, Bustos C, Largo R, González E, Ortiz A, Egado J. ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. *Kidney Int* 1995;48:1778-1791
  32. Esteban J, Albalate M, Caramelo C, Reyero A, Carriazo MA, Hernandez J, Ortiz A, Soriano F. Peritonitis involving a *Capnocytophaga* sp. in a patient undergoing continuous ambulatory peritoneal dialysis. *J Clin Microbiol* 1995;33:2471-2472
  33. González-Cuadrado S, López-Armada MJ, Gómez-Guerrero C, Subirá D, Ortiz-González A, Neilson EG, Egado J, Ortiz A. Anti-Fas antibodies induce cytolysis and apoptosis in cultured human mesangial cells. *Kidney Int* 1996;49:1064-1070
  34. Ortiz A, Gomez-Chiarri M, González-Cuadrado S, Serón D, Emancipator SN, Hamilton TA, Barat A, Plaza JJ, González E, Egado J. Interferon-inducible protein 10 (IP-10) is highly expressed in rats with experimental nephrosis. *Am J Pathol* 1996;148:301-311
  35. Albalate M, Alcazar R, Ortiz A, Reyero AM, Casado S, Caramelo C. Acute pneumoperitoneum in a patient on nocturnal intermittent peritoneal dialysis. *Nephron* 1996;72:358
  36. Bustos C, González E, González-Cuadrado S, Ortiz A, Muley R, de Nicolás R, Plaza JJ, Egado J. Urinary excretion of platelet-activating factor in human and experimental nephrosis. *Nephrol Dial Transplant* 1996;11:282-286
  37. Ortiz A, Gonzalez Cuadrado S, Lorz C, Egado J. Apoptosis in renal diseases. *Front Biosci* 1996;1:D30-D47 (<http://www.bioscience.org/1996/v1/d/Ortiz1/htmls/30-47.htm>)
  38. Albalate M, Velasco L, Ortiz A, Monzú B, Casado S, Caramelo C. High risk of retinal damage by desferrioxamine in dialysis patients. *Nephron* 1996;73:726-727
  39. De Sequera P, Albalate M, Hernandez J, Vazquez A, Abad J, Ramiro E, Fernández Guerrero M, Caramelo C, Casado S, Ortiz A. Acute renal failure due to sulphadiazine crystalluria in AIDS patients. *Postgrad Med J* 1996;72:557-558
  40. Alonso J, Gomez-Chiarri M, Ortiz A, Serón D, Condom E, Lopez-Armada MJ, Largo R, Barat A, Egado J. Glomerular upregulation of EIIIA and V120 fibronectin isoforms in proliferative immune complex nephritis. *Kidney Int* 1996;50:908-919
  41. Caramelo C, Albalate M, Bermejillo T, Navas S, Ortiz A, Casado S, de Sequera P, Carreño V. Relationships between plasma ferritin and aminotransferase profile in hemodialysis patients with hepatitis C virus. *Nephrol Dial Transplant* 1996;11:1792-1796
  42. Caramelo C, Bartolomé J, Albalate M, de Sequera P, Navas S, Bermejillo T, Oliva H, Marriott E, Ortiz A, Ruiz Tuñón C, Casado S, Carreño V. Undiagnosed hepatitis C virus (HCV) infection in hemodialysis patients: value of HCV RNA determination and liver enzyme levels in HCV antibody negative patients. *Kidney Int* 1996; 50:2027-2031
  43. Ortiz-Arduan A, Danoff TM, Kalluri R, González-Cuadrado S, Karp SL, Elkon K, Egado J, Neilson EG. Regulation of Fas and Fas ligand expression in cultured murine renal cells and in the kidney during endotoxemia. *Am J Physiol* 1996;241:F1193-F1201
  44. Gonzalez-Cuadrado S, Bustos C, Ruiz Ortega M, Ortiz A, Guijarro C, Plaza JJ, Egado J. Expression of leukocyte chemoattractants by interstitial renal fibroblasts: upregulation by drugs associated with interstitial fibrosis. *Clin Exp Immunol* 1996;106:512-518
  45. Ortiz A, Ziyadeh FN, Neilson EG. Expression of apoptosis-regulatory genes in renal proximal tubular epithelial cells exposed to high ambient glucose and in diabetic kidneys. *J Invest Med* 1997;45:50-56
  46. Albalate M, García López D, Vazquez A, de Sequera P, Marriott E, Tan D, Ortiz A, Casado S, Carreño V, Caramelo C. Concentrated ascitic fluid reinfusion in cirrhotic patients: a simplified method. *Am J Kidney Dis* 1997;29:392-398
  47. González-Cuadrado S, Lorz C, García del Moral R, O'Valle F, Alonso C, Ramiro F, OrtizGonzález A, Egado J, Ortiz

- A. anti-Fas antibodies induce glomerular cell apoptosis in mice in vivo. *Kidney Int* 1997;51:-1746
48. Ortiz A, Gonzalez-Cuadrado S, Lorz C, Garcia del Moral R, O'Valle F, Egido J. Cytokines and Fas regulate apoptosis in murine renal interstitial fibroblasts. *J Am Soc Nephrol* 1997;8:1845-1854
  49. Ortiz A, Lorz C, Catalán MP, Ortiz A, Coca S, Egido J. Cyclosporine A induces apoptosis in murine tubular epithelial cells: role of caspases. *Kidney Int* 1998;suppl 68:S25-S29
  50. Diaz C, Selgas R, Castro MA, Bajo MA, Fernández de Castro M, Molina S, Jiménez C, Ortiz A, Vara F. Ex-vivo proliferation of mesothelial cells directly obtained from peritoneal effluent. Its relationship with peritoneal antecedents and functional parameters. *Adv Perit Dial* 1998;14:19-24
  51. Guijarro C, Blanco-Colío LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, Díaz C, Hernández G, Egido J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. *Circ Res* 1998;83:490-500
  52. Esteban J, Calvo R, Gutierrez F, Soriano F, Ortiz A, Reyero-López A. Peritonitis due to CDC Coryneform group A-4 in a patient undergoing continuous cycling peritoneal dialysis. *Eur J Clin Microbiol Infect Dis* 1998;17:213-214
  53. Goicoechea M, Martin J, de Sequera P, Quiroga JA, Ortiz A, Carreño V, Caramelo C. Role of cytokines in the response to erythropoietin in hemodialysis patients. *Kidney Int* 1998;54:1337-1343
  54. Ortiz A. Circulating activated endothelial cells in sickle cell anemia. *N Engl J Med* 1998; 338:1162
  55. Ortiz A, De Sequera P, Caramelo C, Carreño V. Hepatitis B hepatitis. *N Engl J Med* 1998;338:1311
  56. Ortiz A, Gallegos G, Esteban J, Gadea I, Reyero A, Fortes JR, Caramelo C. Peritoneal catheter colonization by *Penicillium* sp: case report and review of *Penicillium*-related complications in peritoneal dialysis. *Am J Kidney Dis* 1999;33:E5 [http://www.ajkdjournal.org/abs33\\_3/v33n3pe5.html](http://www.ajkdjournal.org/abs33_3/v33n3pe5.html)
  57. Ortiz A, Lorz C, Egido J. The Fas ligand/Fas system in renal injury. *Nephrol Dial Transplant* 1999;14:1831-1834
  58. Ortiz A, Lorz C, Egido J. New kids in the block: the role of FasL and Fas in kidney damage. *J Nephrol* 1999;12:150-158
  59. Caramelo C, de Sequera P, López MD, Ortiz A. Hand-bore mechanisms of dissemination of hepatitis C virus in dialysis units: basis for new addenda to the present preventive strategies. *Clin Nephrol* 1999;51:59-60
  60. Alvarez L, Ortiz A. Apoptosis in the intervertebral disc. *Spine* 1999;24, 500
  61. Esteban J, Ortiz A, Rollán E, Reyero A, Soriano F. Peritonitis due to *Ochrobactrum anthropi* in a patient undergoing continuous ambulatory peritoneal dialysis. *J Infection* 2000;40:205-206
  62. Ortiz A, Lorz C, Catalán MP, Danoff TM, Yamasaki Y, Egido J, Neilson EG. Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure. *Kidney Int* 2000;57:969-981
  63. Lorz C, Ortiz A, Justo P, González-Cuadrado S, Duque N, Gómez-Guerrero C, Egido J. Proapoptotic ligand is expressed by normal kidney tubular epithelium and injured glomeruli. *J Am Soc Nephrol* 2000;11: 1266-1277
  64. Rodríguez-Iñigo E, Casqueiro M, Bartolomé J, Barat A, Caramelo C, Ortiz A, Albalade M, Oliva H, Manzano ML, Carreño V. Hepatitis C virus RNA in kidney biopsies from infected patients with renal disease. *J Viral Hepat* 2000;7: 23-29
  65. Ortiz A. Apoptotic regulatory proteins in renal injury. *Kidney Int* 2000; 58:467-485
  66. Goicoechea M, Caramelo C, Ochando A, Andrea C, Garvia R, Ortiz A. Antiplatelet therapy alters iron requirements in hemodialysis patients. *Am J Kidney Dis* 2000;36:80-87
  67. Ortiz A, Lorz C, Catalan MP, Justo P, Egido J. Role and regulation of apoptotic cell death in the kidney. Y2K update. *Front Biosci* 2000;5:D735-D749 (<http://www.bioscience.org/2000/v5/d/Ortiz/fulltext.htm>)
  68. Ortiz A. Renal cell loss through cell suicide. *Kidney Int* 2000;58:2235-6
  69. Marrón B, Ortiz A. Treatment of tuberculous peritonitis. *Perit Dial Int* 2000;20: 828-9
  70. Ortiz A, Lorz C, Justo P, Catalan MP, Egido J. Contribution of apoptotic cell death to renal injury. *J Cell Molec Med* 2001;5:18-32
  71. Catalán MP, Reyero A, Egido J, Ortiz A. Regulation of neutrophil apoptosis by glucose-containing peritoneal dialysis solutions: role of caspases *J Am Soc Nephrol* 2001;12:2442-9
  72. Goicoechea M, Caramelo C, Rodríguez P, Verde E, Gruss E, Albalade M, Ortiz A, Casado S, Valderrabano F. Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis. *Nephrol Dial Transplant* 2001;16:2188-93
  73. Berlanga JR, Marrón B, Reyero A, Caramelo C, Ortiz A. Peritoneal dialysis retardation of progression of advanced renal failure *Perit Dial Int* 2002;22:239-42
  74. Esteban J, Martin J, Ortiz A, Santos-O'Connor F, Cabria F, Reyero A. *Pseudomonas oryzihabitans* peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis. *Clin Microbiol Infect* 2002;8:607-8
  75. Ortiz A, Justo P, Catalán MP, Sanz AB, Lorz C, Egido J. Apoptotic cell death in renal injury: the rationale for intervention. *Current Drug Targets: Immune, endocrine and metabolic disorders* 2002; 2:181-192
  76. Alvarez Arroyo MV, Suzuki Y, Yagüe S, Lorz C, Jimenez S, Soto C, Barat A, Belda E, Gonzalez Pacheco FR,

- Deudero JJP, Castilla MA; Egido J, Ortiz A, Caramelo C. Role of vascular endothelial growth factor in tubular cell protection against acute cyclosporine toxicity. *Transplantation* 2002;74:1618-1624
77. Catalán MP, Esteban J, Subirá D, Egido J, Ortiz A. Inhibition of caspases improves bacterial clearance in experimental peritonitis *Perit Dial Int* 2003;23:123-126
  78. Catalan MP, Subirá D, Reyero A, Selgas, Ortiz A, Egido J, Ortiz A. Regulation of apoptosis by lethal cytokines in human mesothelial cells. *Kidney Int* 2003;64:321-330
  79. Ortiz A. Staining for cell death. *Lancet* 2003;361: 1748
  80. Blanco-Colio LM, Daehn I, Justo P, Lorz C, Ortiz A, Egido J. BCL-XL overexpression protects from apoptosis induced by HMG-CoA reductase inhibitors in murine tubular cells. *Kidney Int* 2003;64:181-191
  81. Justo P, Sanz A, Lorz C, Egido J, Ortiz A. Expression of Smac/Diablo in tubular epithelial cells and during acute renal failure. *Kidney Int* 2003;64 (supl 86): 52-56
  82. Ruiz-Ortega M, Esteban V, Suzuki Y, Ruperez M, Mezzano S, Ardiles L, Justo P, Ortiz A, Egido J. Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. *Kidney Int* 2003;64 (supl 86): 21-26
  83. Ortiz A, Justo P, Sanz A, Lorz C, Egido J. Targeting apoptosis in acute tubular necrosis. *Biochem Pharmacol* 2003;66:1589-94
  84. Ortiz A, Caramelo C. What should the plasma bicarbonate levels be in the peritoneal dialysis patients? *Perit Dial Int* 2003;23:606-7
  85. Martin A, Sansone G, Cirugeda A, Sanchez-Tomero JA, Muñoz C, Selgas R, on behalf of the Grupo Centro de Diálisis Peritoneal (Ortiz A, Caparrós G, Bajo MA, Ruiz E, Castellanos I, Sequera P, Coronel F). Severe peritoneal mononucleosis associated with icodextrin use in CAPD. *Adv Peritoneal Dial* 2003;19:191-4
  86. Justo P, Lorz C, Sanz A, Egido J, Ortiz A. Intracellular mechanisms of cyclosporine A-induced tubular cell apoptosis. *J Am Soc Nephrol* 2003;14: 3072-3080
  87. Soto K, Gómez-Garre D, Largo R, Gallego-Delgado J, Tejera N, Catalán MP, Ortiz A, Plaza JJ, Alonso C, Egido J. Tight blood pressure control decreases apoptosis during renal damage. *Kidney Int* 2004;65:811-822
  88. Lorz C, Justo P, Sanz A, Subirá D, Egido J, Ortiz A. Paracetamol nephrotoxicity: a role for ER stress. *J Am Soc Nephrol* 2004;15:380-9
  89. Tejera N, Gómez-Garre D, Lázaro A, Gallego-Delgado J, Alonso C, Blanco J, Ortiz A, Egido J. Persistent proteinuria upregulates angiotensin II type 2 receptor and induces apoptosis in proximal tubular cells. *Am J Pathol* 2004;164:1817-26
  90. Ortiz A, Catalán MP. Will modulation of cell death increase PD technique survival? *Perit Dial Int* 2004; 24:105-14
  91. García-Moreno C, Catalán MP, Ortiz A, Alvarez L, De la Piedra C. Modulation of survival in osteoblasts from postmenopausal women. *Bone* 2004;35:170-7
  92. Teixidó-Planas J, Ortiz A, Coronel F, Montenegro J, López-Menchero R, Ortiz R, Gómez C, Doñate T. Oral Protein-Energy Supplements in Peritoneal Dialysis: A Multicenter Study. *Perit Dial Int* 2005;25:163-172
  93. Lorz C, Justo P, Sanz AB, Egido J, Ortiz A. Role of Bcl-xL in paracetamol-induced tubular epithelial cell death. *Kidney Int* 2005;67:592-601
  94. Ortiz A, Justo J, Sanz A, Melero R, Caramelo C, Fernández Guerrero M, Strutz F, Müller G, Barat A, Egido J. Tubular cell apoptosis and cidofovir-induced acute renal failure. *Antiviral Therapy* 2005; 10: 185-190
  95. Lazaro A, Gallego-Delgado J, Justo P, Esteban V, Osende J, Mezzano S, Ortiz A, Egido J. Long-term blood pressure control prevents oxidative renal injury *Antioxid Redox Signal* 2005;7:1285-93
  96. Ruiz-Ortega M, Ortiz A. Angiotensin II and oxidative stress *Antioxid Redox Signal* 2005;7:1258-60
  97. Catalan MP, Santamaría B, Reyero A, Ortiz-Gonzalez A, Egido E, Ortiz A. 3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis *Kidney Int* 2005;68:1303-11
  98. Justo P, Sanz AB, Egido J, Ortiz A. 3,4-di-deoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. *Diabetes* 2005;54:2424-9
  99. Santamaria B, Sanz A, Justo P, Sanchez Niño MD, Benito A, Ortiz A. Peritoneal defence--lessons learned which apply to diabetes complications. *Nephrol Dial Transplant* 2006; 21 (suppl 2): 12-15
  100. Marrón B, Ortiz A, de Sequera P, Martín-Reyes G, de Arriba G, Lamas JM, Martínez Ocaña JC, Arrieta J, Martínez F, on behalf of the Spanish Group for CKD. Impact of a planned dialysis start on clinical outcomes and type of renal replacement therapy in a spanish multicenter experience. *Nephrol Dial Transplant* 2006; 21 (suppl 2): 51-55
  101. Lorz C, Benito-Martin A, Justo P, Sanz AB, Sanchez Niño MD, Egido J, Ortiz A. Modulation of renal tubular cell survival: where is the evidence? **Current Medicinal Chemistry** 2006, 13, 763-771
  102. Casquero A, Ramos A, Barat A, Mampaso F, Caramelo C, Egido J, Ortiz A. Acute postinfectious glomerulonephritis in an adult with selective IgA deficiency. *Clin Nephrol* 2006;66:51-3
  103. Justo J, Sanz AB, Lorz C, Egido J, Ortiz A. Lethal activity of FADD death domain in renal tubular epithelial cells. *Kidney Int* 2006; 69, 2205-2211

104. Ortiz A, Wieslander A, Linden T, Santamaria B, Sanz AB, Justo P, Sanchez-Niño MD, Benito A, Kjellstrand P. 3,4-DGE is important for side effects in peritoneal dialysis. What about its role in diabetes? **Current Medicinal Chemistry** 2006;13: 2695-702
105. Muñoz-García B, Martín-Ventura JL, Martínez E, Sánchez S, Hernández G, Ortega L, Ortiz A, Egido J, Blanco-Colio LM. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques. Modulation by atorvastatin. **Stroke** 2006;37:2044-53
106. Justo P, Sanz AB, Sanchez-Niño MD, Winkles JA, Lorz C, Egido J, Ortiz A. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. *Kidney Int* 2006;70:1750-8
107. Blanco-Colio M, Martín-Ventura JL, Muñoz-García B, Moreno JA, Meilhac O, Ortiz A, Egido J. TWEAK and Fn14. New players in the pathogenesis of atherosclerosis. *Front Biosci* 2007;12:3648-55
108. Blanco-Colio LM, Martín-Ventura JL, Muñoz-García B, Orbe J, Páramo JA, Michel JB, Ortiz A, Meilhac O, Egido J. **Identification of Soluble Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (sTWEAK) as a Possible Biomarker of Subclinical Atherosclerosis.** *Arterioscler Thromb Vasc Biol* 2007;27:916-22
109. Fernández Guerrero ML, Urbano J, Ortiz A, Caramelo C, de Górgolas M. Endovascular Repair of Mycotic Aneurysms of the Aorta. An alternative to conventional bypass surgery in patients with acute sepsis. *Scand J Infect Dis* 2007;39:268-271
110. Ortiz A, Petkov V, Urbano J, Contreras J, Alexandru S, Garcia-Pérez A, Ramos A, Cabrera JM, Albalade M, Garcia-Cardoso JV. Emphysematous pyelonephritis in a dialysis patient following embolization of a failed allograft. *Urology* 2007;70:372.e17-9
111. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP. Females with Fabry Disease Frequently have Major Organ Involvement: Lessons from the Fabry Registry. *Mol Genet Metab* 2008;93:112-28
112. Servais H, Ortiz A, Devuyst O, Denamur S, Tulkens PM, Mingot-Leclercq MP. Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. *Apoptosis* 2008;13:11-32
113. Sanz AB, Moreno JA, Sanchez-Niño MD, Ucero AC, Benito A, Santamaria B, Justo P, Izquierdo MC, Egido J, Blanco-Colio LM, Ortiz A. TWEAKing renal injury. *Front Biosci* 2008; 13 580-589
114. Marrón B, Remón C, Pérez-Fontán M, Quirós P, Ortíz A. Benefits of preserving residual renal function in peritoneal dialysis. *Kidney Int* 2008, 73: S42-S51
115. Lorz C, Benito-Martín A, Boucherot A, Ucero AC, Rastaldi MP, Henger A, Armelloni S, Santamaría B, Kretzler M, Egido J, Ortiz A. The death ligand TRAIL in diabetic nephropathy. *J Am Soc Nephrol.* 2008, 19:904-14
116. Sanz AB, Justo P, Sanchez-Niño MD, Blanco-Colio LM, Winkles JA, Kretzler M, Jakubowski A, Egido J, Ruiz-Ortega M, Ortiz A. The Cytokine TWEAK Modulates Renal Tubulointerstitial Inflammation. *J Am Soc Nephrol.* 2008;19:695-703
117. Sanz AB, Santamaria B, Ruiz Ortega M, Egido J, Ortiz A\*. Mechanisms of renal apoptosis in health and disease. *J Am Soc Nephrol.* 2008;19:1634-42
118. Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C, on behalf of the Fabry Registry Nephropathy in males and females with Fabry disease: Cross-sectional description of patients before treatment with enzyme replacement therapy *Nephrol Dial Transplant* 2008;23:1600-7
119. Alexandru S, Criado C, Fernandez-Guerrero ML, de Górgolas M, Petkov V, Garcia. Perez A, Egido J, Barat A, Manzarbeitia F, Caramelo C, Ortiz A. Nephrotic syndrome complicating chronic visceral leishmaniasis: Re-emergence in patients with AIDS. *Clin Nephrol* 2008, 70: 65-68
120. Ortiz A, Oliveira JP, Wanner C, Brenner B, Waldek S, Warnock D. Diagnosis and treatment of Fabry nephropathy, with clinical practice recommendations and guidelines. *Nature Clinical Practice Nephrology* 2008;4:327-36
121. Carvajal G, Rodríguez-Vita J, Rodrigues-Díez R, Sánchez-López E, Rupérez M, Cartier C, Esteban V, Ortiz A, Egido J, Mezzano SA, Ruiz-Ortega M. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. *Kidney Int* 2008;74:585-95
122. Ortiz A. Hutchinson–Gilford progeria syndrome. *N Engl J Med* 2008;358:2410
123. Moreno JA, Sanchez-Niño MD, Sanz AB, Lassila M, Holthofer H, Blanco-Colio LM, Egido J, Ruiz-Ortega M, Ortiz A. A slit in podocyte death. **Current Medicinal Chemistry** 2008;15:1645-54.
124. Santamaría B, Ucero AC, Reyero A, Selgas R, Ruiz-Ortega M, Catalán M, Egido J, Ortiz A. 3,4-di-deoxyglucosone-3-ene as a mediator of peritoneal mesothelialization. *Nephrol Dial Transplant* 2008;23:3307-15
125. Alexandru S, Baldovi S, Ortiz A, Ruíz E, Milicua JM, Egido J, Plaza JJ. Severe everolimus-associated pneumonitis in a renal transplant recipient. *Nephrol Dial Transplant* 2008;23:3353-5
126. Moscoso-Solorzano GT, Ortega F, Rodríguez I, García-Castro M, Gómez E, Díaz-Corte C, Baltar JM, Alvarez V,

- Ortiz A, Coto E. A search for Cyclophilin-A gene variants in CsA-treated renal transplanted patients. *Clin Transplant* 2008; (6):722-9
127. Egido J, Ortiz A. ACE gene polymorphism and the prognosis and treatment of overt diabetic nephropathy. *Nature Clinical Practice Nephrology* 2008;4:472-3.
  128. Fernández-Reyes MJ, Bajo MA, del Peso G, Regidor D, Hevia C, Sánchez R, Sánchez-Villanueva R, Ortiz A, Selgas R. Extracellular Volume Expansion Caused by Protein Malnutrition in Peritoneal Dialysis Patients with Appropriate Salt and Water Removal. *Perit Dial Int* 2008; 28:407-412
  129. Rodrigues-Díez R, Carvajal-González G, Sánchez-López E, Rodríguez-Vita J, Rodrigues Díez R, Selgas R, Ortiz A, Egido J, Mezzano S, Ruiz-Ortega M. Pharmacological Modulation of Epithelial Mesenchymal Transition Caused by Angiotensin II. Role of ROCK and MAPK Pathways. *Pharm Res.* 2008;25:2447-61
  130. Santamaría B, Benito-Martin A, Ucero AC, Reyero A, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A. BclxL prevents PD solution-induced leukocyte apoptosis. *Perit Dial Int* 2008; 28, Suppl 5: -52
  131. Ramos AM, Albalade M, Vazquez S, Caramelo C, Egido J, Ortiz A. Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients. *Kidney Int* 2008 Dec;(111):S88-93
  132. Rodríguez-Vita J, Sánchez-Galán E, Santamaría B, Sánchez-López E, Rodrigues-Díez R, Blanco-Colio LM, Egido J, Ortiz A, Ruiz-Ortega M. Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation. *PLOS one* 2008;3(12):e3959
  133. Vlahou A, Schanstra J, Frokiaer J, El Nahas M, Spasovski G, Mischak H, Domon B, Allmaier G, Bongcam-Rudloff E, Attwood T; European Kidney and Urine Proteomics Network: Collaborators: Ortiz AA, G, Allory Y, Arthur J, Attwood T, Banks R, Baumann M, Benigni A, Bezerianos A, Bongcam-Rudloff E, Candiano G, Carpentier S, Cattaneo D, Charonis A, Dadlez M, Deltas C, De Zeeuw D, Decramer S, Dihazi H, Domon B, Enlich N, d'Alche-Buc F, D'Haese P, Edelman A, Egido J, El Nahas M, Fernandez-Llama P, Feldt-Rasmussen B, Frokiaer J, Gansevoort R, Garbis S, Garin J, Ghiggeri GM, Granier C, Goumenos D, Hilario M, Holthofer H, Kalousis A, Kaski S, Knepper M, Korneti P, Kossida S, Langham R, Lopez-Novoa J, Luider T, Malats N, Mayrhofer C, Mischak H, Monsarrat B, Mueller G, Nielsen S, O'Connell S, Planelles G, Polenakovic M, Promponas V, Rehulka P, Righetti PG, Ronco P, Ryan M, Martín MS, Schanstra J, Semmes J, Spasovski G, Stenman UH, Stodkilde-Jorgensen L, Tasic V, Theodorescu D, Thongboonkerd V, Toncheva D, Tsiotis G, Unwin R, Vanholder R, Vassilev D, Verhulst A, Vlahakos D, Vlahou A, Vonk R, Yamamoto T, Zielenkiewicz P. Establishment of a European Network for Urine and Kidney Proteomics. *J Proteomics.* 2008;71:490-2
  134. Marrón B, Remón C, Pérez-Fontán M, Quirós P, Ortiz A. Korzyści z utrzymania resztkowej funkcji nerek w dializie otrzewnowej. *Nefrologia i Nadciśnienie Tętnicze* 2009; 40, 1: 1–12
  135. Santamaria B, Ucero AC, Benito-Martin A, Selgas R, Ruiz Ortega M, Sanz AB, Egido J, Ortiz A. Taming apoptosis in peritoneal dialysis. *Perit Dial Int* 2009; 29, Suppl 2: -S48
  136. Lorz C, Benito A, Ucero AC, Santamaría B, Ortiz A. **TRAIL and kidney disease.** *Front Biosci* 2009;14:3740-9
  137. Carrero JJ, Ortiz A, Qureshi AR, Martín-Ventura JL, Bárány P, Heimbürger O, Marrón B, Metry G, Snaedal S, Lindholm B, Egido J, Stenvinkel P, Blanco-Colio LM. Additive effects of soluble TWEAK and inflammation on mortality in patients undergoing hemodialysis. *Clin J Am Soc Nephrol* 2009;4:110-8
  138. Sanchez-Niño MD, Sanz AB, Ihalmo P, Lassila M, Holthofer H, Mezzano S, Aros C, Groop PH, Saleem MA, Mathiesen PW, Langham R, Kretzler M, Nair V, Lemley KV, Nelson RG, Mervaala E, Mattinzoli D, Rastaldi MP, Ruiz-Ortega M, Martín-Ventura JL, Egido J, Ortiz A. The MIF receptor CD74 in diabetic podocyte injury. *J Am Soc Nephrol* 2009 Feb;20(2):353-62
  139. Neria F, Castilla MA, Fernandez-Sanchez R, Gonzalez Pacheco FR, Deudero JJP, Calabria O, Tejedor A, Manzarbeitia F, Ortiz A, Caramelo C. JAK2 inhibition protects endothelial and renal tubular cells from oxidative stress and cyclosporin A toxicity. *Kidney Int* 2009;75(2):227-34
  140. Pozo M, Izquierdo MC, de Nicolás R, Egido J, Ortiz A, González-Cabrero J. Gliotoxin inhibits neointimal hyperplasia after vascular injury in rats. *J Vasc Res* 2009;46:278-289
  141. Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S. Efficacy and Safety of Sevelamer Hydrochloride and Calcium Acetate in Patients on Peritoneal Dialysis. *Nephrol Dial Transplant* 2009;24(1):278-85
  142. Öqvist B, Brenner BM, Oliveira JP, Ortiz A, Schaefer R, Svarstad E, Wanner C, Zhang K, Warnock DG. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations *Nephrol Dial Transplant* 2009;24(6):1736-43
  143. Santín S, Ars E, Rossetti S, Salido E, Silva I, García-Maset R, Giménez I, Ruiz P, Mendizábal S, Nieto JL, Peña A, Camacho JA, Fraga G, Cobo M, Bernis C, Ortiz A, Luque A, Sánchez A, Pintos G, Mirapeix E, Fernández-Llama P, Ballarín J, Torra R, on behalf of the FSGS Study Group. *TRPC6* mutational analysis in a large cohort of patients with Focal Segmental Glomerulosclerosis. *Nephrol Dial Transplant* 2009;24(10):3089-96



144. de Solís AJ, González-Pacheco FR, Deudero JJP, Neria F, Albalate M, Petkov V, Susanibar L, Fernández-Sánchez R, Calabia O, Ortíz A, Caramelo C. Alkalinization potentiates vascular calcium deposition in an uremic milieu. *J Nephrol* 2009;22(5):647-53
145. Sánchez-López E, Rayego S, Rodrigues-Díez R, Sánchez Rodríguez J, Rodríguez-Vita J, Carvajal G, Stark Aroeira L, Selgas R, Mezzano SA, Ortiz A, Egido J, Ruiz-Ortega M. Interstitial cell infiltration is regulated by CTGF-induced NF-kB. *J Am Soc Nephrol* 2009;20(7):1513-26
146. Sanz AB, Sánchez-Niño MD, Izquierdo MC, Jakubowski A, Justo P, Blanco-Colio LM, Ruiz-Ortega M, Egido J, Ortiz A. TWEAK proliferation in renal tubular epithelium: a role in uninephrectomy-induced renal hyperplasia. *J Cell Molec Med* 2009;13:3329-42
147. Martin-Ventura JL, Madrigal-Mature J, Muñoz-García B, Blanco-Colio LM, Van Oostrom M, Zalba G, Fortuño A, Gomez-Guerrero C, Ortega L, Ortiz A, Diez J, Egido J. Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. *Cardiovasc Res* 2009 Aug 1;83(3):586-94
148. Ortiz A, Sanz AB, Muñoz García B, Moreno JA, Sanchez Niño MD, Martin-Ventura JL, Egido J, Blanco-Colio LM. Considering TWEAK as a target for therapy in renal and vascular injury. *Cytokine Growth Factor Rev.* 2009 Jun;20(3):251-8
149. Santamaría B, Benito-Martin A, Ucero AC, Stark Aroeira L, Reyero A, Vicent MJ, Orzáez M, Celdrán A, Esteban J, Selgas R, Ruíz-Ortega M, López Cabrera M, Egido J, Pérez-Payá E, Ortiz A. A nanoconjugate Apaf-1 inhibitor protects mesothelial cells from cytokine-induced injury. *PLoS ONE* 2009 Aug 13;4(8):e6634
150. Rodriguez-Garcia ME, Quiroga AG, Castro J, Ortiz A, Aller P, Mata F. Inhibition of p38-MAPK potentiates cisplatin-induced apoptosis via GSH depletion and increases intracellular drug accumulation in growth-arrested kidney tubular epithelial cells. *Toxicol Sci* 2009, Oct;111(2):413-23
151. Santín S, García-Maset R, Ruíz P, Giménez I, Zamora I, Peña A, Madrid A, Camacho JA, Fraga G, Sánchez-Moreno A, Cobo MA, Bernis C, Ortiz A, Luque de Pablos A, Pintos G, Justa ML, Hidalgo-Barquero E, Fernández-Llama P, Ballarín J, Ars E, Torra R, on behalf of the FSGS Spanish Study Group. Nephtrin Mutations can cause not only Childhood-Onset but also Adult-Onset Focal segmental glomerulosclerosis. *Kidney Int* 2009 Dec;76(12):1268-76. PubMed PMID: 19812541.
152. Yilmaz MI, Carrero JJ, Ortiz A, Martin-Ventura JL, Sonmez A, Saglam M, Yaman H, Yenicesu M, Egido J, Blanco-Colio LM. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in subjects with chronic kidney disease. *Clin J Am Soc Nephrol* 2009 Nov;4(11):1716-23.
153. Muñoz-García B, Moreno JA, López-Franco O, Sanz AB, Martín-Ventura JL, Blanco J, Jakubowski A, Burkly LC, Ortiz A, Egido J, Blanco-Colio LM. Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK) Enhances Vascular and Renal Damage Induced by Hyperlipidemic Diet in ApoE-Knockout Mice. *Arterioscler Thromb Vasc Biol.* 2009 Dec;29(12):2061-8. PubMed PMID: 19778942
154. Ares-Carrasco S, Picatoste B, Benito-Martín A, Zubiri I, Sanz AB, Sanchez-Niño MD, Ortiz A, Egido J, Tuñón J, Lorenzo O. Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes. *Am J Physiol Heart Circ Physiol.* 2009 Dec;297(6):H2109-19
155. Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, Villalobos J, Vujkovic B, Waldek S, Wanner C, Warnock DG. End Stage Renal Disease in Patients with Fabry Disease: Natural History Data from the Fabry Registry. *Nephrol Dial Transplant* 2010 Mar;25(3):769-75
156. Sanchez Niño MD, Sanz AB, Lorz C, Gnirke A, Rastaldi MP, Nair V, Egido J, Ruiz-Ortega M, Kretzler M, Ortiz A. functional genomics identifies BASP-1 as a pro-apoptotic factor in diabetic nephropathy. *J Am Soc Nephrol.* 2010 Apr;21(4):610-21 PubMed PMID: 20110383
157. Loureiro J, Schilte M, Aguilera A, Albar-Vizcaíno P, Ramírez-Huesca M, Pérez-Lozano ML, González-Mateo G, Aroeira LS, Selgas R, Mendoza L, Ortiz A, Ruíz-Ortega M, van den Born J, Beelen RH, López-Cabrera M. BMP-7 blocks mesenchymal conversion of mesothelial cells and prevents peritoneal damage induced by dialysis fluid exposure. *Nephrol Dial Transplant.* 2010 Apr;25(4):1098-108 PubMed PMID: 20067910.
158. Ortiz-Muñoz G, Lopez-Parra V, Lopez-Franco O, Fernandez-Vizarra P, Mallavia B, Flores C, Sanz A, Blanco J, Mezzano S, Ortiz A, Egido J, Gomez-Guerrero C. Suppressors of Cytokine Signaling Abrogate Diabetic Nephropathy. *J Am Soc Nephrol.* 2010 May;21(5):763-72 PubMed PMID: 20185635.
159. Sanz AB, Sanchez-Niño MD, Izquierdo MC, Jakubowski A, Justo P, Blanco-Colio LM, Ruiz-Ortega M, Selgas R, Egido J, Ortiz A. TWEAK Activates the Non-canonical NF-kappaB Pathway in Murine Renal Tubular Cells: Modulation of CCL21. *PLOS one,* 2010 Jan 29;5(1):e8955
160. Gonçalves S, Fernandez-Sanchez R, Sanchez-Niño MD, Tejedor A, Neria F, Egido J, Ruiz-Ortega M, Ortiz A. Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury. *Current Medicinal Chemistry* 2010;17(10):974-86
161. Ucero AC, Gonçalves S, Benito-Martin A, Santamaría B, Ramos AM, Berzal S, Ruiz-Ortega M, Egido J, Ortiz A.

- Obstructive renal injury: from fluid mechanics to molecular cell biology. *Research and Reports in Urology* 2010;2: 41-55
162. Mas S, Martínez-Pinna R, Martín-Ventura JL, Pérez R, Gomez-Garré D, Ortiz A, Fernandez-Cruz A, Vivanco F, Egido J. Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes. *Diabetes* 2010 Jun;59(6):1292-301
  163. Sanz AB, Sanchez-Niño MD, Ramos AM, Moreno JA, Santamaria B, Ruiz-Ortega M, Egido J, Ortiz A. NF- $\kappa$ B in renal inflammation. *J Am Soc Nephrol* 2010 Aug;21(8):1254-62 PubMed PMID: 20651166.
  164. Sandoval P, Loureiro J, Gonzalez-Mateo G, Perez-Lozano M, Maldonado-Rodriguez A, Sanchez-Tomero JA, Mendoza L, Santamaria B, Ortiz A, Ruiz-Ortega M, Selgas R, Martin P, Sanchez-Madrid F, Aguilera A, Lopez-Cabrera M. PPAR-gamma; agonist Rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage. *Lab Invest* 2010;90(10):1517-32 PMID: 20531289. 2
  165. Sanchez-Niño MD, Sanz AB, Ortiz A. Caspase-12: from mice to men? *J Am Soc Nephrol* 2010 Jun;21(6):886-8
  166. Torra R, Oliveira JP, Ortiz A. UGA hopping: a sport for nephrologists too? *Nephrol Dial Transplant* 2010 Aug;25(8):2391-5.
  167. Rojas-Rivera J, De La Piedra C, Ramos A, Ortiz A, Egido J. The Expanding Spectrum of Biological Actions of Vitamin D. *Nephrol Dial Transplant* 2010 Sep;25(9):2850-65
  168. Marrón B, Craver L, Remón C, Prieto M, Gutierrez JM, Ortiz A. Reality and desire in the care of advanced chronic kidney disease. *NDT Plus* 2010;3, 431-435
  169. Adames H, Baldoví S, Martin-Cleary C, Ortiz A, Esteban J. Peritonitis due to Microbacterium sp. in a patient on cyclor peritoneal dialysis. *Perit Dial Int* 2010;30:669-70
  170. Soto K, Wu YL, Ortiz A, Aparício SR, Yu CY. Familial C4B Deficiency and Immune Complex Glomerulonephritis. *Clin Immunol* 2010;137(1):166-75.
  171. Coto E, Tavira B, Marín R, Ortega F, López-Larrea C, Marta Ruiz-Ortega, Ortiz A, Díaz M, Corao AI, Alonso B, Alvarez V. Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy. *Biochem Biophys Res Commun* 2010 Jul 2;397(3):576-9.
  172. Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, Serra AL, Maródi M, Mignani R, Cianciaruso B, Vujkovic B, Lemay R, Beitner-Johnson D, Waldek S, Warnock DG. Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease: Natural History Data from the Fabry Registry. *Clin J Am Soc Nephrol* 2010 Dec;5(12):2220-8. Epub 2010 Sep 2. PubMed PMID: 20813854
  173. Sanchez-Niño, M.D, Benito-Martin, A, Ortiz, A. New paradigms in cell death in human diabetic nephropathy. *Kidney Int* 2010;78:737-44 PMID: 20703212.
  174. Coll B, Rodríguez JA, Craver L, Orbe J, Martínez-Alonso M, Ortiz A, Díez J, Borrás M, Valdivielso JM, Fernández E, Páramo JA. Serum Matrix Metalloproteinase 10 is associated with the severity of atherosclerosis in patients with chronic kidney disease. *Kidney Int* 2010 Dec;78(12):1275-80. Epub 2010 Sep 15. PubMed PMID: 20844474.
  175. Martín Cleary C, Moreno JA, Fernández B, Ortiz A, Gonzalez Parra E, Gracia C, Blanco-Colio LM, Barat A, Egido J. Glomerular hematuria, renal interstitial hemorrhage and acute kidney injury *Nephrol Dial Transplant* 2010 Dec;25(12):4103-6. PubMed PMID: 20709744.
  176. Ortiz A, Ucero AC, Egido J. Unraveling fibrosis: two newcomers and an old foe. *Nephrol Dial Transplant* 2010;25:3492-5
  177. Sanchez-Niño MD, Benito-Martin A, Gonçalves S, Sanz AB, Ucero AC, Izquierdo MC, Ramos AM, Berzal S, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A. TNF Superfamily: A Growing Saga of Kidney Injury Modulators. *Mediators Inflamm.* 2010. pii: 182958. Epub 2010 Oct 4. PubMed PMID: 20953353
  178. Rodrigues Díez R, Rodrigues-Díez R, Lavozy C, Rayego-Mateos S, Civantos E, Rodríguez-Vita J, Mezzano S, Ortiz A, Egido J, Ruiz-Ortega M. Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF- $\beta$ -independent process. *PLoS One.* 2010 Nov 30;5(11):e14145. PubMed PMID: 21152444
  179. Sanchez-Niño MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, Ruiz-Ortega M, Egido J, Ortiz A. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. *Nephrol Dial Transplant* 2011 Jun;26(6):1797-802: 20504837
  180. Gonzalez-Parra E, Martin-Cleary C, Martin J, Ortiz A. Calcific uremic arteriopathy while on cinacalcet. *J Postgrad Med.* 2011 Jan-Mar;57(1):51-2. PubMed PMID: 21206121.
  181. Santín S, Tazón-Vega B, Silva I, Cobo MA, Giménez I, Ruíz P, García-Maset R, Ballarín J, Torra R, Ars E; on behalf of the FSGS Spanish Study Group (incluye Ortiz A). Clinical Value of NPHS2 Analysis in Early- and Adult-Onset Steroid-Resistant Nephrotic Syndrome. *Clin J Am Soc Nephrol* 2011 Feb;6(2):344-54 PubMed PMID: 20947785.
  182. Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Çakar M, Egido J, Altun B, Stenvinkel P, Yenicesu M, Blanco-Colio LM, Carrero JJ. Soluble TWEAK and PTX3 in non-dialysis CKD

- patients; Impact on endothelial dysfunction and cardiovascular outcomes. *Clin J Am Soc Nephrol*. 2011 Apr;6(4):785-92
183. Ortiz A, Sanchez-Niño MD, Izquierdo MC, Blanco-Colio LM, Selgas R, Ruiz-Ortega M, Egido J, Sanz AB. TWEAK and the Kidney: the Dual Role of a Multifunctional Cytokine. *Adv Exp Med Biol*. 2011;691:323-35. PubMed PMID: 21153336.
  184. Blanco-Colio LM, Martín-Ventura JL, Carrero JJ, Yilmaz MI, Moreno JA, Gómez-Guerrero C, Ortiz A, Egido J. Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK. *Proteomics Clin Appl*. 2011 Jun;5(5-6):281-8 PubMed PMID: 21538911.
  185. Spasovski G, Ortiz A, Vanholder R, El Nahas M. Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for. *Proteomics Clin Appl*. 2011 Jun;5(5-6):233-40
  186. López-Novoa JM, Rodríguez-Peña AB, Martínez-Salgado C, Ortiz A, López Hernández FJ. Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications *J Transl Med* 2011;9:13
  187. Ortiz A, Sanchez Niño MD, Rojas JE, Egido J. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. *Lancet* 2011 Feb 19;377(9766):635-6 PubMed PMID: 21334525.
  188. Zaragoza C, Gomez-Guerrero C, Martín-Ventura JL, Blanco-Colio L, Lavin B, Mallavia B, Tarin C, Mas S, Ortiz A, Egido J. Animal models of cardiovascular diseases *J Biomed Biotechnol*. 2011;2011:497841
  189. Linthorst G, Germain DP, Hollak CEM, Hughes D, Rolfs A, Wanner C, Mehta A on behalf of the expert group (A Ortiz included). Expert consensus opinion on temporary treatment recommendations for Fabry disease during the shortage of Enzyme Replacement Therapy (ERT). *Mol Genet Metab* 2011;102:99-102
  190. Gonzalez-Parra E, Gonzalez-Casaus ML, Galán A, Martinez-Calero A, Navas V, Rodriguez M, Ortiz A. Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. *Nephrol Dial Transplant*. 2011 Aug;26(8):2567-71 PMID: 21436379
  191. Moreno JA, Izquierdo MC, Sanchez-Niño MD, Suárez-Alvarez B, Lopez-Larrea C, Jakubowski A, Ramirez R, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A, Sanz AB. NFκB-dependent regulation of Klotho expression by the inflammatory cytokines TWEAK and TNFα in kidney cells. *J Am Soc Nephrol*, 2011;22:1315-25. PMID: 21719790
  192. Acuña M, Ramos A, Santonja C, Barat A, Egido J, Ortiz A. Delayed Graft Function and Cotrimoxazole. *Transplant Proc* 2011 Sep;43(7):2502-4. 21911113
  193. Ortiz A, Sanchez-Niño MD, Sanz AB. The meaning of urinary creatinine concentration. *Kidney Int*. 2011 Apr;79(7):791. PubMed PMID: 21403655.
  194. Sanz AB, Sanchez-Niño MD, Ortiz A. TWEAK, a multifunctional cytokine in kidney injury. *Kidney Int* 2011 Oct;80(7):708-18 PMID: 21697814
  195. Agarwal R, Martinez-Castelao A, Wiecek A, Massy Z, Suleymanlar G, Ortiz A, Blankestijn PJ, Covic A, Dekker FW, Jager KJ, Lindholm B, Goldsmith D, Fliser D, London G, Zoccali C for EUROpean RENal and CARDiovascular Medicine working group of the European Renal Association–European Dialysis and Transplant Association (ERA–EDTA). The lingering dilemma of arterial pressure in CKD: What do we know, where do we go? *Kidney Int* 2011; Sup 1: 17-20
  196. Blankestijn PJ, London G, Fliser D, Jager KJ, Lindholm B, Goldsmith D, Wiecek A, Suleymanlar G, Agarwal R, Ortiz A, Massy Z, Martinez-Castelao A, Covic A, Dekker FW, Zoccali C for EUROpean RENal and CARDiovascular Medicine working group of the European Renal Association–European Dialysis and Transplant Association (ERA–EDTA). Major pathways of the reno - cardiovascular link: the sympathetic and renin-angiotensin systems. *Kidney Int* 2011 Sup 1: 13-16
  197. Fliser D, Wiecek A, Suleymanlar G, Ortiz A, Massy Z, Lindholm B, Martinez-Castelao A, Agarwal R, Jager KJ, Dekker FW, Blankestijn PJ, Goldsmith D, Covic A, London G, Zoccali C for EUROpean RENal and CARDiovascular Medicine working group of the European Renal Association–European Dialysis and Transplant Association (ERA–EDTA). The dysfunctional endothelium in CKD and in cardiovascular disease. Mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda. *Kidney Int* 2011 Sup 1: 6-9
  198. London G, Covic A, Goldsmith D, Wiecek A, Suleymanlar G, Ortiz A, Massy Z, Lindholm B, Martinez-Castelao A, Fliser D, Agarwal R, Jager KJ, Dekker FW, Blankestijn PJ, Zoccali C for EUROpean RENal and CARDiovascular Medicine working group of the European Renal Association–European Dialysis and Transplant Association (ERA–EDTA). Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow—implications for CKD and cardiovascular disease. *Kidney Int* 2011 Sup 1: 10-12
  199. Zoccali C, Goldsmith D, Agarwal R, Blankestijn PJ, Fliser D, Wiecek A, Suleymanlar G, Ortiz A, Massy Z, Covic A, Martinez-Castelao A, Jager KJ, Dekker FW, Lindholm B, London G for EUROpean RENal and CARDiovascular Medicine working group of the European Renal Association–European Dialysis and Transplant Association (ERA–

- EDTA). The complexity of the cardio-renal link: taxonomy, syndromes and diseases. *Kidney Int* 2011 Sup 1, 2–5
200. Jager KJ, Lindholm B, Goldsmith D, Fliser D, Wiecek A, Suleymanlar G, Ortiz A, Massy Z, Martinez-Castelao A, Agarwal R, Blankestijn PJ, Covic A, London G, Zoccali C, Dekke FW for European RENal and Cardiovascular Medicine working group of the European Renal Association–European Dialysis and Transplant Association (ERA–EDTA). Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link? *Kidney Int* 2011 Sup 1: 21-23
  201. Ballarín J, Arce Y, Torra Balcells R, Diaz Encarnación M, Manzarbeitia F, Ortiz A, Egido J, Moreno JA. Acute renal failure associated to paroxysmal nocturnal haemoglobinuria leads to intratubular haemosiderin accumulation and CD163 expression. *Nephrol Dial Transplant*. 2011 Oct;26(10):3408-11
  202. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Niño MD, Izquierdo MC, Poveda J, Sainz-Prestel V, Ortiz-Martin N, Parra-Rodriguez A, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A. Tenofovir nephrotoxicity: 2011 update. *AIDS Res Treat*. 2011;2011:354908. PMID: 21716719
  203. Sanz AB, Izquierdo MC, Ucero AC, Sanchez Niño MD, Egido J, Ortiz A. TWEAK as a Biomarker. *Recent Patents on Biomarkers* 2011, 1: 213-221
  204. Ortiz A, Massy Z, Fliser D, Lindholm B, Wiecek A, Martinez-Castelao A, Covic A, Goldsmith D, Suleymanlar G, London G, Zoccali C. Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. *Nat. Rev. Nephrol*. 2011;89:141-150
  205. González-Mateo GT, Aroeira LS, López-Cabrera M, Ruiz-Ortega M, Ortiz A, Selgas R. Pharmacological modulation of peritoneal injury induced by dialysis fluids: is it an option? *Nephrol Dial Transplant*. 2012;27:478-481 PMID: 21965583.
  206. Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, Maródi L, Mignani R, Vujkovic B, Beitner-Johnson D, Lemay R, Cole JA, Svarstad E, Waldek S, Germain DP, Wanner C; on behalf of the Fabry Registry. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. *Nephrol Dial Transplant*. 2012;27:1042-9 PMID: 21804088
  207. Sanchez-Niño MD, Sanz AB, Sanchez-Lopez E, Ruiz-Ortega M, Benito-Martin A, Saleem MA, Mathieson PW, Mezzano S, Egido J, Ortiz A. HSP27/HSPB1 as an adaptive podocyte antiapoptotic protein activated by high glucose and angiotensin II. *Lab Invest*. 2012 Jan;92(1):32-45. PMID: 21931298.
  208. Alvarez-Prats A, Hernández-Perera O, Díaz-Herrera P, Ucero AC, Anabitarte-Prieto A, Losada-Cabrera A, Ortiz A, Rodríguez-Pérez JC. Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy. *Nephrol Dial Transplant*. 2012 Jul;27(7):2720-33 PMID: 22302208.
  209. Moreno JA, Martín-Cleary C, Gutiérrez E, Rubio-Navarro A, Ortiz A, Praga M, Egido J. Haematuria: the forgotten CKD factor? *Nephrol Dial Transplant*. 2012 Jan;27(1):28-34. PubMed PMID: 22287699.
  210. Izquierdo MC, Sanz AB, Mezzano S, Blanco J, Carrasco S, Sanchez-Niño MD, Benito-Martín A, Ruiz-Ortega M, Egido J, Ortiz A. TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. *Kidney Int*. 2012;81:1098-107 PMID: 22278019.
  211. Heine G, Ortiz A, Massy Z, Lindholm B, Wiecek A, Castelao AM, Covic A, Goldsmith D, Suleymanlar G, London G, Parati G, Sicari R, Zoccali C, Fliser D. Monocyte subpopulations and cardiovascular risk in chronic kidney disease. *Nat Rev Nephrol*. 2012 Mar 13;8(6):362-9 PMID: 22410492.
  212. Ortiz A, Sanchez-Niño MD. The Human Plasma Lipidome. *N Engl J Med* 2012; 366:668-669
  213. Sanchez-Niño MD, Bozic M, Cordoba-Lanus E, Valcheva P, Gracia O, Ibarz M, Fernandez E, Navarro-Gonzalez JF, Ortiz A, Valdivielso JM. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. *Am J Physiol Renal Physiol*. 2012;302: F647-57 PMID: 22169009.
  214. Moreno JA, Martín-Cleary C, Gutiérrez E, Toldos O, Blanco-Colio LM, Praga M, Ortiz A, Egido J. AKI Associated with Macroscopic Glomerular Hematuria: Clinical and Pathophysiologic Consequences. *Clin J Am Soc Nephrol*. 2012 Jan;7(1):175-84. PMID: 22096039.
  215. Ares-Carrasco S, Picatoste B, Camafeita E, Carrasco-Navarro S, Zubiri I, Ortiz A, Egido J, López JA, Tuñón J, Lorenzo O. Proteome changes in the myocardium of experimental chronic diabetes and hypertension Role of PPAR $\alpha$  in the associated hypertrophy. *J Proteomics* 2012 Mar 16;75(6):1816-29 PMID: 22234359.
  216. Román-García P, Carrillo-López N, Naves-Díaz M, Rodríguez I, Ortiz A, Cannata-Andía JB. Dual-Specificity Phosphatases Are Implicated in Severe Hyperplasia and Lack of Response to FGF23 of Uremic Parathyroid Glands from Rats. *Endocrinology*. 2012 Apr;153(4):1627-37. PMID: 22334717.
  217. Tavira B, Coto E, Torres A, Díaz-Corte C, Díaz-Molina B, Ortega F, Arias M, Díaz JM, Selgas R, López-Larrea C, Ruiz-Ortega M, Ortiz A, González E, Campistol JM, Alvarez V; The Pharmacogenetics of tacrolimus REDINREN study group. Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus. *Mol Genet Metab*. 2012 Mar;105(3):525-527 PMID: 22264780
  218. Gallegos-Bayas G, Pascual-Pareja JF, Sanchez-Niño MD, Manzarbeitia F, Ortiz A. Undetectable serum calcidiol:

- not everything that glitters is gold. *Clinical Kidney Journal*, 2012;5:37-40
219. Gonzalez-Parra E, Tuñón J, Egido J, Ortiz A. Phosphate: a stealthier killer than previously thought? *Cardiovasc Pathol*. 2012 Sep-Oct;21(5):372-81
  220. Humanes B, Lazaro A, Camano S, Moreno-Gordaliza E, Lazaro JA, Blanco-Codesido M, Lara JM, Ortiz A, Gomez-Gomez MM, Martín-Vasallo P, Tejedor A. Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. *Kidney Int*. 2012 Sep;82(6):652-63. PMID: 22718191.
  221. Berzal S, Alique M, Ruiz-Ortega M, Egido J, Ortiz A, Ramos AM. GSK3, Snail and adhesion molecule regulation by Cyclosporine A in renal tubular cells. *Toxicol Sci*. 2012 Jun;127(2):425-37 PubMed PMID: 22416070
  222. Mischak H, Ioannidis JP, Argiles A, Attwood TK, Bongcam-Rudloff E, Broenstrup M, Charonis A, Chrousos GP, Delles C, Dominiczak A, Dylag T, Ehrich J, Egido J, Findeisen P, Jankowski J, Johnson RW, Julien BA, Lankisch T, Leung HY, Maahs D, Magni F, Manns MP, Manolis E, Mayer G, Navis G, Novak J, Ortiz A, Persson F, Peter K, Riese HH, Rossing P, Sattar N, Spasovski G, Thongboonkerd V, Vanholder R, Schanstra JP, Vlahou A. Implementation of proteomic biomarkers: making it work. *Eur J Clin Invest*. 2012 Sep;42(9):1027-36 PMID: 22519700.
  223. Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Barat A, Martin-Cleary C, Egido J. Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis? *BMC Nephrol*. 2012 Apr 25;13(1):21 PubMed PMID: 22533828.
  224. González-Parra E, Gracia-Iguacel C, Egido J, Ortiz A. Phosphorus and nutrition in chronic kidney disease. *Int J Nephrol*. 2012;2012:597605. PMID: 22701173.
  225. Rojas-Rivera J, Ortiz A, Egido J. Antioxidants in kidney diseases: the impact of bardoxolone methyl. *Int J Nephrol*. 2012;2012:321714. PMID: 22701794
  226. González-Parra E, Avila PJ, Mahillo-Fernández I, Lentisco C, Gracia C, Egido J, Ortiz A. High prevalence of winter 25-hydroxyvitamin D deficiency despite supplementation according to guidelines for hemodialysis patients. *Clin Exp Nephrol*. 2012 Dec;16(6):945-51. PMID: 22644091
  227. Fernández-Sánchez R, Berzal S, Sánchez-Niño MD, Neria F, Gonçalves S, Calabia O, Tejedor A, Calzada MJ, Caramelo C, Deudero JJ, Ortiz A. AG490 Promotes HIF-1A Accumulation by Inhibiting Its Hydroxylation. *Curr Med Chem*. 2012;19(23):4014-23 PubMed PMID: 22709000
  228. Moreno JA, Moreno S, Rubio-Navarro A, Sastre C, Blanco-Colio LM, Gómez-Guerrero C, Ortiz A, Egido J. Targeting chemokines in proteinuria-induced renal disease. *Expert Opinion on Therapeutic Targets*. 2012 Aug;16(8):833-45
  229. Alvarez-Llamas G, Zubiri I, Maroto AS, de la Cuesta F, Posada-Ayala M, Martin-Lorenzo M, Barderas MG, Fernandez-Fernandez B, Ramos A, Ortiz A, Vivanco F. Role for the membrane proteome in human chronic kidney disease erythrocytes. *Transl Res*. 2012 Nov;160(5):374-83
  230. Fernández Fernández B, Elewa U, Sánchez-Niño MD, Rojas-Rivera JE, Martin-Cleary C, Egido J, Ortiz A. 2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials. *Minerva Med*. 2012 Aug;103(4):219-34
  231. Lavoiz C, Rodrigues-Diez R, Benito-Martin A, Rayego-Mateos S, Rodrigues-Diez RR, Alique M, Ortiz A, Mezzano S, Egido J, Ruiz-Ortega M. Angiotensin II Contributes to Renal Fibrosis Independently of Notch Pathway Activation. *PLoS One*. 2012;7(7):e40490. PMID: 22792351
  232. Izquierdo MC, Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, Ruiz-Andres O, Poveda J, Moreno JA, Egido J, Ortiz A. Klotho, phosphate and inflammation/ageing in chronic kidney disease. *Nephrol Dial Transplant*. 2012 Dec;27 Suppl 4:iv6-iv10. PMID: 23258814.
  233. Gonzalez-Parra E, Rojas-Rivera J, Tuñón J, Praga M, Ortiz A, Egido J. Vitamin D receptor activation and cardiovascular disease. *Nephrol Dial Transplant*. 2012 Dec;27 Suppl 4:iv17-iv21. PMID: 23258805
  234. Sánchez-Niño MD, Ortiz A. Is it or is it not a pathogenic mutation? Is it or is it not the podocyte? *J Nephropathology*. 2012; 1(3): 152-154
  235. Sanchez-Niño MD, Ortiz A. Notch3 and kidney injury: Never two without three. *J Pathol*. 2012 Nov;228(3):266-73. PubMed PMID: 22952000.
  236. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A; European Uremic Toxin Work Group. (Abou Deif O, Argiles A, Druke T, Baurmeister U, Beige J, Brunet P, Cohen G, Fliser D, Glorieux G, Herget-Rosenthal S, Jankowski V, Jankowski J, Massy Z, Mischak H, Ortiz A, Perna A, Rodriguez Portillo JM, Spasovski G, Stegmayr B, Stenvinkel P, Thornalley P, Vanholder R, Wanner C, Wiecek A. Normal and pathologic concentrations of uremic toxins. *J Am Soc Nephrol*. 2012 Jul;23(7):1258-70. PMID: 22626821;
  237. Elewa U, Sanchez-Niño MD, Martin-Cleary C, Fernandez-Fernandez B, Egido J, Ortiz A. Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled. *Int Urol Nephrol*. 2012 Dec;44(6):1731-44. PMID: 22965378. Q3 IF 1,471 2011

238. Carracedo J, Buendía P, Merino A, Madueño JA, Peralbo E, Ortiz A, Martín-Malo A, Aljama P, Rodríguez M, Ramírez R. Klotho modulates the stress response in human senescent endothelial cells. *Mech Ageing Dev.* 2012 Nov;133(11-12):647-54 PMID: 23000105
239. Gutiérrez E, Egido J, Rubio-Navarro A, Buendía I, Blanco Colio LM, Toldos O, Manzarbeitia F, de Lorenzo A, Sanchez R, Ortiz A, Praga M, Moreno JA. Oxidative Stress, Macrophage Infiltration and CD163 Expression Are Determinants of Long-Term Renal Outcome in Macrohematuria-Induced Acute Kidney Injury of IgA Nephropathy. *Nephron Clin Pract.* 2012 Oct 19;121(1):c42-c53. PMID: 23095372.
240. Sanz AB, Sanchez-Niño MD, Carrasco S, Manzarbeitia F, Ruiz-Andres O, Selgas R, Ruiz-Ortega M, Gonzalez-Enguita C, Egido J, Ortiz A. Inflammatory Cytokines and Survival Factors from Serum Modulate Tweak-Induced Apoptosis in PC-3 Prostate Cancer Cells. *PLoS One.* 2012;7(10):e47440. PubMed PMID: 23077618
241. Albalade M, de la Piedra C, Ortiz A, Hernández Pérez J, Rubert M, Pérez Garcia R, Zazo P, Nieto L, de Sequera P, Egido J. Risk in Dosing Regimens for 25-OH Vitamin D Supplementation in Chronic Haemodialysis Patients. *Nephron Clin Pract.* 2012 Nov 27;121(3-4):c112-c119. PMID: 23221739
242. Sanchez-Niño MD, Sanz AB, Ortiz A. Uromodulin, inflammasomes, and pyroptosis. *J Am Soc Nephrol.* 2012 Nov;23(11):1761-3. PubMed PMID: 23085634.
243. Torra R, Ortiz A. Fabry disease: the many faces of a single disorder. *Clin Kidney J* 2012 5: 379–82
244. Calleros L, Cortés MA, Luengo A, Mora I, Guijarro B, Martín P, Ortiz-Arduán A, Selgas R, Rodríguez-Puyol D, Rodríguez-Puyol M. Start-up of a clinical sample processing, storage and management platform: organisation and development of the REDinREN Biobank. *Nefrologia.* 2012;32(1):28-34. English, Spanish. PubMed PMID: 22294002.
245. Izquierdo MC, Sanz AB, Sánchez-Niño MD, Pérez-Gómez MV, Ruiz-Ortega M, Poveda J, Ruiz-Andrés O, Ramos AM, Moreno JA, Egido J, Ortiz A. Acute kidney injury transcriptomics unveils a relationship between inflammation and ageing. *Nefrologia.* 2012;32(6):715-23 PMID: 23093094.
246. Ucero AC, Berzal S, Ocaña-Salceda C, Sancho M, Orzáez M, Messeguer A, Ruiz-Ortega M, Egido J, Vicent MJ, Ortiz A, Ramos AM. A polymeric nanomedicine diminishes inflammatory events in renal tubular cells. *PLoS One.* 2013;8(1):e51992. PMID: 23300960;
247. Bolignano D, Rastelli S, Agarwal R, Fliser D, Massy Z, Ortiz A, Wiecek A, Martinez-Castelao A, Covic A, Goldsmith D, Suleymanlar G, Lindholm B, Parati G, Sicari R, Gargani L, Mallamaci F, London G, Zoccali C. Pulmonary Hypertension in CKD. *Am J Kidney Dis.* 2013 Apr;61(4):612-22 PMID: 23164943.
248. Fernández-Sánchez A, Baragaño Raneros A, Carvajal Palao R, Sanz AB, Ortiz A, Ortega F, Suárez-Álvarez B, López-Larrea C. DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8 (+) T and NK cells. *Epigenetics.* 2013 Jan 1;8(1):66-78 PMID: 23235109.
249. Terryn W, Cochat P, Froissart R, Ortiz A, Pirson Y, Poppe B, Serra A, Van Biesen W, Vanholder R, Wanner C. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. *Nephrol Dial Transplant.* 2013;28(3):505-17 PMID: 23234755.
250. Ardura JA, Sanz AB, Ortiz A, Esbrit P. Parathyroid hormone-related protein protects renal tubuloepithelial cells from apoptosis by activating transcription factor Runx2. *Kidney Int.* 2013 May;83(5):825-34. PMID: 23364519.
251. Ucero AC, Sabban B, Benito-Martin A, Carrasco S, Joeken S, Ortiz A. Laser Therapy in Metabolic Syndrome-related Kidney Injury. *Photochem Photobiol.* 2013 Jul;89(4):953-60 PMID: 23360312.
252. Sanchez-Niño MD, Sanz AB, Ruiz-Andres O, Poveda J, Izquierdo MC, Selgas R, Egido J, Ortiz A. MIF, CD74 and other partners in kidney disease: Tales of a promiscuous couple. *Cytokine Growth Factor Rev.* 2013 Feb;24(1):23-40 PMID: 229597227.812. BIOCHEMISTRY & MOLECULAR
253. Sicari R, Gargani L, Wiecek A, Covic A, Goldsmith D, Suleymanlar G, Parati G, Ortiz A, Massy Z, Martinez-Castelao A, Lindholm B, Heine GH, Fliser D, Mallamaci F, London G, Zoccali C; European Renal and Cardiovascular Medicine (EURECA-m)working group of the European Renal Association-European Dialysis Transplantation Association (ERA-EDTA). The use of echocardiography in observational clinical trials: the EURECA-m registry. *Nephrol Dial Transplant.* 2013 Jan;28(1):19-23.] PMID: 23048175.
254. Linthorst GE, Burlina AP, Cecchi F, Cox TM, Fletcher JM, Feldt-Rasmussen U, Giugliani R, Hollak CE, Houge G, Hughes D, Kantola I, Lachmann R, Lopez M, Ortiz A, Parini R, Rivera A, Rolfs A, Ramaswami U, Svarstad E, Tondel C, Tylki-Szymanska A, Vujkovic B, Waldek S, West M, Weidemann F, Mehta A. Recommendations on reintroduction of agalsidase Beta for patients with Fabry disease in europe, following a period of shortage. *JIMD Rep.* 2013;8:51-6. PMID: 23430520;
255. Rodrigues-Diez R, Lavoz C, Carvajal G, Rayego-Mateos S, Rodrigues Diez R, Ortiz A, Egido J, Mezzano S, Ruiz-Ortega M. Gremlin Is a Downstream Profibrotic Mediator of Transforming Growth Factor-Beta in Cultured Renal Cells. *Nephron Exp Nephrol* 2013;122:62-74 2.743
256. Sanchez-Niño MD, Sanz AB, Ortiz A. Klotho to treat kidney fibrosis. *J Am Soc Nephrol* 2013 Apr;24(5):687-9

257. Sanz AB; Sanchez-Niño MD, Martín-Cleary C, Ortiz A, Ramos AM. Progress in the development of animal models of acute kidney injury and its impact on drug discovery. *Expert Opin Drug Discovery* 2013 Jul;8(7):879-95 PMID: 23627598
258. Rodrigues-Díez R, Rodrigues Díez R, Rayego-Mateos S, Suarez-Álvarez B, Lavoz C, Aroeira L, Sánchez-López E, Orejudo M, Alique M, López-Larrea C, Ortiz A, Egido J, Ruíz-Ortega M. The C-terminal module IV of connective tissue growth factor is a novel immune modulator of the Th17 response. *Lab Invest* 2013 Jul;93(7):812-24 PMID: 23648563
259. Gracia-Iguacel C, Gonzalez-Parra E, Rodriguez-Orsorio L, Sanz AB, Almaden Y, de la Piedra C, Egido J, Rodriguez M, Ortiz A. Correction of hypocalcemia allows optimal recruitment of FGF-23-dependent phosphaturic mechanisms in acute hyperphosphatemia post-phosphate enema. *J Bone Miner Metab.* 2013 Nov;31(6):703-7 PMID: 23677707
260. Gracia-Iguacel C, Qureshi AR, Avesani CM, Heimbürger O, Huang X, Lindholm B, Bárány P, Ortiz A, Stenvinkel P, Carrero JJ. Subclinical versus overt obesity in dialysis patients: more than meets the eye. *Nephrol Dial Transplant.* 2013 Nov;28 Suppl 4:iv175-81. doi: 10.1093/ndt/gft024. PubMed PMID: 24179011
261. Ucero AC, Benito-Martin A, Fuentes-Calvo I, Santamaria B, Blanco J, Lopez-Novoa JM, Ruiz-Ortega M, Egido J, Burkly LC, Martinez-Salgado C, Ortiz A. TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast. *Biochim Biophys Acta.* 2013 Jun 6;1832(10):1744-1755: 23748045.
262. Sanchez-Niño MD, Ortiz A. The demise of calcium-based phosphate binders. *Lancet* 2013 Oct 12;382(9900):1232-4.
263. Jankowski V, Tölle M, Tran TN, van der Giet M, Schuchardt M, Lehmann K, Janke D, Flick B, Ortiz A, Sanchez-Niño MD, Tepel M, Zidek W, Jankowski J. Identification of a potent endothelium-derived angiogenic factor. *PLoS One.* 2013 Jul 29;8(7):e68575. PMID: 23922657
264. Linkermann A, Bräsen JH, Darding M, Jin MK, Sanz AB, Heller JO, De Zen F, Weinlich R, Ortiz A, Walczak H, Weinberg JM, Green DR, Kunzendorf U, Krautwald S. Two Independent Pathways of Regulated Necrosis Mediate Ischemia-Reperfusion Injury. *Proc Natl Acad Sci USA* 2013 Jul 16;110(29):12024-9.
265. Rayego-Mateos S, Rodrigues-Díez R, Morgado-Pascual JL, Rodrigues Díez RR, Mas S, Lavoz C, Alique M, Pato J, Keri G, Ortiz A, Egido J, Ruiz-Ortega M. Connective tissue growth factor is a new ligand of epidermal growth factor receptor. *J Mol Cell Biol.* 2013 Oct;5(5):323-335. PMID: 23929714.
266. Gonzalez-Parra E, Herrero JA, Elewa U, Bosch RJ, Ortiz A, Egido de los Rios J. Bisphenol A in chronic kidney disease. *Int J Nephrol* 2013;2013:437857. doi: 10.1155/2013/437857. PMID: 23997953 (Arduan AO)
267. Sainz-Prestel V, Hernandez-Perez J, Rojas-Rivera J, Milicua-Muñoz JM, Egido J, Ortiz A. Rituximab-associated interstitial lung disease in fibrillary glomerulonephritis. *Clin Kidney J* 2013;6: 510-512. doi: 10.1093/ckj/sft081 *Urology Nephrology*
268. Távira B, Gómez J, Ortega F, Tranche S, Díaz-Corte C, Alvarez F, Ortiz A, Santos F, Sánchez-Niño MD, Coto E. A *CLCNKA* polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort. *Gene* 2013 Sep 25;527(2):670-2
269. Sanchez-Niño MD, Ortiz A. HCV infection and miravirsin. *N Engl J Med.* 2013;369(9):877-8
270. Weidemann F, Sanchez-Niño MD, Polítei J, Oliveira JP, Wanner C, Warnock DG, Ortiz A. Fibrosis: a key feature of Fabry disease with potential therapeutic implications. *Orphanet J Rare Dis* 2013 Aug 6;8(1):116. PMID: 23915644
271. González-Guerrero C, Ocaña-Salcedo C, Berzal S, Carrasco S, Fernández-Fernández B, Cannata-Ortiz P, Egido J, Ortiz A, Ramos AM. Calcineurin inhibitors recruit protein kinases JAK2 and JNK, TLR signaling and the UPR to activate NF-κB-mediated inflammatory responses in kidney tubular cells. *Toxicol Applied Pharmacol.* 2013 Nov 1;272(3):825-41 PMID: 23958496.
272. Sanchez-Niño MD; Poveda J; Sanz AB; Mezzano S, Fernandez-Fernandez B; Burkly LC; Nair V; Kretzler M; Hodgin JB; Ruiz-Ortega M; Selgas R; Egido J; Ortiz A. Fn14 in Podocytes and Proteinuric Kidney Disease. *BBA - Molecular Basis of Disease* 2013 Dec;1832(12):2232-43
273. Husi H, Sanchez-Niño MD, Delles C, Mullen W, Vlahou A, Ortiz A, Mischak H. A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI. *BMC Syst Biol.* 2013 Oct 30;7(1):110. PMID: 24172336.
274. Poveda J, Tabara LC, Fernandez-Fernandez B, Martín-Cleary C, Sanz AB, Selgas R, Ortiz A, Sanchez-Niño MD. TWEAK/Fn14 and Non-Canonical NF-kappaB Signaling in Kidney Disease. *Front Immunol.* 2013 Dec 10;4:447. PMID: 24339827
275. Benito-Martin A, Ucero AC, Izquierdo MC, Santamaria B, Picatoste B, Carrasco S, Lorenzo O, Ruiz-Ortega M, Egido J, Ortiz A. Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells. *Biochim Biophys Acta.* 2013 Nov 25;1842(2):293-303. PMID: 24287278.
276. Benito-Martin A, Ucero AC, Zubiri I, Posada-Ayala M, Fernandez-Fernandez B, Cannata-Ortiz P, Sanchez-Niño

- MD, Ruiz-Ortega M, Egido J, Alvarez-Llamas G, Ortiz A. Osteoprotegerin in exosome-like vesicles from human cultured tubular cells and urine. *PLoS One*. 2013 Aug 23;8(8):e72387. PMID: 24058411
277. Zubiri I, Posada-Ayala M, Sanz-Maroto A, Calvo E, Martin-Lorenzo M, Gonzalez-Calero L, de la Cuesta F, Lopez JA, Fernandez-Fernandez B, Ortiz A, Vivanco F, Alvarez-Llamas G. Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis. *J Proteomics*. 2013 Nov 7;96C:92-102. PMID: 24211404.
278. Sastre C, Rubio-Navarro A, Buendía I, Gómez-Guerrero C, Blanco J, Mas S, Egido J, Blanco-Colio LM, Ortiz A, Moreno JA. Hyperlipidemia-Associated Renal Damage Decreases Klotho Expression in Kidneys from ApoE Knockout Mice. *PLoS One*. 2013 Dec 30;8(12):e83713. PubMed PMID: 24386260.
279. Rayego-Mateos S, Morgado J, Sanz AB, Ramos AM, Eguchi S, Batlle D, Pato J, Keri G, Egido J, Ortiz A, Ruiz-Ortega M. TWEAK transactivation of the Epidermal growth factor receptor mediates renal inflammation. *J Pathol* 2013 Dec;231(4):480-94
280. Gracia-Iguacel C, González-Parra E, Pérez-Gómez MV, Mahíllo I, Egido J, Ortiz A, Carrero JJ. Prevalence of protein-energy wasting syndrome and its association with mortality in haemodialysis patients in a centre in Spain. *Nefrologia*. 2013;33:495-505
281. Pérez-Gómez MV, Ortiz-Arduán A, Lorenzo-Sellares V. Vitamin D and proteinuria: a critical review of molecular bases and clinical experience. *Nefrologia*. 2013;33(5):716-26. PMID: 24089164
282. Portolés J, Janeiro D, Lou-Arnal LM, López-Sánchez P, Ortega M, del Peso G, Felipe C, Tato AM, Velo M, Castellano I, Pérez-Díaz V; Grupo Centro de Diálisis Peritoneal (GCDP, incluye A Ortiz). First episodes of peritoneal infection: description and prognostic factors. *Nefrologia*. 2013;33(3):316-24. PMID: 23712221.
283. Egido J, Mas S, Rojas-Rivera J, Gracia-Iguacel C, Fernández B, Tuñón J, Ortiz A, González-Parra E. Abordaje terapéutico a la dislipemia del paciente con enfermedad renal crónica, incluido el trasplante renal. *Nefrología Suplemento Extraordinario* 2013;4(4):18-27
284. Ucero AC, Benito-Martin A, Izquierdo MC, Sanchez-Niño MD, Sanz AB, Ramos AM, Berzal S, Ruiz-Ortega M, Egido J, Ortiz A. Unilateral ureteral obstruction: beyond obstruction. *Int Urol Nephrol Int Urol Nephrol*. 2014 Apr;46(4):765-76
285. Sanz AB, Sanchez-Niño MD, Izquierdo MC, Gonzalez-Espinoza L, Ucero AC, Poveda J, Ruiz-Andres O, Ruiz Ortega M, Selgas R, Egido J, Ortiz A. Macrophages and recently identified forms of cell death. *Int Rev Immunol* 2014 Jan;33(1):9-22 2012
286. Poveda J, Sanchez-Niño MD, Glorieux G, Sanz AB, Egido J, Vanholder R, Ortiz A. p-cresylsulfate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. *Nephrol Dial Transplant*. 2014 Jan;29(1):56-64
287. Sanchez-Niño MD, Poveda J, Sanz AB, Carrasco S, Ruiz-Ortega M, Selgas R, Egido J, Ortiz A. 3,4-DGE is cytotoxic and decreases HSP27/HSPB1 in podocytes. *Arch Toxicol*. 2014 Mar;88(3):597-608 PMID: 24337777.
288. Boutouyrie P, Fliser D, Goldsmith D, Covic A, Wiecek A, Ortiz A, Martinez-Castelao A, Lindholm B, Massy ZA, Suleymanlar G, Sicari R, Gargani L, Parati G, Mallamaci F, Zoccali C, London GM. Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry. *Nephrol Dial Transplant*. 2014 Feb;29(2):232-9 PMID: 24084326.
289. Liabeuf S, Okazaki H, Desjardins L, Fliser D, Goldsmith D, Covic A, Wiecek A, Ortiz A, Martinez-Castelao A, Lindholm B, Suleymanlar G, Mallamaci F, Zoccali C, London G, Massy ZA. Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario? *Nephrol Dial Transplant* 2014 Jul;29(7):1275-84. PMID: 24009287
290. Sanz AB, Izquierdo MC, Sanchez-Niño MD, Ucero AC, Egido J, Ruiz-Ortega M, Ramos AM, Putterman C, Ortiz A. TWEAK and the progression of renal disease: clinical translation. *Nephrol Dial Transplant*. 2014 Feb;29 Suppl 1:i54-i62
291. Alique M, Civantos E, Sanchez-Lopez E, Lavoz C, Rayego-Mateos S, Rodrigues-Diez R, Garcia-Redondo AB, Egido J, Ortiz A, Rodriguez-Puyol D, Rodriguez-Puyol M, Ruiz-Ortega M. Integrin Linked Kinase Plays A Key Role In The Regulation Of Angiotensin II-Induced Renal Inflammation. *Clin Sci (Lond)*. 2014 Jul;127(1):19-31 PMID: 24383472.
292. Ruiz-Ortega M, Ortiz A, Ramos AM. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and kidney disease. *Curr Opin Nephrol Hypertens*. 2014 Jan;23(1):93-100. PMID: 24257157.
293. Posada-Ayala M, Zubiri I, Martin-Lorenzo M, Sanz-Maroto A, Molero D, Gonzalez-Calero L, Fernandez-Fernandez B, de la Cuesta F, Laborde CM, Barderas MG, Ortiz A, Vivanco F, Alvarez-Llamas G. Identification of a urine metabolomics signature in patients with advanced-stage chronic kidney disease. *Kidney Int*. 2014 Jan;85(1):103-11. PMID: 24048377.
294. Siwy J, Schanstra JP, Argiles A, Bakker SJL, Beige J, Boucek P, Brand K, Delles C, Duranton F, Fernandez-



- Fernandez B, Jankowski ML, Al Khatib M, Kunt T, Lajer M, Lichtinghagen R, Lindhardt M, Maahs D, Mischak H, Mullen W, Navis G, Noutson M, Ortiz A, Persson F, Petrie JR, Roob JM, Rossing P, Ruggerenti P, Rychlik I, Serra A, Snell-Bergeon J, Spasovski G, von der Leyen H, Winklhofer-Roob BM, Zürbig P, Jankowski J. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. *Nephrol Dial Transplant* 2014 Aug;29(8):1563-70
295. Sanz AB, Stark Aroeira L, Bellon T, del Peso G, Jimenez-Heffernan J, Santamaria B, Sanchez-Niño MD, Blanco-Colio LM, Lopez-Cabrera M, Ruiz-Ortega M, Egido J, Selgas R, Ortiz A. TWEAK promotes peritoneal inflammation. *PLoS One*. 2014;9:e90399.
296. Moreno JA, Moreno S, Rubio-Navarro A, Gómez-Guerrero C, Ortiz A, Egido J. Role of chemokines in proteinuric kidney disorders. *Expert Rev Mol Med*. 2014 Feb 17;16:e3. PMID: 24534600
297. Rodrigues-Díez R, Aroeira LS, Orejudo M, Bajo MA, Heffernan JJ, Rodrigues-Díez RR, Rayego-Mateos S, Ortiz A, Gonzalez-Mateo G, López-Cabrera M, Selgas R, Egido J, Ruiz-Ortega M. IL-17A is a novel player in dialysis-induced peritoneal damage. *Kidney Int*. 2014 Aug;86(2):303-15 PMID: 24552849.
298. García-Camín RM, Goma M, Osuna RG, Rubio-Navarro A, Buendía I, Ortiz A, Egido J, Manzarbeitia F, Chevarria JL, Gluksmann MC, Moreno JA. Molecular mediators of favism-induced acute kidney injury. *Clin Nephrol*. 2014 Mar;81(3):203-9 PMID: 23006341
299. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn E, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, Van Biesen W, Nagler E; on behalf of the Hyponatraemia Guideline Development Group (people involved in appraising the implementability of preliminary statements include A Ortiz). Clinical practice guideline on diagnosis and treatment of hyponatraemia. *Nephrol Dial Transplant*. 2014 Feb 25. [Epub ahead of print] PMID: 24569496.
300. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn E, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, Van Biesen W, Nagler E; Hyponatraemia Guideline Development Group (people involved in appraising the implementability of preliminary statements include A Ortiz). Clinical practice guideline on diagnosis and treatment of hyponatraemia. *Eur J Endocrinol*. 2014 Feb 25;170(3):G1-G47. doi: 10.1530/EJE-13-1020. Print 2014. PMID: 24569125.
301. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn E, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, Van Biesen W, Nagler E (people involved in appraising the implementability of preliminary statements include A Ortiz). Clinical practice guideline on diagnosis and treatment of hyponatraemia. *Intensive Care Med*. 2014 Feb 22. [Epub ahead of print] PMID: 24562549.
302. Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egido J. Therapeutic approaches to diabetic nephropathy-beyond the RAS. *Nat Rev Nephrol*. 2014 Jun;10(6):325-46 PMID: 24802062.
303. Alvarez-Llamas G, Vivanco F, Ortiz A. The authors reply: The urinary metabolome of chronic kidney disease'. *Kidney Int*. 2014 May;85(5):1240. PubMed PMID: 24786881.
304. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, Wiecek A, Zoccali C, London GM; Board of the EURECA-m Working Group of ERA-EDTA. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. *Lancet*. 2014 May 24;383(9931):1831-43. PMID: 24856028.
305. Izquierdo MC, Martin-Cleary C, Fernandez-Fernandez B, Elewa U, Sanchez-Niño MD, Carrero JJ, Ortiz A. CXCL16 in kidney and cardiovascular injury. *Cytokine Growth Factor Rev*. 2014 Jun;25(3):317-25 PubMed PMID: 24861945. IF 8.831
306. Martín P, Mora I, Cortes MA, Calleros L, García-Jerez A, Ortiz A, Rodríguez-Puyol M, Rodríguez-Puyol D, Olmos G. Relevant role of PKG in the progression of fibrosis induced by TNF-like weak inducer of apoptosis. *Am J Physiol Renal Physiol*. 2014 Jul 1;307(1):F75-85. PMID: 24872318
307. Martin-Lorenzo M, Gonzalez-Calero L, Zubiri I, Diaz-Payno PJ, Sanz-Maroto A, Posada-Ayala M, Ortiz A, Vivanco F, Alvarez-Llamas G. Urine 2-DE proteome analysis in healthy condition and kidney disease. *Electrophoresis*. 2014 Sep;35(18):2634-41 PMID: 24913465. IF 3.261
308. Nastou D, Fernández-Fernández B, Elewa U, González-Espinoza L, González-Parra E, Sanchez-Niño MD, Ortiz A. Next-generation phosphate binders: focus on iron-based binders. *Drugs*. 2014 Jun;74(8):863-77. PMID: 24848754.
309. Rodriguez-Osorio L, Fernandez-Fernandez B, Martin-Cleary C, Ortiz A. Increasing serum calcium levels and recent return from transplantation as clues to the tuberculous nature of refractory peritoneal dialysis peritonitis. *J Postgrad Med*. 2014 Apr-Jun;60(2):200-1. PMID: 24823525.
310. Rodrigues-Diez R, Rodrigues-Diez RR, Lavoz C, Carvajal G, Droguett A, Garcia-Redondo AB, Rodriguez I, Ortiz A, Egido J, Mezzano S, Ruiz-Ortega M. Gremlin activates the smad pathway linked to epithelial mesenchymal transdifferentiation in cultured tubular epithelial cells. *Biomed Res Int*. 2014;2014:802841. PMID: 24949470.
311. Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Niño MD, Villarrubia J, Ortiz A.

- Deferasirox nephrotoxicity-the knowns and unknowns. *Nat Rev Nephrol*. 2014 Oct;10(10):574-86 PMID: 25048549.
312. Gallegos-Villalobos A, Portolés J, Ortiz A. Application of the new cholesterol guidelines. *N Engl J Med*. 2014 Jul 3;371(1):77-8. PMID: 24988563.
313. Madrigal-Matute J, Lindholt JS, Fernandez-Garcia CE, Benito-Martin A, Burillo E, Zalba G, Belouqui O, Llamas-Granda P, Ortiz A, Egido J, Blanco-Colio LM, Martin-Ventura JL. Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. *J Am Heart Assoc*. 2014 Aug 5;3(4). pii: e000785. PMID: 25095870.
314. Gonzalez-Parra E, González-Casaus ML, Arenas MD, Sainz-Prestel V, Gonzalez-Espinoza L, Muñoz Rodriguez MA, Tabikh A, Egido J, Ortiz A. Individualization of dialysate calcium concentration according to baseline predialysis serum calcium. *Blood Purif*. 2014 Dec 19;38(3-4):224-233. PMID: 25531119.
315. Betriu A, Martinez-Alonso M, Arcidiacono MV, Cannata-Andia J, Pascual J, Valdivielso JM, Fernández E; Investigators from the NEFRONA Study (collaborators 87: A Ortiz). Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study. *Nephrol Dial Transplant*. 2014 Jul;29(7):1415-22. PMID: 24586070. *Urology Nephrology FI* 3,371
316. Tábara LC, Poveda J, Martin-Cleary C, Selgas R, Ortiz A, Sanchez-Niño MD. Mitochondria-targeted therapies for acute kidney injury. *Expert Rev Mol Med*. 2014 Aug 8;16:e13. PMID: 25104110
317. Ars E, Bernis C, Fraga G, Martínez V, Martins J, Ortiz A, Rodríguez-Pérez JC, Sans L, Torra R; on behalf of the Spanish Working Group on Inherited Kidney Disease. Spanish guidelines for the management of autosomal dominant polycystic kidney disease. *Nephrol Dial Transplant*. 2014 Sep;29(suppl 4):iv95-iv105. PMID: 25165191.
318. Gracia-Iguacel C, González-Parra E, Egido J, Lindholm B, Mahillo I, Carrero JJ, Ortiz A. Cortisol levels are associated with mortality risk in hemodialysis patients. *Clin Nephrol*. 2014 Oct;82:247-256
319. Fernandez-Fernandez B, Martin-Cleary C, Ortiz A. Bicarbonate therapy, phosphate binders, and risk for vascular calcification. *Kidney Int*. 2014 Nov;86(5):1056. PMID: 25360495
320. Montañez-Barragán A, Gómez-Barrera I, Sanchez-Niño MD, Uceró AC, González-Espinoza L, Ortiz A. Osteoprotegerin and kidney disease. *J Nephrol*. 2014 Dec;27(6):607-17. doi: 10.1007/s40620-014-0092-x. PubMed PMID: 24756971
321. Sanchez-Niño MD, Ortiz A. Differential effects of oral and intravenous l-carnitine on serum lipids: is the microbiota the answer? *Clin Kidney J*. 2014 Oct;7(5):437-41. doi: 10.1093/ckj/sfu099. PubMed PMID: 25878774
322. Martín-Cleary C, Ortiz A. CKD hotspots around the world: where, why and what the lessons are. A CKJ review series. *Clin Kidney J*. 2014 Dec;7(6):519-23. doi: 10.1093/ckj/sfu118. PubMed PMID: 25859368
323. Arroyo D, Betriu A, Martinez-Alonso M, Vidal T, Valdivielso JM, Fernández E; investigators from the NEFRONA study. Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study. *BMC Nephrol*. 2014 Oct 18;15:168. doi: 10.1186/1471-2369-15-168. PubMed PMID: 25326683;
324. Benito-Martin A, Uceró AC, Izquierdo MC, Santamaria B, Picatoste B, Carrasco S, Lorenzo O, Ruiz-Ortega M, Egido J, Ortiz A. Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells. *Biochim Biophys Acta*. 2014 Feb;1842(2):293-303. doi: 10.1016/j.bbadis.2013.11.022. Epub 2013 Nov 25. PubMed PMID: 24287278.
325. Zubiri I, Posada-Ayala M, Sanz-Maroto A, Calvo E, Martin-Lorenzo M, Gonzalez-Calero L, de la Cuesta F, Lopez JA, Fernandez-Fernandez B, Ortiz A, Vivanco F, Alvarez-Llamas G. Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis. *J Proteomics*. 2014 Jan 16;96:92-102. doi: 10.1016/j.jpro.2013.10.037. Epub 2013 Nov 7. PubMed PMID: 24211404.
326. Arce JM, Hernando L, Ortiz A, Díaz M, Polo M, Lombardo M, Robles A. Designing a method to assess and improve the quality of healthcare in Nephrology by means of the Delphi technique. *Nefrologia*. 2014 Mar 19;34(2):158-174
327. Lavoz C, Droguett A, Burgos ME, Carpio DJ, Ortiz A, Egido J, Mezzano S, Ruiz-Ortega M. Translational study of the Notch pathway in hypertensive nephropathy. *Nefrologia*. 2014 May 21;34(3):369-76 PMID: 24798563.
328. Cortés MA, Irrazábal E, García-Jerez A, Bohórquez-Magro L, Luengo A, Ortiz-Arduán A, Calleros L, Rodríguez-Puyol M. Impact of implementing ISO 9001:2008 standard on the Spanish Renal Research Network biobank sample transfer process. *Nefrologia*. 2014 Sep 26;34(5):552-60. PMID: 25036260.
329. Gracia-Iguacel C, González-Parra E, Barril-Cuadrado G, Sánchez R, Egido J, Ortiz-Arduán A, Carrero JJ. Defining protein-energy wasting syndrome in chronic kidney disease: prevalence and clinical implications. *Nefrologia*. 2014 Jul 14;34(4):507-519. PMID: 25036065.
330. Martín-Navarro JA, Gutiérrez-Sánchez MJ, Petkov-Stoyanov V, Ortiz-Arduán A. Rapid progression of polycystic kidney disease during treatment with tumour necrosis factor-neutralising antibodies. *Nefrologia*. 2014;34(5):681-3. doi: 10.3265/Nefrologia.pre2014.Jun.12600. PubMed PMID: 25259825

331. Sanchez-Niño MD, Ortiz A. Thrombotic microangiopathy: expanding genetic, clinical and therapeutic spectra and the need for worldwide implementation of recent advances. *Clin Kidney J.* 2015 Dec;8(6):686-9. doi: 10.1093/ckj/sfv115. PMID: 26613024
332. Zoccali C, Amodeo D, Argiles A, Arici M, D'arrigo G, Evenepoel P, Fliser D, Fox J, Gesualdo L, Jadoul M, Ketteler M, Malyszko J, Massy Z, Mayer G, Ortiz A, Sever M, Vanholder R, Vinck C, Wannier C, Więcek A. The fate of triaged and rejected manuscripts. *Nephrol Dial Transplant.* 2015 Dec;30(12):1947-50. doi: 10.1093/ndt/gfv387. PMID: 26597920
333. Ortiz A, Sanchez-Niño MD. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered. *Drug Des Devel Ther.* 2015 Nov 2;9:5873-4. doi: 10.2147/DDDT.S93371. PMID: 26586938
334. Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, Goldsmith D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Ortiz A, Vanholder R, Wiecek A, Zoccali C, London GM, Stengel B, Fouque D; ERA-EDTA EURECA-m working group; Red de Investigación Renal (REDINREN) network; Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT) network. The double challenge of resistant hypertension and chronic kidney disease. *Lancet.* 2015 Oct 17;386(10003):1588-98. doi: 10.1016/S0140-6736(15)00418-3. PMID: 26530623.
335. Valiño-Rivas L, Baeza-Bermejillo C, Gonzalez-Lafuente L, Sanz AB, Ortiz A, Sanchez-Niño MD. CD74 in Kidney Disease. *Front Immunol.* 2015 Sep 23;6:483. doi: 10.3389/fimmu.2015.00483. PMID: 26441987
336. Perez-Gomez MV, Gonzalez-Parra E, Ortiz A. Haemodialysate: long neglected, difficult to optimize, may modify hard outcomes. *Clin Kidney J.* 2015 Oct;8(5):576-9. doi: 10.1093/ckj/sfv088. PMID: 26413284.
337. Rojas-Rivera J, Fernández-Juárez G, Ortiz A, Hofstra J, Gesualdo L, Tesar V, Wetzels J, Segarra A, Egido J, Praga M. A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study. *Clin Kidney J.* 2015 Oct;8(5):503-10. doi: 10.1093/ckj/sfv075. PMID: 26413273
338. Santamaria B, Marquez E, Lay A, Carew RM, González-Rodríguez Á, Welsh GI, Ni L, Hale LJ, Ortiz A, Saleem MA, Brazil DP, Coward RJ, Valverde ÁM. IRS2 and PTEN are key molecules in controlling insulin sensitivity in podocytes. *Biochim Biophys Acta.* 2015 Dec;1853(12):3224-34. doi: 10.1016/j.bbamcr.2015.09.020. PMID: 26384875.
339. Bozic M, Álvarez Á, de Pablo C, Sanchez-Niño MD, Ortiz A, Dolcet X, Encinas M, Fernandez E, Valdivielso JM. Impaired Vitamin D Signaling in Endothelial Cell Leads to an Enhanced Leukocyte-Endothelium Interplay: Implications for Atherosclerosis Development. *PLoS One.* 2015 Aug 31;10(8):e0136863. doi: 10.1371/journal.pone.0136863. PMID: 26322890
340. GBD 2013 DALYs and HALE Collaborators, . Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. *Lancet.* 2015 Nov 28;386(10009):2145-91. doi: 10.1016/S0140-6736(15)61340-X. PMID: 26321261.
341. Esteras R, Perez-Gomez MV, Rodriguez-Osorio L, Ortiz A, Fernandez-Fernandez B. Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function. *Ther Adv Drug Saf.* 2015 Aug;6(4):166-76. doi: 10.1177/2042098615589905. PMID: 26301070
342. Rodríguez-Osorio L, Zambrano DP, Gracia-Iguacel C, Rojas-Rivera J, Ortiz A, Egido J, González Parra E. Use of sevelamer in chronic kidney disease: beyond phosphorus control. *Nefrologia.* 2015;35(2):207-17. doi: 10.1016/j.nefro.2015.05.022. PMID: 26300515.
343. Rodriguez-Osorio L, Ortiz A. Timing of eculizumab therapy for C3 glomerulonephritis. *Clin Kidney J.* 2015 Aug;8(4):449-52. doi: 10.1093/ckj/sfv065. PMID: 26251715
344. Afsar B, Ortiz A, Covic A, Gaipov A, Esen T, Goldsmith D, Kanbay M. Phosphodiesterase type 5 inhibitors and kidney disease. *Int Urol Nephrol.* 2015 Sep;47(9):1521-8. doi: 10.1007/s11255-015-1071-4. PMID: 26242375.
345. Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, Martín-Cleary C, Ruiz-Ortega M, Egido J, Navarro-González JF, Ortiz A, Fernandez-Fernandez B. Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade. *J Clin Med.* 2015 Jun 18;4(6):1325-47. doi: 10.3390/jcm4061325. PMID: 26239562
346. Sanchez-Niño MD, Carpio D, Sanz AB, Ruiz-Ortega M, Mezzano S, Ortiz A. Lyso-Gb3 activates Notch1 in human podocytes. *Hum Mol Genet.* 2015 Oct 15;24(20):5720-32. doi: 10.1093/hmg/ddv291. PMID: 26206887.
347. Rodriguez-Osorio L, Vanessa Perez-Gomez M, Ortiz A. Decreasing incidence of renal replacement therapy over time at the critical 50-59-year age range suggests a role for nephroprotective therapy in ADPKD. *Kidney Int.* 2015 Jul;88(1):194. doi: 10.1038/ki.2015.95. PMID: 26126094.

348. Rodrigues-Díez R, Rayego-Mateos S, Orejudo M, Aroeira LS, Selgas R, Ortiz A, Egido J, Ruiz-Ortega M. TGF- $\beta$  Blockade Increases Renal Inflammation Caused by the C-Terminal Module of the CCN2. *Mediators Inflamm.* 2015;2015:506041. doi: 10.1155/2015/506041. PMID: 26074680
349. Zubiri I, Posada-Ayala M, Benito-Martin A, Maroto AS, Martin-Lorenzo M, Cannata-Ortiz P, de la Cuesta F, Gonzalez-Calero L, Barderas MG, Fernandez-Fernandez B, Ortiz A, Vivanco F, Alvarez-Llamas G. Kidney tissue proteomics reveals regucalcin downregulation in response to diabetic nephropathy with reflection in urinary exosomes. *Transl Res.* 2015 Nov;166(5):474-484.e4. doi: 10.1016/j.trsl.2015.05.007. PMID: 26072307.
350. Morgado-Pascual JL, Rayego-Mateos S, Valdivielso JM, Ortiz A, Egido J, Ruiz-Ortega M. Paricalcitol Inhibits Aldosterone-Induced Proinflammatory Factors by Modulating Epidermal Growth Factor Receptor Pathway in Cultured Tubular Epithelial Cells. *Biomed Res Int.* 2015;2015:783538. doi: 10.1155/2015/783538. PMID: 26064952
351. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet.* 2015 Aug 22;386(9995):743-800. doi: 10.1016/S0140-6736(15)60692-4. PMID: 26063472.
352. Gonzalez-Espinoza L, Ortiz A. 2012 ERA-EDTA Registry Annual Report: cautious optimism on outcomes, concern about persistent inequalities and data black-outs. *Clin Kidney J.* 2015 Jun;8(3):243-7. doi: 10.1093/ckj/sfv035. PMID: 26034583
353. Ortiz A, Fernandez-Fernandez B. Humble kidneys predict mighty heart troubles. *Lancet Diabetes Endocrinol.* 2015 Jul;3(7):489-91. doi: 10.1016/S2213-8587(15)00092-3. PMID: 26028595.
354. Zoccali C, Bolignano D, D'Arrigo G, Dekker FW, Fliser D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Massy Z, Ortiz A, Parati G, Rossignol P, Tripepi G, Vanholder R, Wiecek A, London G; European Renal and Cardiovascular Medicine (EURECA-m) Working Group of the European Renal Association-European Dialysis Transplantation Association (ERA-EDTA). Validity of Vascular Calcification as a Screening Tool and as a Surrogate End Point in Clinical Research. *Hypertension.* 2015 Jul;66(1):3-9. doi: 10.1161/HYPERTENSIONAHA.115.04801. PMID: 25966492.
355. Yuste C, Gutierrez E, Sevillano AM, Rubio-Navarro A, Amaro-Villalobos JM, Ortiz A, Egido J, Praga M, Moreno JA. Pathogenesis of glomerular haematuria. *World J Nephrol.* 2015 May 6;4(2):185-95. doi: 10.5527/wjn.v4.i2.185. PMID: 25949932
356. Elewa U, Fernandez-Fernandez B, Alegre R, Sanchez-Niño MD, Mahillo-Fernández I, Perez-Gomez MV, El-Fishawy H, Belal D, Ortiz A. Modifiable risk factors for increased arterial stiffness in outpatient nephrology. *PLoS One.* 2015 Apr 16;10(4):e0123903. doi: 10.1371/journal.pone.0123903. PMID: 25880081.
357. Ramos AM, González-Guerrero C, Sanz A, Sanchez-Niño MD, Rodríguez-Orsorio L, Martín-Cleary C, Fernández-Fernández B, Ruiz-Ortega M, Ortiz A. Designing drugs that combat kidney damage. *Expert Opin Drug Discov.* 2015 May;10(5):541-56. doi: 10.1517/17460441.2015.1033394. PMID: 25840605.
358. Ortiz A, Sanchez-Niño MD, Izquierdo MC, Martín-Cleary C, Garcia-Bermejo L, Moreno JA, Ruiz-Ortega M, Draibe J, Cruzado JM, Garcia-Gonzalez MA, Lopez-Novoa JM, Soler MJ, Sanz AB; Red de Investigación Renal (REDINREN) and Consorcio Madrileño para investigación del fracaso renal agudo (CIFRA). Translational value of animal models of kidney failure. *Eur J Pharmacol.* 2015 Jul 15;759:205-20. doi: 10.1016/j.ejphar.2015.03.026. PMID: 25814248.
359. Santamaría B, Ucero AC, Benito-Martin A, Vicent MJ, Orzáez M, Celdrán A, Selgas R, Ruíz-Ortega M, Ortiz A. Biocompatibility reduces inflammation-induced apoptosis in mesothelial cells exposed to peritoneal dialysis fluid. *Blood Purif.* 2015;39(1-3):200-9. PMID: 25765663.
360. Esteban J, Ortiz A, Fernández-Roblas R. Healthcare-associated infections: new challenges looking for answers. *Clin Kidney J.* 2015 Feb;8(1):100-1. doi: 10.1093/ckj/sfu143. PMID: 25713717
361. Ortiz A. Translational nephrology: what translational research is and a bird's-eye view on translational research in nephrology. *Clin Kidney J.* 2015 Feb;8(1):14-22. doi: 10.1093/ckj/sfu142. PMID: 25713705
362. Ortiz A. Welcome to the new ckj: an open-access resource integrating clinical, translational and educational research into clinical practice. *Clin Kidney J.* 2015 Feb;8(1):1-2. doi: 10.1093/ckj/sfu138. PMID: 25713702
363. Sanchez-Niño MD, Fernandez-Fernandez B, Perez-Gomez MV, Poveda J, Sanz AB, Cannata-Ortiz P, Ruiz-Ortega M, Egido J, Selgas R, Ortiz A. Albumin-induced apoptosis of tubular cells is modulated by BASP1. *Cell Death Dis.* 2015 Feb 12;6:e1644. doi: 10.1038/cddis.2015.1. PMID: 25675304
364. Coto E, Gómez J, Suárez B, Tranche S, Díaz-Corte C, Ortiz A, Ruiz-Ortega M, Coto-Segura P, Batalla A, López-Larrea C. Association between the IL17RA rs4819554 polymorphism and reduced renal filtration rate in the Spanish RENASTUR cohort. *Hum Immunol.* 2015 Mar;76(2-3):75-8. doi: 10.1016/j.humimm.2015.01.027. PMID: 25636567.
365. Schanstra JP, Zürgbig P, Alkhalaf A, Argiles A, Bakker SJ, Beige J, Bilo HJ, Chatzikyrkou C, Dakna M, Dawson J, Delles C, Haller H, Haubitz M, Husi H, Jankowski J, Jerums G, Kleefstra N, Kuznetsova T, Maahs DM, Menne J,

- Mullen W, Ortiz A, Persson F, Rossing P, Ruggenti P, Rychlik I, Serra AL, Siwy J, Snell-Bergeon J, Spasovski G, Staessen JA, Vlahou A, Mischak H, Vanholder R. Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. *J Am Soc Nephrol*. 2015 Aug;26(8):1999-2010. doi: 10.1681/ASN.2014050423. PMID: 25589610
366. Berzal S, González-Guerrero C, Rayego-Mateos S, Uceró Á, Ocaña-Salceda C, Egido J, Ortiz A, Ruiz-Ortega M, Ramos AM. TNF-related weak inducer of apoptosis (TWEAK) regulates junctional proteins in tubular epithelial cells via canonical NF- $\kappa$ B pathway and ERK activation. *J Cell Physiol*. 2015 Jul;230(7):1580-93. doi: 10.1002/jcp.24905. PMID: 25536182.
367. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015 Jan 10;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2. PMID: 25530442.
368. Ferreira S, Ortiz A, Germain DP, Viana-Baptista M, Caldeira-Gomes A, Camprecios M, Fenollar-Cortés M, Gallegos-Villalobos Á, Garcia D, García-Robles JA, Egido J, Gutiérrez-Rivas E, Herrero JA, Mas S, Oancea R, Péres P, Salazar-Martín LM, Solera-García J, Alves H, Garman SC, Oliveira JP. The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies. *Mol Genet Metab*. 2015 Feb;114(2):248-58. doi: 10.1016/j.ymgme.2014.11.004. PMID: 25468652
369. Alique M, Sánchez-López E, Rayego-Mateos S, Egido J, Ortiz A, Ruiz-Ortega M. Angiotensin II, via angiotensin receptor type 1/nuclear factor- $\kappa$ B activation, causes a synergistic effect on interleukin-1- $\beta$ -induced inflammatory responses in cultured mesangial cells. *J Renin Angiotensin Aldosterone Syst*. 2015 Mar;16(1):23-32. doi: 10.1177/1470320314551564. PMID: 25354522.
370. Janeiro D, Portolés J, Tato AM, López-Sánchez P, Del Peso G, Rivera M, Castellano I, Fernández-Reyes MJ, Pérez-Gómez V, Ortega M, Martínez-Miguel P, Felipe C, Caparrós G, Ortiz A, Selgas R; Grupo Centro de Diálisis Peritoneal (GCDP). Peritoneal Dialysis Can Be an Option for Dominant Polycystic Kidney Disease: an Observational Study. *Perit Dial Int*. 2015 Sep-Oct;35(5):530-6. doi: 10.3747/pdi.2014.00029. PMID: 25292408.
371. Buendía P, Carracedo J, Soriano S, Madueño JA, Ortiz A, Martín-Malo A, Aljama P, Ramírez R. Klotho Prevents NF $\kappa$ B Translocation and Protects Endothelial Cell From Senescence Induced by Uremia. *J Gerontol A Biol Sci Med Sci*. 2015 Oct;70(10):1198-209. doi: 10.1093/gerona/glu170. PMID: 25246106.
372. van der Tol L, Svarstad E, Ortiz A, Tøndel C, Oliveira JP, Vogt L, Waldek S, Hughes DA, Lachmann RH, Terry W, Hollak CE, Florquin S, van den Bergh Weerman MA, Wanner C, West ML, Biegstraaten M, Linthorst GE. Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis. *Mol Genet Metab*. 2015 Feb;114(2):242-7. doi: 10.1016/j.ymgme.2014.08.007. PMID: 25187469.
373. Rodrigues-Diez RR, Garcia-Redondo AB, Orejudo M, Rodrigues-Diez R, Briones AM, Bosch-Panadero E, Kery G, Pato J, Ortiz A, Salaces M, Egido J, Ruiz-Ortega M. The C-terminal module IV of connective tissue growth factor, through EGFR/Nox1 signaling, activates the NF- $\kappa$ B pathway and proinflammatory factors in vascular smooth muscle cells. *Antioxid Redox Signal*. 2015 Jan 1;22(1):29-47. doi: 10.1089/ars.2013.5500. PMID: 25065408
374. Sanchez-Niño MD, Ortiz A. 'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians. *Nephrol Dial Transplant*. 2015 Mar;30(3):394-400. doi: 10.1093/ndt/gfu213. PMID: 24914092.
375. Ronco C, Verger C, Crepaldi C, Pham J, De Los Ríos T, Gauly A, Wabel P, Van Biesen W; IPOD-PD Study Group. Baseline hydration status in incident peritoneal dialysis patients: the initiative of patient outcomes in dialysis (IPOD-PD study). *Nephrol Dial Transplant*. 2015 May;30(5):849-58. doi: 10.1093/ndt/gfv013. PMID: 25762355
376. Campos P, Ortiz A, Soto K. HIV and kidney diseases: 35 years of history and consequences. *Clin Kidney J*. 2016 Dec;9(6):772-781. PMID:27994853.
377. Turkmen K, Guclu A, Sahin G, Kocyigit I, Demirtas L, Erdur FM, Sengül E, Ozkan O, Emre H, Turgut F, Unal H, Karaman M, Acikel C, Esen H, Balli E, Bitirgen G, Tonbul HZ, Yilmaz MI, Ortiz A. The Prevalence of Fabry Disease in Patients with Chronic Kidney Disease in Turkey: The TURKFAB Study. *Kidney Blood Press Res*. 2016 Dec 23;41(6):1016-1024. doi: 10.1159/000452605. PMID: 28006774
378. Solak Y, Siriopol D, Yildiz A, Yilmaz MI, Ortiz A, Covic A, Kanbay M. Colchicine in Renal Medicine: New Virtues of an Ancient Friend. *Blood Purif*. 2016 Dec 13;43(1-3):125-135. PMID: 27951538
379. Fernandez-Prado R, Castillo-Rodriguez E, Velez-Arribas FJ, Gracia-Iguacel C, Ortiz A. Creatinine Clearance Is Not Equal to Glomerular Filtration Rate and Cockcroft-Gault Equation Is Not Equal to CKD-EPI Collaboration Equation. *Am J Med*. 2016 Dec;129(12):1259-1263. PMID: 27612441
380. Ruiz-Andres O, Sanchez-Niño MD, Moreno JA, Ruiz-Ortega M, Ramos AM, Sanz AB, Ortiz A. Downregulation of kidney expression of protective factors by renal and systemic inflammation: role of transcription factors and epigenetic mechanisms. *Am J Physiol Renal Physiol*. 2016 Dec 1;311(6):F1329-F1340. doi: 10.1152/ajprenal.00487.2016. PMID: 27760772.

381. Elewa U, Sanchez-Niño MD, Mahillo-Fernández I, Martin-Cleary C, Belen Sanz A, Perez-Gomez MV, Fernandez-Fernandez B, Ortiz A. Circulating CXCL16 in Diabetic Kidney Disease. *Kidney Blood Press Res.* 2016;41(5):663-671. PMID: 27665581.
382. Wiraswati HL, Hangen E, Sanz AB, Lam NV, Reinhardt C, Sauvat A, Mogha A, Ortiz A, Kroemer G, Modjtahedi N. Apoptosis inducing factor (AIF) mediates lethal redox stress induced by menadione. *Oncotarget.* 2016 Nov 22;7(47):76496-76507. doi: 10.18632/oncotarget.12562. PMID: 27738311
383. GBD 2015 Risk Factors Collaborators (Alberto Ortiz included). Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet.* 2016 Oct 8;388(10053):1659-1724. doi: 10.1016/S0140-6736(16)31679-8. PMID: 27733284.
384. GBD 2015 DALYs and HALE Collaborators (Alberto Ortiz included). Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet.* 2016 Oct 8;388(10053):1603-1658. doi: 10.1016/S0140-6736(16)31460-X. PMID: 27733283.
385. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (Alberto Ortiz included). Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet.* 2016 Oct 8;388(10053):1545-1602. doi: 10.1016/S0140-6736(16)31678-6. PMID: 27733282.
386. GBD 2015 Mortality and Causes of Death Collaborators (Alberto Ortiz included). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet.* 2016 Oct 8;388(10053):1459-1544. doi: 10.1016/S0140-6736(16)31012-1. PMID: 27733281.
387. Trimarchi H, Canzonieri R, Schiel A, Costales-Collaguazo C, Politei J, Stern A, Paulero M, Rengel T, Andrews J, Forrester M, Lombi M, Pomeranz V, Iriarte R, Muryan A, Zotta E, Sanchez-Niño MD, Ortiz A. Increased urinary CD80 excretion and podocyturia in Fabry disease. *J Transl Med.* 2016 Oct 13;14(1):289. PMID: 27733175
388. GBD 2015 SDG Collaborators (Alberto Ortiz included). Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. *Lancet.* 2016 Oct 8;388(10053):1813-1850. doi: 10.1016/S0140-6736(16)31467-2. PMID: 27665228.
389. Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, Zheng B, Martín-Cleary C, Ruiz-Ortega M, Ortiz A, Fernandez-Fernandez B. Targeting inflammation in diabetic kidney disease: early clinical trials. *Expert Opin Investig Drugs.* 2016 Sep;25(9):1045-58. doi: 10.1080/13543784.2016.1196184. PMID: 27268955
390. Hopkin RJ, Cabrera G, Charrow J, Lemay R, Martins AM, Mauer M, Ortiz A, Patel MR, Sims K, Waldek S, Warnock DG, Wilcox WR. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. *Mol Genet Metab.* 2016 Sep;119(1-2):151-9. doi: 10.1016/j.ymgme.2016.06.007. PMID: 27510433.
391. González-Parra E, Aceña Á, Lorenzo Ó, Tarín N, González-Casaus ML, Cristóbal C, Huelmos A, Mahillo-Fernández I, Pello AM, Carda R, Hernández-González I, Alonso J, Rodríguez-Artalejo F, López-Bescós L, Ortiz A, Egido J, Tuñón J. Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate. *J Bone Miner Metab.* 2016 Sep;34(5):587-98. PMID: 26298279.
392. Hénaut L, Sanz AB, Martin-Sanchez D, Carrasco S, Villa-Bellosta R, Aldamiz-Echevarria G, Massy ZA, Sanchez-Niño MD, Ortiz A. TWEAK favors phosphate-induced calcification of vascular smooth muscle cells through canonical and non-canonical activation of NFκB. *Cell Death Dis.* 2016 Jul 21;7:e2305. doi: 10.1038/cddis.2016.220. PMID: 27441657.
393. Elewa U, Fernández-Fernández B, Mahillo-Fernández I, Martin-Cleary C, Sanz AB, Sanchez-Niño MD, Ortiz A. PCSK9 in diabetic kidney disease. *Eur J Clin Invest.* 2016 Sep;46(9):779-86. doi: 10.1111/eci.12661. PMID: 27438893.
394. Valiño-Rivas L, Gonzalez-Lafuente L, Sanz AB, Ruiz-Ortega M, Ortiz A, Sanchez-Niño MD. Non-canonical NFκB activation promotes chemokine expression in podocytes. *Sci Rep.* 2016 Jun 29;6:28857. doi: 10.1038/srep28857. PMID: 27353019
395. Sanz AB, Ruiz-Andres O, Sanchez-Niño MD, Ruiz-Ortega M, Ramos AM, Ortiz A. Out of the TWEAKlight: Elucidating the Role of Fn14 and TWEAK in Acute Kidney Injury. *Semin Nephrol.* 2016 May;36(3):189-98. doi: 10.1016/j.semnephrol.2016.03.006. PMID: 27339384.
396. Rodrigues-Diez R, González-Guerrero C, Ocaña-Salceda C, Rodrigues-Diez RR, Egido J, Ortiz A, Ruiz-Ortega M, Ramos AM. Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling. *Sci Rep.* 2016 Jun 13;6:27915. doi: 10.1038/srep27915. PMID: 27295076

397. Fernandez-Juarez G, Villacorta J, Ruiz-Roso G, Panizo N, Martinez-Marín I, Marco H, Arrizabalaga P, Díaz M, Perez-Gómez V, Vaca M, Rodríguez E, Cobelo C, Fernandez L, Avila A, Praga M, Quereda C, Ortiz A. Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis. *Clin Kidney J.* 2016 Jun;9(3):381-6. doi: 10.1093/ckj/sfw028. PMID: 27274821.
398. Sanchez-Niño MD, Sanz AB, Ortiz A. Chronicity following ischaemia-reperfusion injury depends on tubular-macrophage crosstalk involving two tubular cell-derived CSF-1R activators: CSF-1 and IL-34. *Nephrol Dial Transplant.* 2016 Sep;31(9):1409-16. PMID: 27190368.
399. Voroneanu L, Ortiz A, Nistor I, Covic A. Atrial fibrillation in chronic kidney disease. *Eur J Intern Med.* 2016 Sep;33:3-13. doi: 10.1016/j.ejim.2016.04.007. PMID: 27155803.
400. Parati G, Ochoa JE, Bilo G, Agarwal R, Covic A, Dekker FW, Fliser D, Heine GH, Jager KJ, Gargani L, Kanbay M, Mallamaci F, Massy Z, Ortiz A, Picano E, Rossignol P, Sarafidis P, Sicari R, Vanholder R, Wiecek A, London G, Zoccali C; European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis Transplantation Association (ERA-EDTA). Hypertension in Chronic Kidney Disease Part 1: Out-of-Office Blood Pressure Monitoring: Methods, Thresholds, and Patterns. *Hypertension.* 2016 Jun;67(6):1093-101. doi: 10.1161/HYPERTENSIONAHA.115.06895. PMID: 27141058.
401. Parati G, Ochoa JE, Bilo G, Agarwal R, Covic A, Dekker FW, Fliser D, Heine GH, Jager KJ, Gargani L, Kanbay M, Mallamaci F, Massy Z, Ortiz A, Picano E, Rossignol P, Sarafidis P, Sicari R, Vanholder R, Wiecek A, London G, Zoccali C; European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis Transplantation Association (ERA-EDTA). Hypertension in Chronic Kidney Disease Part 2: Role of Ambulatory and Home Blood Pressure Monitoring for Assessing Alterations in Blood Pressure Variability and Blood Pressure Profiles. *Hypertension.* 2016 Jun;67(6):1102-10. doi: 10.1161/HYPERTENSIONAHA.115.06896. PMID: 27141057.
402. Ruiz-Andres O, Sanchez-Niño MD, Cannata-Ortiz P, Ruiz-Ortega M, Egido J, Ortiz A, Sanz AB. Histone lysine-crotonylation in acute kidney injury. *Dis Model Mech.* 2016 Jun 1;9(6):633-45. PMID: 27125278
403. Del Pino MD, Ortiz A, Torra R, Hernandez D. PrEFiNe Plan: Strategic plan for Fabry diseases in Nephrology. *Nefrologia.* 2016 Jul-Aug;36(4):376-80. doi: 10.1016/j.nefro.2016.03.009. PMID: 27118193.
404. Yilmaz MI, Siritopol D, Saglam M, Unal HU, Karaman M, Gezer M, Kilinc A, Eyiletten T, Guler AK, Aydin İ, Vural A, Oguz Y, Covic A, Ortiz A, Kanbay M. Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events. *Calcif Tissue Int.* 2016 Aug;99(2):121-30. doi: 10.1007/s00223-016-0136-4. PMID: 27016924.
405. Kanbay M, Afsar B, Siritopol D, Unal HU, Karaman M, Saglam M, Eyiletten T, Gezer M, Verim S, Oguz Y, Vural A, Ortiz A, Johnson RJ, Covic A, Yilmaz MI. Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients. *Int Urol Nephrol.* 2016 Jul;48(7):1129-36. doi: 10.1007/s11255-016-1271-6. PMID: 27007614.
406. Sag AA, Sos TA, Benli C, Sal O, Rossignol P, Ortiz A, Solak Y, Kanbay M. Atherosclerotic renal artery stenosis in the post-CORAL era part 2: new directions in Transcatheter Nephron Salvage following flawed revascularization trials. *J Am Soc Hypertens.* 2016 Apr;10(4):368-77. doi: 10.1016/j.jash.2016.02.005. PMID: 26996432.
407. Ortiz A, Abiose A, Bichet DG, Cabrera G, Charrow J, Germain DP, Hopkin RJ, Jovanovic A, Linhart A, Maruti SS, Mauer M, Oliveira JP, Patel MR, Politei J, Waldek S, Wanner C, Yoo HW, Warnock DG. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase  $\beta$ : data from the Fabry Registry. *J Med Genet.* 2016 Jul;53(7):495-502. doi: 10.1136/jmedgenet-2015-103486. PMID: 26993266
408. Vanholder R, Fouque D, Glorieux G, Heine GH, Kanbay M, Mallamaci F, Massy ZA, Ortiz A, Rossignol P, Wiecek A, Zoccali C, London GM; European Renal Association European Dialysis; Transplant Association (ERA-EDTA) European Renal; Cardiovascular Medicine (EURECA-m) working group. Clinical management of the uraemic syndrome in chronic kidney disease. *Lancet Diabetes Endocrinol.* 2016 Apr;4(4):360-73. doi: 10.1016/S2213-8587(16)00033-4. PMID: 26948372.
409. Sag AA, Inal I, Okcuoglu J, Rossignol P, Ortiz A, Afsar B, Sos TA, Kanbay M. Atherosclerotic renal artery stenosis in the post-CORAL era part 1: the renal penumbra concept and next-generation functional diagnostic imaging. *J Am Soc Hypertens.* 2016 Apr;10(4):360-7. doi: 10.1016/j.jash.2016.02.009. PMID: 26944791.
410. Lindhardt M, Persson F, Currie G, Pontillo C, Beige J, Delles C, von der Leyen H, Mischak H, Navis G, Noutsou M, Ortiz A, Ruggerenti PL, Rychlik I, Spasovski G, Rossing P. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephropathy in Type 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. *BMJ Open.* 2016 Mar 2;6(3):e010310. doi: 10.1136/bmjopen-2015-010310. PMID: 26936907
411. Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt KU, Emma F, Knebelmann B, Le Meur Y, Massy ZA, Ong AC, Ortiz A, Schaefer F, Torra R, Vanholder R, Wiecek A, Zoccali C,

- Van Biesen W. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. *Nephrol Dial Transplant*. 2016 Mar;31(3):337-48. doi: 10.1093/ndt/gfv456. PMID: 26908832
412. Janeiro D, Portolés J, Lopez-Sanchez P, Tornero F, Felipe C, Castellano I, Rivera M, Fernandez-Cusicanqui J, Cirugeda A, Fernandez-Reyes MJ, Rodriguez-Palomares JR, Bajo MA, Caparrós G, Ortiz A; Grupo Centro de Diálisis Peritoneal (GCDP) RedinRen. How should we analyze and present mortality in our patients?: A multicentre GCDP experience. *Nefrologia*. 2016;36(2):149-55. doi:10.1016/j.nefro.2015.09.014. PMID: 26851832.
413. Afsar B, Ortiz A, Covic A, Solak Y, Goldsmith D, Kanbay M. Focus on renal congestion in heart failure. *Clin Kidney J*. 2016 Feb;9(1):39-47. doi: 10.1093/ckj/sfv124. PMID: 26798459;
414. Gonzalez-Calero L, Martin-Lorenzo M, Ramos-Barron A, Ruiz-Criado J, Maroto AS, Ortiz A, Gomez-Alamillo C, Arias M, Vivanco F, Alvarez-Llamas G. Urinary Kininogen-1 and Retinol binding protein-4 respond to Acute Kidney Injury: predictors of patient prognosis? *Sci Rep*. 2016 Jan 21;6:19667. doi: 10.1038/srep19667. PMID: 26792617.
415. Hénaut L, Sanchez-Nino MD, Aldamiz-Echevarría Castillo G, Sanz AB, Ortiz A. Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification. *Expert Opin Ther Targets*. 2016;20(1):89-105. doi: 10.1517/14728222.2015.1081685. PMID: 26788590.
416. Poveda J, Sanz AB, Rayego-Mateos S, Ruiz-Ortega M, Carrasco S, Ortiz A, Sanchez-Niño MD. NFκB protein downregulation in acute kidney injury: Modulation of inflammation and survival in tubular cells. *Biochim Biophys Acta*. 2016 Apr;1862(4):635-46. doi: 10.1016/j.bbadis.2016.01.006. PMID: 26776679.
417. Cannata-Ortiz P, Gracia C, Aouad Y, Barat A, Martinez-Gonzalez MA, Rossello G, Martin-Cleary C, Fernández-Fernández B, Requena L, Ortiz A. Small vessel microembolization and acute glomerulonephritis following infection of aesthetic filler implants. *Diagn Pathol*. 2016 Jan 8;11:2. doi: 10.1186/s13000-016-0453-y. PMID: 26746693;
418. Donate-Correa J, Martín-Núñez E, Delgado NP, de Fuentes MM, Arduan AO, Mora-Fernández C, Navarro González JF. Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes. *Cytokine Growth Factor Rev*. 2016 Apr;28:71-7. doi: 10.1016/j.cytogfr.2015.12.003. PMID: 26706229.
419. Gracia M, Betriu À, Martínez-Alonso M, Arroyo D, Abajo M, Fernández E, Valdivielso JM; NEFRONA Investigators. Predictors of Subclinical Atheromatosis Progression over 2 Years in Patients with Different Stages of CKD. *Clin J Am Soc Nephrol*. 2016 Feb 5;11(2):287-96. doi: 10.2215/CJN.01240215. PMID: 26668022
420. Ruiz-Andres O, Suarez-Alvarez B, Sánchez-Ramos C, Monsalve M, Sanchez-Niño MD, Ruiz-Ortega M, Egido J, Ortiz A, Sanz AB. The inflammatory cytokine TWEAK decreases PGC-1 $\alpha$  expression and mitochondrial function in acute kidney injury. *Kidney Int*. 2016 Feb;89(2):399-410. PMID: 26535995.
421. Bosch-Panadero E, Mas S, Sanchez-Ospina D, Camarero V, Pérez-Gómez MV, Saez-Calero I, Abaigar P, Ortiz A, Egido J, González-Parra E. The Choice of Hemodialysis Membrane Affects Bisphenol A Levels in Blood. *J Am Soc Nephrol*. 2016 May;27(5):1566-74. doi: 10.1681/ASN.2015030312. PMID: 26432902
422. Land WG, Agostinis P, Gasser S, Garg AD, Linkermann A on behalf of: Abendroth DK, Adam D, Anders HJ, Arbogast HP, Baan C, Bahram S, Becker JU, Bonventre JV, Brasen JH, Cantley LG, Chandraker A, Daar A, Daehn I, Dragun D, Dubernard JM, Falk CS, Georgel P, Green DR, Grinyo J, Haberal M, Haller H, Halloran PF, Heller JO, Hertig A, Hilbrands L, Huber TB, Janssen O, Jevnikar AM, Kirk AD, Kitsis RN, Kupiec-Weglinski J, Kundendorf U, Kroemer G, Kurts C, Ma D, Maltzman J, Margreiter R, Massard G, Messmer K, Morris R, Murphy J, Nashan B, Oberst A, Ortiz A, Overholtzer M, Ponticelli C, Rothstein DM, Sanz AB, Schiffer M, Schroppel B, Schulte K, Seong SY, Sibilía J, Siedlecki AM; Sollinger HW, Strom TB, Stockwell BR, Szabo AT, Tonnus W, Trivedi HL, Tullius SG, Turka LA, Turnquist H, Vandenabeele P, Vanden Berghe T, Henning Walczak, Weinberg JM, Wolf P, Zierleyn A. DAMP-Induced Allograft and Tumor Rejection: The Circle Is Closing. *Am J Transplant*. 2016 Dec;16(12):3322-3337. doi: 10.1111/ajt.14012. Epub 2016 Sep 21. Review. PubMed PMID: 27529775.
423. Ortiz A, Sanchez-Niño MD. Glucosylceramides and kidney disease. *Port J Nephrol Hypert* 2017;31:200-206.
424. Ortiz A, Sanchez-Niño MD. Diagnosis and treatment of Fabry disease. *Med Clin (Barc)*. 2017 Feb 9;148(3):132-138 PMID: 27912900.
425. Martínez-Miguel P, Medrano-Andrés D, Griera-Merino M, Ortiz A, Rodríguez-Puyol M, Rodríguez-Puyol D, López-Ongil S. Tweak Up-Regulates Endothelin-1 System in Mouse and Human Endothelial Cells. *Cardiovasc Res*. 2017 Feb;113(2):207-221. doi: 10.1093/cvr/cvw239. PMID: 28025386
426. Abajo M, Betriu À, Arroyo D, Gracia M, Del Pino MD, Martínez I, Valdivielso JM, Fernández E; investigators of the NEFRONA study. Mineral metabolism factors predict accelerated progression of common carotid intima-media thickness in chronic kidney disease: the NEFRONA study. *Nephrol Dial Transplant*. 2017 Nov 1;32(11):1882-1891. PMID: 27566835.
427. Schiffmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, West ML, Wanner C; Conference Participants. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney



- Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. *Kidney Int.* 2017 Feb;91(2):284-293. doi: 10.1016/j.kint.2016.10.004. PMID: 27998644.
428. Siwy J, Zürbig P, Argiles A, Beige J, Haubitz M, Jankowski J, Julian BA, Linde PG, Marx D, Mischak H, Mullen W, Novak J, Ortiz A, Persson F, Pontillo C, Rossing P, Rupperecht H, Schanstra JP, Vlahou A, Vanholder R. Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. *Nephrol Dial Transplant.* 2017 Dec 1;32(12):2079-2089. PMID: 27984204
429. Poveda J, Sanz AB, Fernandez-Fernandez B, Carrasco S, Ruiz-Ortega M, Cannata-Ortiz P, Ortiz A, Sanchez-Niño MD. MXRA5 is a TGF- $\beta$ 1-regulated human protein with anti-inflammatory and anti-fibrotic properties. *J Cell Mol Med.* 2017 Jan;21(1):154-164. doi: 10.1111/jcmm.12953. PMID: 27599751.
430. González-Guerrero C, Cannata-Ortiz P, Guerri C, Egido J, Ortiz A, Ramos AM. TLR4-mediated inflammation is a key pathogenic event leading to kidney damage and fibrosis in cyclosporine nephrotoxicity. *Arch Toxicol.* 2017 Apr;91(4):1925-1939. PMID: 27585667
431. Guillén-Gómez E, Dasilva I, Silva I, Arce Y, Facundo C, Ars E, Breda A, Ortiz A, Guirado L, Ballarín JA, Díaz-Encarnación MM. Early macrophage infiltration and sustained inflammation in kidneys from deceased donors are associated with long-term renal function. *Am J Transplant.* 2017 Mar;17(3):733-743. doi: 10.1111/ajt.13998. PMID: 27496082
432. Martin-Sanchez D, Ruiz-Andres O, Poveda J, Carrasco S, Cannata-Ortiz P, Sanchez-Niño MD, Ruiz Ortega M, Egido J, Linkermann A, Ortiz A, Sanz AB. Ferroptosis, but Not Necroptosis, Is Important in Nephrotoxic Folic Acid-Induced AKI. *J Am Soc Nephrol.* 2017 Jan;28(1):218-229. PMID: 27352622.
433. Suarez-Alvarez B, Morgado-Pascual JL, Rayego-Mateos S, Rodriguez RM, Rodrigues-Diez R, Cannata-Ortiz P, Sanz AB, Egido J, Tharaux PL, Ortiz A, Lopez-Larrea C, Ruiz-Ortega M. Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage. *J Am Soc Nephrol.* 2017 Feb;28(2):504-519. PMID: 27436852.
434. Ortiz A, Husi H, Gonzalez-Lafuente L, Valiño-Rivas L, Fresno M, Sanz AB, Mullen W, Albalat A, Mezzano S, Vlahou T, Mischak H, Sanchez-Niño MD. Mitogen-Activated Protein Kinase 14 Promotes AKI. *J Am Soc Nephrol.* 2017 Mar;28(3):823-836 PMID: 27620989.
435. Castillo-Rodriguez E, Fernandez-Prado R, Martin-Cleary C, Pizarro-Sánchez MS, Sanchez-Niño MD, Sanz AB, Fernandez-Fernandez B, Ortiz A. Kidney Injury Marker 1 and Neutrophil Gelatinase-Associated Lipocalin in Chronic Kidney Disease. *Nephron.* 2017;136(4):263-267 PMID: 27771693.
436. Magalhães P, Pejchinovski M, Markoska K, Banasik M, Klinger M, Švec-Billá D, Rychlík I, Rroji M, Restivo A, Capasso G, Bob F, Schiller A, Ortiz A, Perez-Gomez MV, Cannata P, Sanchez-Niño MD, Naumovic R, Brkovic V, Polenakovic M, Mullen W, Vlahou A, Zürbig P, Pape L, Ferrario F, Denis C, Spasovski G, Mischak H, Schanstra JP. Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies? *Sci Rep.* 2017 Dec 5;7(1):16915. doi: 10.1038/s41598-017-17083-w. PMID: 29208969.
437. Burlacu A, Genovesi S, Goldsmith D, Rossignol P, Ortiz A, Kalra PA, Małyszko J, Banach M, Kanbay M, Covic A. Bleeding in advanced CKD patients on antithrombotic medication - A critical appraisal. *Pharmacol Res.* 2017 Dec 2. pii: S1043-6618(17)31445-7. doi: 10.1016/j.phrs.2017.12.004. PMID: 29208494.
438. Rubio-Navarro A, Sanchez-Niño MD, Guerrero-Hue M, García-Caballero C, Gutiérrez E, Yuste C, Sevillano Á, Praga M, Egea J, Román E, Cannata P, Ortega R, Cortegano I, de Andrés B, Gaspar ML, Cadenas S, Ortiz A, Egido J, Moreno JA. Podocytes are new cellular targets of hemoglobin-mediated renal damage. *J Pathol.* 2017 Dec 4. doi: 10.1002/path.5011. PMID: 29205354
439. Goicoechea M, Sanchez-Niño MD, Ortiz A, García de Vinuesa S, Quiroga B, Bernis C, Morales E, Fernández-Juarez G, de Sequera P, Verdalles U, Verde E, Luño J. Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. *Prostaglandins Leukot Essent Fatty Acids.* 2017 Oct;125:8-13. doi: 10.1016/j.plefa.2017.08.009. PMID: 28987723.
440. Sanchez-Niño MD, Zheng-Lin B, Valiño-Rivas L, Sanz AB, Ramos AM, Luño J, Goicoechea M, Ortiz A. Lesinurad: what the nephrologist should know. *Clin Kidney J.* 2017 Oct;10(5):679-687. doi: 10.1093/ckj/sfx036. PMID: 28979780
441. Martin-Lorenzo M, Gonzalez-Calero L, Ramos-Barron A, Sanchez-Niño MD, Gomez-Alamillo C, García-Segura JM, Ortiz A, Arias M, Vivanco F, Alvarez-Llamas G. Urine metabolomics insight into acute kidney injury point to oxidative stress disruptions in energy generation and H(2)S availability. *J Mol Med (Berl).* 2017 Dec;95(12):1399-1409. doi: 10.1007/s00109-017-1594-5. PMID: 28975359
442. Aymé S, Bockenauer D, Day S, Devuyst O, Guay-Woodford LM, Ingelfinger JR, Klein JB, Knoers NVAM, Perrone RD, Roberts J, Schaefer F, Torres VE, Cheung M, Wheeler DC, Winkelmayr WC; Conference Participants. Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int.* 2017 Oct;92(4):796-808. doi: 10.1016/j.kint.2017.06.018. PMID: 28938953.

443. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017 Sep 16;390(10100):1345-1422. doi: 10.1016/S0140-6736(17)32366-8. PMID: 28919119.
444. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017 Sep 16;390(10100):1260-1344. doi: 10.1016/S0140-6736(17)32130-X. PMID: 28919118.
445. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017 Sep 16;390(10100):1211-1259. doi: 10.1016/S0140-6736(17)32154-2. PMID: 28919117.
446. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017 Sep 16;390(10100):1151-1210. doi: 10.1016/S0140-6736(17)32152-9. PMID: 28919116.
447. GBD 2016 Mortality Collaborators. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017 Sep 16;390(10100):1084-1150. doi: 10.1016/S0140-6736(17)31833-0. PMID: 28919115.
448. GBD 2016 SDG Collaborators. Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. *Lancet*. 2017 Sep 16;390(10100):1423-1459. doi: 10.1016/S0140-6736(17)32336-X. Epub 2017 Sep 12. PMID: 28916366.
449. Azpiazu D, González-Parra E, Ortiz A, Egido J, Villa-Bellosta R. Impact of post-dialysis calcium level on ex vivo rat aortic wall calcification. *PLoS One*. 2017 Aug 23;12(8):e0183730. doi: 10.1371/journal.pone.0183730. eCollection 2017. PMID: 28832652.
450. GBD 2015 Eastern Mediterranean Region Adolescent Health Collaborators, Mokdad AH. Adolescent health in the Eastern Mediterranean Region: findings from the global burden of disease 2015 study. *Int J Public Health*. 2017 Aug 3. doi: 10.1007/s00038-017-1003-4. PMID: 28776253.
451. GBD 2015 Eastern Mediterranean Region Neonatal, Infant, and under-5 Mortality Collaborators, Mokdad AH. Neonatal, infant, and under-5 mortality and morbidity burden in the Eastern Mediterranean region: findings from the Global Burden of Disease 2015 study. *Int J Public Health*. 2017 Aug 3. doi: 10.1007/s00038-017-0998-x. PMID: 28776242.
452. GBD 2015 Eastern Mediterranean Region Diabetes and CKD Collaborators, Mokdad AH. Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. *Int J Public Health*. 2017 Aug 3. doi: 10.1007/s00038-017-1014-1. PMID: 28776240.
453. Poveda J, Sanz AB, Carrasco S, Ruiz-Ortega M, Cannata-Ortiz P, Sanchez-Niño MD, Ortiz A. Bcl3: a regulator of NF- $\kappa$ B inducible by TWEAK in acute kidney injury with anti-inflammatory and antiapoptotic properties in tubular cells. *Exp Mol Med*. 2017 Jul 7;49(7):e352. doi: 10.1038/emmm.2017.89. PMID: 28684863.
454. Martínez-Castelao A, Górriz JL, Ortiz A, Navarro-González JF. ERBP guideline on management of patients with diabetes and chronic kidney disease stage 3B or higher. Metformin for all? *Nefrologia*. 2017 Nov - Dec;37(6):567-571. doi: 10.1016/j.nefro.2017.06.001. PMID: 28669489.
455. Sanchez-Niño MD, Sanz AB, Ramos AM, Ruiz-Ortega M, Ortiz A. Translational science in chronic kidney disease. *Clin Sci (Lond)*. 2017 Jun 30;131(14):1617-1629. doi: 10.1042/CS20160395. PMID: 28667063.
456. Argilés À, Rodríguez M, Ortiz A. Is Plasma Proteomics Able to Provide Alternative Paths to Better Understand Hypertension? *Hypertension*. 2017 Aug;70(2):250-252. doi: 10.1161/HYPERTENSIONAHA.117.09049. PMID: 28652468.
457. Ortiz A, Sanchez-Niño MD. Reply. *Med Clin (Barc)*. 2017 Sep 20;149(6):271-272. doi: 10.1016/j.medcli.2017.05.016. English, Spanish. PMID: 28651882
458. Martin-Sanchez D, Poveda J, Fontecha-Barriuso M, Ruiz-Andres O, Sanchez-Niño MD, Ruiz-Ortega M, Ortiz A, Sanz AB. Targeting of regulated necrosis in kidney disease. *Nefrologia*. 2017 Jun 21. pii: S0211-6995(17)30105-4. doi: 10.1016/j.nefro.2017.04.004. PMID: 28647049.
459. Sanchez-Niño MD, Ortiz A. Does wealth make health? Cherchez la renal replacement therapy. *Clin Kidney J*. 2017 Feb;10(1):45-48. doi: 10.1093/ckj/sfw149. PMID: 28643820
460. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, van Biesen W, Nagler E, Gonzalez-Espinoza L, Ortiz A; Hyponatraemia Guideline Development Group. Hyponatraemia diagnosis and treatment clinical practice

- guidelines. *Nefrologia* 2017 Jul-Aug;37(4):370-380. doi: 10.1016/j.nefro.2017.03.021. PMID: 28619670.
461. Arce JM, Martín Cleary C, Cenfor C, Ramos Á, Ortiz A. Designing a Method with Physician Participation to Assess and Improve Quality of Healthcare in Otolaryngology. *J Int Adv Otol.* 2017 Apr;13(1):128-135. doi: 10.5152/iao.2017.2880. PMID: 28555604.
462. GBD 2015 Healthcare Access and Quality Collaborators. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. *Lancet.* 2017 Jul 15;390(10091):231-266. doi: 10.1016/S0140-6736(17)30818-8. PMID: 28528753.
463. Trimarchi H, Canzonieri R, Schiel A, Politei J, Costales-Collaguazo C, Stern A, Paulero M, Rengel T, Valiño-Rivas L, Forrester M, Lombi F, Pomeranz V, Iriarte R, Muryan A, Ortiz A, Sanchez-Niño MD, Zotta E. Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease. *Int J Nephrol.* 2017;2017:1287289. doi: 10.1155/2017/1287289. PMID: 28523190;
464. Wilcox WR, Feldt-Rasmussen U, Martins AM, Ortiz A, Lemay RM, Jovanovic A, Germain DP, Varas C, Nicholls K, Weidemann F, Hopkin RJ. Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry. *JIMD Rep.* 2017 May 17. doi: 10.1007/8904\_2017\_28. PMID: 28510034
465. Fernandez-Prado R, Esteras R, Perez-Gomez MV, Gracia-Iguacel C, Gonzalez-Parra E, Sanz AB, Ortiz A, Sanchez-Niño MD. Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease. *Nutrients.* 2017 May 12;9(5). pii: E489. doi: 10.3390/nu9050489. PMID: 28498348.
466. Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, Fliser D, Fouque D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Parati G, Rossignol P, Wiecek A, London G; European Renal and Cardiovascular Medicine (EURECA-m) Working Group of the European Renal Association – European Dialysis Transplantation Association (ERA-EDTA). The systemic nature of CKD. *Nat Rev Nephrol.* 2017 Jun;13(6):344-358. doi: 10.1038/nrneph.2017.52. PMID: 28435157.
467. Thomas B, Matsushita K, Abate KH, Al-Aly Z, Ärnlöv J, Asayama K, Atkins R, Badawi A, Ballew SH, Banerjee A, Barregård L, Barrett-Connor E, Basu S, Bello AK, Bensenor I, Bergstrom J, Bikbov B, Blosser C, Brenner H, Carrero JJ, Chadban S, Cirillo M, Cortinovis M, Courville K, Dandona L, Dandona R, Estep K, Fernandes J, Fischer F, Fox C, Gansevoort RT, Gona PN, Gutierrez OM, Hamidi S, Hanson SW, Himmelfarb J, Jassal SK, Jee SH, Jha V, Jimenez-Corona A, Jonas JB, Kengne AP, Khader Y, Khang YH, Kim YJ, Klein B, Klein R, Kokubo Y, Kolte D, Lee K, Levey AS, Li Y, Lotufo P, El Razek HM, Mendoza W, Metoki H, Mok Y, Muraki I, Muntner PM, Noda H, Ohkubo T, Ortiz A, Perico N, Polkinghorne K, Al-Radaddi R, Remuzzi G, Roth G, Rothenbacher D, Satoh M, Saum KU, Sawhney M, Schöttker B, Shankar A, Shlipak M, Silva DA, Toyoshima H, Ukwaja K, Umesawa M, Vollset SE, Warnock DG, Werdecker A, Yamagishi K, Yano Y, Yonemoto N, Zaki ME, Naghavi M, Forouzanfar MH, Murray CJ, Coresh J, Vos T; Global Burden of Disease 2013 GFR Collaborators.; CKD Prognosis Consortium.; Global Burden of Disease Genitourinary Expert Group. Global Cardiovascular and Renal Outcomes of Reduced GFR. *J Am Soc Nephrol.* 2017 Jul;28(7):2167-2179. doi: 10.1681/ASN.2016050562. PMID: 28408440.
468. Sanchez-Niño MD, Sanz AB, Ramos AM, Fernandez-Fernandez B, Ortiz A. Clinical proteomics in kidney disease as an exponential technology: heading towards the disruptive phase. *Clin Kidney J.* 2017 Apr;10(2):188-191. doi: 10.1093/cjkj/sfx023. PMID: 28396735
469. Global Burden of Disease Child and Adolescent Health Collaboration, Child and Adolescent Health From 1990 to 2015: Findings From the Global Burden of Diseases, Injuries, and Risk Factors 2015 Study. *JAMA Pediatr.* 2017 Jun 1;171(6):573-592. doi: 10.1001/jamapediatrics.2017.0250. PMID: 28384795
470. Burlacu A, Genovesi S, Ortiz A, Kanbay M, Rossignol P, Banach M, Malyszko J, Goldsmith D, Covic A. The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients. *Nephrol Dial Transplant.* 2017 Dec 1;32(12):1967-1976. doi: 10.1093/ndt/gfx041. PMID: 28371905.
471. Ortiz A. Not all extracellular vesicles were created equal: clinical implications. *Ann Transl Med.* 2017 Mar;5(5):111. doi: 10.21037/atm.2017.01.40. PMID: 28361076
472. Sarafidis PA, Persu A, Agarwal R, Burnier M, de Leeuw P, Ferro CJ, Halimi JM, Heine GH, Jadoul M, Jarraya F, Kanbay M, Mallamaci F, Mark PB, Ortiz A, Parati G, Pontremoli R, Rossignol P, Ruilope L, Van der Niepen P, Vanholder R, Verhaar MC, Wiecek A, Wuerzner G, London GM, Zoccali C. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). *Nephrol Dial Transplant.* 2017 Apr 1;32(4):620-640. doi: 10.1093/ndt/gfw433. PMID: 28340239.
473. Villa-Bellosta R, Rodriguez-Osorio L, Mas S, Abadi Y, Rubert M, de la Piedra C, Gracia-Iguacel C, Mahillo I, Ortiz

- A, Egido J, González-Parra E. A decrease in intact parathyroid hormone (iPTH) levels is associated with higher mortality in prevalent hemodialysis patients. *PLoS One*. 2017 Mar 24;12(3):e0173831. doi: 10.1371/journal.pone.0173831. PMID: 28339474.
474. Castillo-Rodríguez E, Pizarro-Sánchez S, Sanz AB, Ramos AM, Sanchez-Niño MD, Martin-Cleary C, Fernandez-Fernandez B, Ortiz A. Inflammatory Cytokines as Uremic Toxins: "Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son". *Toxins (Basel)* 2017 Mar 23;9(4). pii: E114. doi: 10.3390/toxins9040114. PMID:28333114.
475. El Dib R, Gomaa H, Ortiz A, Politei J, Kapoor A, Barreto F. Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. *PLoS One*. 2017 Mar 15;12(3):e0173358. doi: 10.1371/journal.pone.0173358. PMID: 28296917
476. Prieto I, Del Puerto-Nevado L, Gonzalez N, Portal-Nuñez S, Zazo S, Corton M, Minguez P, Gomez-Guerrero C, Arce JM, Sanz AB, Mas S, Aguilera O, Alvarez-Llamas G, Esbrit P, Ortiz A, Ayuso C, Egido J, Rojo F, Garcia-Foncillas J; DiabetesCancerConnect Consortium. Colon cancer modulation by a diabetic environment: A single institutional experience. *PLoS One*. 2017 Mar 2;12(3):e0172300. doi: 10.1371/journal.pone.0172300. PMID: 28253286
477. Sarafidis PA, Persu A, Agarwal R, Burnier M, de Leeuw P, Ferro C, Halimi JM, Heine G, Jadoul M, Jarraya F, Kanbay M, Mallamaci F, Mark PB, Ortiz A, Parati G, Pontremoli R, Rossignol P, Ruilope L, Van der Niepen P, Vanholder R, Verharr MC, Wiecek A, Wuerzner G, London GM, Zoccali C. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m)working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). *J Hypertens*. 2017 Apr;35(4):657-676. doi: 10.1097/HJH.0000000000001283. PMID: 28157814.
478. Martin-Sanchez D, Gallegos-Villalobos A, Fontecha-Barriuso M, Carrasco S, Sanchez-Niño MD, Lopez-Hernandez FJ, Ruiz-Ortega M, Egido J, Ortiz A, Sanz AB. Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells. *Sci Rep*. 2017 Jan 31;7:41510. doi: 10.1038/srep41510. PMID: 28139717
479. González N, Prieto I, Del Puerto-Nevado L, Portal-Nuñez S, Ardura JA, Corton M, Fernández-Fernández B, Aguilera O, Gomez-Guerrero C, Mas S, Moreno JA, Ruiz-Ortega M, Sanz AB, Sanchez-Niño MD, Rojo F, Vivanco F, Esbrit P, Ayuso C, Alvarez-Llamas G, Egido J, García-Foncillas J, Ortiz A, Consortium DC. 2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. *Oncotarget*. 2017 Mar 14;8(11):18456-18485. doi: 10.18632/oncotarget.14472. PMID: 28060743
480. Zheng-Lin B, Ortiz A. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. *Drugs*. 2018 Feb;78(2):215-229. doi: 10.1007/s40265-017-0858-2. PMID: 29299849.
481. Fernandez-Fernandez B, Izquierdo MC, Valiño-Rivas L, Nastou D, Sanz AB, Ortiz A, Sanchez-Niño MD. Albumin downregulates Klotho in tubular cells. *Nephrol Dial Transplant*. 2018 Feb 7. doi: 10.1093/ndt/gfx376. [Epub ahead of print] PubMed PMID: 29425318.
482. Martin-Sanchez D, Fontecha-Barriuso M, Sanchez-Niño MD, Ramos AM, Cabello R, Gonzalez-Enguita C, Linkermann A, Sanz AB, Ortiz A. Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields. *Cell Death Dis*. 2018 Jan 25;9(2):118. doi: 10.1038/s41419-017-0043-2.. PubMed PMID: 29371637.
483. Fernandez-Prado R, Fernandez-Fernandez B, Ortiz A. Women and renal replacement therapy in Europe: lower incidence, equal access to transplantation, longer survival than men. *Clin Kidney J*. 2018 Feb;11(1):1-6. doi: 10.1093/ckj/sfx154. PubMed PMID: 29423194
484. Bosch-Panadero E, Mas S, Civantos E, Abaigar P, Camarero V, Ruiz-Priego A, Ortiz A, Egido J, González-Parra E. Bisphenol A is an exogenous toxin that promotes mitochondrial injury and death in tubular cells. *Environ Toxicol*. 2018 Mar;33(3):325-332. doi: 10.1002/tox.22519. PMID: 29214717.
485. Rayego-Mateos S, Morgado-Pascual JL, Rodrigues-Diez RR, Rodrigues-Diez R, Falke L, Mezzano S, Ortiz A, Egido J, Goldschmeding R, Ruiz-Ortega M. Connective tissue growth factor induces renal fibrosis via epidermal growth factor receptor activation. *J Pathol*. 2018 Feb;244(2):227-241. doi: 10.1002/path.5007. PMID: 29160908.
486. Fernandez-Fernandez B, Ortiz A. Paricalcitol and albuminuria: tread carefully. *Lancet Diabetes Endocrinol*. 2018 Jan;6(1):3-5. doi: 10.1016/S2213-8587(17)30361-3. PMID: 29104157.
487. von Mässenhausen A, Tonnus W, Himmerkus N, Parmentier S, Saleh D, Rodriguez D, Ousingsawat J, Ang RL, Weinberg JM, Sanz AB, Ortiz A, Zierleyn A, Becker JU, Baratte B, Desban N, Bach S, Schiessl IM, Nogusa S, Balachandran S, Anders HJ, Ting AT, Bleich M, Degterev A, Kunzelmann K, Bornstein SR, Green DR, Hugo C, Linkermann A. Phenytoin inhibits necroptosis. *Cell Death Dis*. 2018 Mar 2;9(3):359. doi: 10.1038/s41419-018-0394-3. PubMed PMID: 29500402
488. Bozic M, Betriu A, Bermudez-Lopez M, Ortiz A, Fernandez E, Valdivielso JM; NEFRONA investigators.

- Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients. *Clin J Am Soc Nephrol*. 2018 Mar 8. pii: CJN.07980717. doi: 10.2215/CJN.07980717. [Epub ahead of print] PubMed PMID: 29519952.
489. Mas S, Bosch-Panadero E, Abaigar P, Camarero V, Mahillo I, Civantos E, Sanchez-Ospina D, Ruiz-Priego A, Egido J, Ortiz A, González-Parra E. Influence of dialysis membrane composition on plasma bisphenol A levels during online hemodiafiltration. *PLoS One*. 2018 Mar 12;13(3):e0193288. doi: 10.1371/journal.pone.0193288. eCollection 2018. PubMed PMID: 29529055.
490. Fontecha-Barriuso M, Martin-Sanchez D, Ruiz-Andres O, Poveda J, Sanchez-Niño MD, Valiño-Rivas L, Ruiz-Ortega M, Ortiz A, Sanz AB. Targeting epigenetic DNA and histone modifications to treat kidney disease. *Nephrol Dial Transplant*. 2018 Mar 9. doi: 10.1093/ndt/gfy009. [Epub ahead of print] PubMed PMID: 29534238.
491. Ortiz A, Germain DP, Desnick RJ, Polítei J, Mauer M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A, Waldek S, Wallace E, Weidemann F, Wilcox WR. Fabry disease revisited: Management and treatment recommendations for adult patients. *Mol Genet Metab*. 2018 Apr;123(4):416-427. doi: 10.1016/j.ymgme.2018.02.014. [Epub ahead of print] Review. PubMed PMID: 29530533
492. Gil RB, Ortiz A, Sanchez-Niño MD, Markoska K, Schepers E, Vanholder R, Glorieux G, Schmitt-Kopplin P, Heinzmann SS. Increased urinary osmolyte excretion indicates chronic kidney disease severity and progression rate. *Nephrol Dial Transplant*. 2018 Mar 14. doi: 10.1093/ndt/gfy020. [Epub ahead of print] PubMed PMID: 29554320.
493. Martin-Sanchez D, Fontecha-Barriuso M, Carrasco S, Sanchez-Niño MD, Mässenhausen AV, Linkermann A, Cannata-Ortiz P, Ruiz-Ortega M, Egido J, Ortiz A, Sanz AB. TWEAK and RIPK1 mediate a second wave of cell death during AKI. *Proc Natl Acad Sci U S A*. 2018 Apr 17;115(16):4182-4187. doi: 10.1073/pnas.1716578115. [Epub ahead of print] PMID: 29588419.
494. Germain DP, Brand E, Burlina A, Cecchi F, Garman SC, Kempf J, Laney DA, Linhart A, Maródi L, Nicholls K, Ortiz A, Pieruzzi F, Shankar SP, Waldek S, Wanner C, Jovanovic A. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. *Mol Genet Genomic Med*. 2018 Apr 12. doi: 10.1002/mgg3.389. [Epub ahead of print] PubMed PMID: 29649853.
495. Ortiz A, Sanchez-Niño MD. Enzyme replacement therapy dose and Fabry nephropathy. *Nephrol Dial Transplant*. 2018 Apr 18. doi: 10.1093/ndt/gfy089. [Epub ahead of print] PubMed PMID: 29684184.
496. Lavoz C, Poveda J, Márquez-Expósito L, Rayego-Mateos S, Rodrigues-Diez RR, Ortiz A, Egido J, Mezzano S, Ruiz-Ortega M. Gremlin activates the Notch pathway linked to renal inflammation. *Clin Sci (Lond)*. 2018 May 2. pii: CS20171553. doi: 10.1042/CS20171553. [Epub ahead of print] PubMed PMID: 29720422.
497. Afsar B, Kuwabara M, Ortiz A, Yerlikaya A, Siriopol D, Covic A, Rodriguez-Iturbe B, Johnson RJ, Kanbay M. Salt Intake and Immunity. *Hypertension*. 2018 May 14. pii: HYPERTENSIONAHA.118.11128. doi: 10.1161/HYPERTENSIONAHA.118.11128. [Epub ahead of print] Review. PubMed PMID: 29760151
498. Tofte N, Lindhardt M, Adamova K, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Kooy A, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Ruggerenti PL, Rutters F, Rychlík I, Spasovski G, Speeckaert M, Trillini M, von der Leyen H, Rossing P. Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes. *Diabet Med*. 2018 May 21. doi: 10.1111/dme.13669. [Epub ahead of print] PubMed PMID: 29781558.
499. Navarro-González JF, Sánchez-Niño MD, Donate-Correa J, Martín-Núñez E, Ferri C, Pérez-Delgado N, Górriz JL, Martínez-Castelao A, Ortiz A, Mora-Fernández C. Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease. *Diabetes Care*. 2018 Jun 4. pii: dc180078. doi: 10.2337/dc18-0078. [Epub ahead of print] PMID: 29866645.
500. GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. *Lancet*. 2018 Jun 2;391(10136):2236-2271. doi: 10.1016/S0140-6736(18)30994-2. Epub 2018 Jun 1. PMID: 29893224
501. Vanholder R, Van Laecke S, Glorieux G, Verbeke F, Castillo-Rodriguez E, Ortiz A. Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). *Toxins (Basel)*. 2018 Jun 12;10(6). pii: E237. doi: 10.3390/toxins10060237. PubMed PMID: 29895722
502. Valiño-Rivas L, Cuarental L, Grana O, Bucala R, Leng L, Sanz A, Gomez G, Ortiz A, Sanchez-Niño MD. TWEAK increases CD74 expression and sensitizes to DDT proinflammatory actions in tubular cells. *PLoS One*. 2018 Jun 20;13(6):e0199391. doi: 10.1371/journal.pone.0199391. eCollection 2018. PubMed PMID: 29924850.
503. Goicoechea M, de Vinuesa SG, Quiroga B, Verde E, Bernis C, Morales E, Fernández-Juárez G, de Sequera P, Verdalles U, Delgado R, Torres A, Arroyo D, Abad S, Ortiz A, Luño J. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter

- Randomized Clinical Trial (AASER Study). *Cardiovasc Drugs Ther.* 2018 Jun;32(3):255-263. doi: 10.1007/s10557-018-6802-1. PubMed PMID: 29943364
504. Castillo-Rodriguez E, Fernandez-Prado R, Ortiz A. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. *N Engl J Med.* 2018 Jun 28;378(26):2539. doi: 10.1056/NEJMc1805679. PubMed PMID: 29952173
505. Afsar B, Covic A, Ortiz A, Afsar RE, Kanbay M. The Future of IL-1 Targeting in Kidney Disease. *Drugs.* 2018 Jul 2. doi: 10.1007/s40265-018-0942-2. [Epub ahead of print] PMID: 29968152
506. Afsar B, Afsar RE, Dagal T, Kaya E, Erus S, Ortiz A, Covic A, Kanbay M. Capillary rarefaction from the kidney point of view. *Clin Kidney J.* 2018 Jun;11(3):295-301. doi: 10.1093/ckj/sfx133. Epub 2017 Nov 28. PubMed PMID: 29988260; PubMed Central PMCID: PMC6007395.
507. González-Guerrero C, Morgado-Pascual JL, Cannata-Ortiz P, Ramos-Barron MA, Gómez-Alamillo C, Arias M, Mezzano S, Egido J, Ruiz-Ortega M, Ortiz A, Ramos AM. CCL20 blockade increases the severity of nephrotoxic folic acid-induced acute kidney injury. *J Pathol.* 2018 Jul 8. doi: 10.1002/path.5132. [Epub ahead of print] PubMed PMID: 29984403.
508. Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, Kantola I, Linhart A, Mignani R, Monserrat L, Namdar M, Nowak A, Oliveira JP, Ortiz A, Pieroni M, Spada M, Tylki-Szymańska A, Tøndel C, Viana-Baptista M, Weidemann F, Hilz MJ. European expert consensus statement on therapeutic goals in Fabry disease. *Mol Genet Metab.* 2018 Jul;124(3):189-203. doi: 10.1016/j.yimgme.2018.06.004. [Epub ahead of print] Review. PubMed PMID: 30017653.
509. Castillo-Rodriguez E, Fernandez-Prado R, Esteras R, Perez-Gomez MV, Gracia-Iguacel C, Fernandez-Fernandez B, Kanbay M, Tejedor A, Lazaro A, Ruiz-Ortega M, Gonzalez-Parra E, Sanz AB, Ortiz A, Sanchez-Niño MD. Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression. *Toxins (Basel).* 2018 Jul 19;10(7). pii: E300. doi: 10.3390/toxins10070300. PMID: 30029499.
510. Soriano JB, Rojas-Rueda D, Alonso J, Antó JM, Cardona PJ, Fernández E, Garcia-Basteiro AL, Benavides FG, Glenn SD, Krish V, Lazarus JV, Martínez-Raga J, Masana MF, Nieuwenhuijsen MJ, Ortiz A, Sánchez-Niño MD, Serrano-Blanco A, Tortajada-Girbés M, Tyrovolas S, Haro JM, Naghavi M, Murray CJL; Colaboradores de GBD en España; Lista de colaboradores de GBD en España. The burden of disease in Spain: Results from the Global Burden of Disease 2016. *Med Clin (Barc).* 2018 Jul 20. pii: S0025-7753(18)30331-2. doi: 10.1016/j.medcli.2018.05.011. [Epub ahead of print] English, Spanish. PubMed PMID: 30037695.
511. Perez-Gomez MV, Martin-Cleary C, Fernandez-Fernandez B, Ortiz A. Meso-American nephropathy: what we have learned about the potential genetic influence on chronic kidney disease development. *Clin Kidney J.* 2018 Aug;11(4):491-495. doi: 10.1093/ckj/sfy070. Epub 2018 Jul 31. PubMed PMID: 30094013; PubMed Central PMCID: PMC6070072.
512. Selby NM, Blankestijn PJ, Boor P, Combe C, Eckardt KU, Eikefjord E, Garcia-Fernandez N, Golay X, Gordon I, Grenier N, Hockings PD, Jensen JD, Joles JA, Kalra PA, Krämer BK, Mark PB, Mendichovszky IA, Nikolic O, Odudu A, Ong ACM, Ortiz A, Pruijm M, Remuzzi G, Rørvik J, de Seigneux S, Simms RJ, Slatinska J, Summers P, Taal MW, Thoeny HC, Vallée JP, Wolf M, Caroli A, Sourbron S. Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. *Nephrol Dial Transplant.* 2018 Sep 1;33(suppl\_2):ii4-ii14. doi: 10.1093/ndt/gfy152. PMID: 30137584.
513. Covic A, Genovesi S, Rossignol P, Kalra PA, Ortiz A, Banach M, Burlacu A. Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. *BMC Med.* 2018 Sep 19;16(1):158. doi: 10.1186/s12916-018-1145-0. PubMed PMID: 30227855.
514. Esteras R, Martín-Navarro J, Ledesma G, Fernández-Prado R, Carreño G, Cintra M, Cidraque I, Sanz I, Tarragón B, Alexandru S, Milla M, Astudillo E, Sánchez E, Mas S, Tejeiro RD, Ortiz A, Sánchez R, González-Parra E. Incidence of Hypersensitivity Reactions During Hemodialysis. *Kidney Blood Press Res.* 2018 Sep 20;43(5):1472-1478. doi: 10.1159/000493662. [Epub ahead of print] PubMed PMID: 30235456.
515. Pérez-Morales RE, Del Pino MD, Valdivielso JM, Ortiz A, Mora-Fernández C, Navarro-González JF. Inflammation in Diabetic Kidney Disease. *Nephron.* 2018 Oct 1:1-5. doi: 10.1159/000493278. [Epub ahead of print]. PubMed PMID: 30273931
516. Sanchez-Niño MD, Ortiz A. Unravelling drug-induced hypertension: molecular mechanisms of aldosterone-independent mineralocorticoid receptor activation by posaconazole. *Clin Kidney J.* 2018 Oct;11(5):688-690. doi: 10.1093/ckj/sfy087. Epub 2018 Sep 20. PubMed PMID: 30289131; PubMed Central PMCID: PMC6165746
517. Perez-Gomez MV, Bartsch LA, Ortiz A. Cardiovascular Safety of Febuxostat. *N Engl J Med.* 2018 Oct 18;379(16):1583. doi: 10.1056/NEJMc1809736. PubMed PMID: 30338967
518. Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C. Lipid management in patients with

- chronic kidney disease. *Nat Rev Nephrol.* 2018 Oct 25. doi: 10.1038/s41581-018-0072-9. [Epub ahead of print] Review. PubMed PMID: 30361677
519. Rodríguez-Ortiz ME, Pontillo C, Rodríguez M, Zürbig P, Mischak H, Ortiz A. Novel Urinary Biomarkers For Improved Prediction Of Progressive eGFR Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease. *Sci Rep.* 2018 Oct 29;8(1):15940. doi: 10.1038/s41598-018-34386-8. PubMed PMID: 30374033.
520. Marquez-Exposito L, Lavoz C, Rodrigues-Diez RR, Rayego-Mateos S, Orejudo M, Cantero-Navarro E, Ortiz A, Egido J, Selgas R, Mezzano S, Ruiz-Ortega M. Gremlin Regulates Tubular Epithelial to Mesenchymal Transition via VEGFR2: Potential Role in Renal Fibrosis. *Front Pharmacol.* 2018 Oct 17;9:1195. doi: 10.3389/fphar.2018.01195. eCollection 2018. PubMed PMID: 30386246
521. Sanz AB, Ramos AM, Soler MJ, Sanchez-Niño MD, Fernandez-Fernandez B, Perez-Gomez MV, Ortega MR, Alvarez-Llamas G, Ortiz A. Advances in understanding the role of angiotensin-regulated proteins in kidney diseases. *Expert Rev Proteomics.* 2018 Nov 9. doi: 10.1080/14789450.2018.1545577. [Epub ahead of print] PubMed PMID: 30412432.
522. Germain DP, Arad M, Burlina A, Elliott PM, Falissard B, Feldt-Rasmussen U, Hilz MJ, Hughes DA, Ortiz A, Wanner C, Weidemann F, Spada M. The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of experts. *Mol Genet Metab.* 2018 Sep 27. pii: S1096-7192(18)30192-6. doi: 10.1016/j.ymgme.2018.09.007. [Epub ahead of print] Review. PubMed PMID: 30413388.
523. GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* 2018 Nov 10;392(10159):1859-1922. doi: 10.1016/S0140-6736(18)32335-3. PubMed PMID: 30415748.
524. GBD 2017 SDG Collaborators. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* 2018 Nov 10;392(10159):2091-2138. doi: 10.1016/S0140-6736(18)32281-5. Epub 2018 Nov 8. PubMed PMID: 30496107.
525. GBD 2017 Population and Fertility Collaborators. Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* 2018 Nov 10;392(10159):1995-2051. doi: 10.1016/S0140-6736(18)32278-5. Epub 2018 Nov 8. PubMed PMID: 30496106.
526. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* 2018 Nov 10;392(10159):1923-1994. doi: 10.1016/S0140-6736(18)32225-6. Epub 2018 Nov 8. PubMed PMID: 30496105.
527. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* 2018 Nov 10;392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8. PubMed PMID: 30496104.
528. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* 2018 Nov 10;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7. Epub 2018 Nov 8. PubMed PMID: 30496103.
529. GBD 2017 Mortality Collaborators. Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* 2018 Nov 10;392(10159):1684-1735. doi: 10.1016/S0140-6736(18)31891-9. Epub 2018 Nov 8. PubMed PMID: 30496102.
530. Dincer N, Dagal T, Afsar B, Covic A, Ortiz A, Kanbay M. The effect of chronic kidney disease on lipid metabolism. *Int Urol Nephrol.* 2018 Dec 5. doi: 10.1007/s11255-018-2047-y. [Epub ahead of print] Review. PubMed PMID: 30519980.
531. Ortiz A, Sanchez-Niño MD, Crespo-Barrio M, De-Sequera-Ortiz P, Fernández-Giráldez E, García-Maset R, Macía-Heras M, Pérez-Fontán M, Rodríguez-Portillo M, Salgueira-Lazo M, Sánchez-Álvarez E, Santamaría-Olmo R, Simal-Blanco F, Pino-Pino MD. The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem. *Nefrologia.* 2018 Nov 28. pii: S0211-6995(18)30159-0. doi: 10.1016/j.nefro.2018.09.002. [Epub ahead of print] English, Spanish. PubMed PMID: 30503082.
532. Valiño-Rivas L, Cuarental L, Agustin M, Husi H, Cannata-Ortiz P, Sanz AB, Mischak H, Ortiz A, Sanchez-Niño MD. MAGE genes in the kidney: identification of MAGED2 as upregulated during kidney injury and in stressed

- tubular cells. *Nephrol Dial Transplant*. 2018 Dec 11. doi: 10.1093/ndt/gfy367. [Epub ahead of print] PubMed PMID: 30541139.
533. Sánchez-González C, Gonzalez-Casaus ML, Sellares VL, Albalade M, Torregrosa JV, Mas S, Ortiz A, Rodriguez M, Gonzalez-Parra E. Higher Proportion of Non-1-84 PTH Fragments in Peritoneal Dialysis Patients Compared to Hemodialysis Patients Using Solutions Containing 1.75 mmol/l Calcium. *Front Physiol*. 2018 Nov 20;9:1643. doi: 10.3389/fphys.2018.01643. eCollection 2018. PubMed PMID: 30524306; PubMed Central PMCID: PMC6262178
534. Eren OC, Ortiz A, Afsar B, Covic A, Kuwabara M, Lanaspa MA, Johnson RJ, Kanbay M. Multilayered Interplay Between Fructose and Salt in Development of Hypertension. *Hypertension*. 2018 Dec 31:HYPERTENSIONAHA11812150. doi: 10.1161/HYPERTENSIONAHA.118.12150. [Epub ahead of print] PubMed PMID: 30595116.
535. Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, Ayre DC, Bach JM, Bachurski D, Baharvand H, Balaj L, Baldacchino S, Bauer NN, Baxter AA, Bebawy M, Beckham C, Bedina Zavec A, Benmoussa A, Berardi AC, Bergese P, Bielska E, Blenkiron C, Bobis-Wozowicz S, Boilard E, Boireau W, Bongiovanni A, Borràs FE, Bosch S, Boulanger CM, Breakefield X, Breglio AM, Brennan MÁ, Brigstock DR, Brisson A, Broekman ML, Bromberg JF, Bryl-Górecka P, Buch S, Buck AH, Burger D, Busatto S, Buschmann D, Bussolati B, Buzás EI, Byrd JB, Camussi G, Carter DR, Caruso S, Chamley LW, Chang YT, Chen C, Chen S, Cheng L, Chin AR, Clayton A, Clerici SP, Cocks A, Cocucci E, Coffey RJ, Cordeiro-da-Silva A, Couch Y, Coumans FA, Coyle B, Crescitelli R, Criado MF, D'Souza-Schorey C, Das S, Datta Chaudhuri A, de Candia P, De Santana EF, De Wever O, Del Portillo HA, Demaret T, Deville S, Devitt A, Dhondt B, Di Vizio D, Dieterich LC, Dolo V, Dominguez Rubio AP, Dominici M, Dourado MR, Driedonks TA, Duarte FV, Duncan HM, Eichenberger RM, Ekström K, El Andaloussi S, Elie-Caille C, Erdbrügger U, Falcón-Pérez JM, Fatima F, Fish JE, Flores-Bellver M, Försönits A, Frelet-Barrand A, Fricke F, Fuhrmann G, Gabrielsson S, Gámez-Valero A, Gardiner C, Gärtner K, Gaudin R, Gho YS, Giebel B, Gilbert C, Gimona M, Giusti I, Goberdhan DC, Görgens A, Gorski SM, Greening DW, Gross JC, Gualerzi A, Gupta GN, Gustafson D, Handberg A, Haraszi RA, Harrison P, Hegyesi H, Hendrix A, Hill AF, Hochberg FH, Hoffmann KF, Holder B, Holthofer H, Hosseinkhani B, Hu G, Huang Y, Huber V, Hunt S, Ibrahim AG, Ikezu T, Inal JM, Isin M, Ivanova A, Jackson HK, Jacobsen S, Jay SM, Jayachandran M, Jenster G, Jiang L, Johnson SM, Jones JC, Jong A, Jovanovic-Talisman T, Jung S, Kalluri R, Kano SI, Kaur S, Kawamura Y, Keller ET, Khamari D, Khomyakova E, Khvorova A, Kierulf P, Kim KP, Kislinger T, Klingeborn M, Klinker DJ 2nd, Kornek M, Kosanović MM, Kovács ÁF, Krämer-Albers EM, Krasemann S, Krause M, Kurochkin IV, Kusuma GD, Kuypers S, Laitinen S, Langevin SM, Languino LR, Lannigan J, Lässer C, Laurent LC, Lavieu G, Lázaro-Ibáñez E, Le Lay S, Lee MS, Lee YXF, Lemos DS, Lenassi M, Leszczynska A, Li IT, Liao K, Libregts SF, Ligeti E, Lim R, Lim SK, Linē A, Linnemannstöns K, Llorente A, Lombard CA, Lorenowicz MJ, Lörincz ÁM, Lötvall J, Lovett J, Lowry MC, Loyer X, Lu Q, Lukomska B, Lunavat TR, Maas SL, Malhi H, Marcilla A, Mariani J, Mariscal J, Martens-Uzunova ES, Martin-Jaular L, Martinez MC, Martins VR, Mathieu M, Mathivanan S, Maugeri M, McGinnis LK, McVey MJ, Meckes DG Jr, Meehan KL, Mertens I, Minciacchi VR, Möller A, Møller Jørgensen M, Morales-Kastresana A, Morhayim J, Mullier F, Muraca M, Musante L, Mussack V, Muth DC, Myburgh KH, Najrana T, Nawaz M, Nazarenko I, Nejsum P, Neri C, Neri T, Nieuwland R, Nimrichter L, Nolan JP, Nolte-t Hoen EN, Noren Hooten N, O'Driscoll L, O'Grady T, O'Loughlin A, Ochiya T, Olivier M, Ortiz A, Ortiz LA, Osteikoetxea X, Østergaard O, Ostrowski M, Park J, Pegtel DM, Peinado H, Perut F, Pfaffl MW, Phinney DG, Pieters BC, Pink RC, Pisetsky DS, Pogue von Strandmann E, Polakovicova I, Poon IK, Powell BH, Prada I, Pulliam L, Quesenberry P, Radeghieri A, Raffai RL, Raimondo S, Rak J, Ramirez MI, Raposo G, Rayaan MS, Regev-Rudzki N, Ricklefs FL, Robbins PD, Roberts DD, Rodrigues SC, Rohde E, Rome S, Rouschop KM, Rughetti A, Russell AE, Saá P, Sahoo S, Salas-Huenuleo E, Sánchez C, Saugstad JA, Saul MJ, Schiffelers RM, Schneider R, Schøyen TH, Scott A, Shahaj E, Sharma S, Shatnyeva O, Shekari F, Shelke GV, Shetty AK, Shiba K, Siljander PR, Silva AM, Skowronek A, Snyder OL 2nd, Soares RP, Sódar BW, Soekmadji C, Sotillo J, Stahl PD, Stoorvogel W, Stott SL, Strasser EF, Swift S, Tahara H, Tewari M, Timms K, Tiwari S, Tixeira R, Tkach M, Toh WS, Tomasini R, Torrecilhas AC, Tosar JP, Toxavidis V, Urbanelli L, Vader P, van Balkom BW, van der Grein SG, Van Deun J, van Herwijnen MJ, Van Keuren-Jensen K, van Niel G, van Royen ME, van Wijnen AJ, Vasconcelos MH, Vechetti IJ Jr, Veit TD, Vella LJ, Velot É, Verweij FJ, Vestad B, Viñas JL, Visnovitz T, Vukman KV, Wahlgren J, Watson DC, Wauben MH, Weaver A, Webber JP, Weber V, Wehman AM, Weiss DJ, Welsh JA, Wendt S, Wheelock AM, Wiener Z, Witte L, Wolfram J, Xagorari A, Xander P, Xu J, Yan X, Yáñez-Mó M, Yin H, Yuana Y, Zappulli V, Zarubova J, Žekas V, Zhang JY, Zhao Z, Zheng L, Zheutlin AR, Zickler AM, Zimmermann P, Zivkovic AM, Zocco D, Zuba-Surma EK. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J Extracell Vesicles*. 2018 Nov 23;7(1):1535750. doi: 10.1080/20013078.2018.1535750. eCollection 2018. PubMed PMID: 30637094; PubMed Central PMCID: PMC6322352.



536. Brown P, RELISH Consortium, Zhou Y. Large expert-curated database for benchmarking document similarity detection in biomedical literature search. *Database*, 2019, 1–66; doi: 10.1093/database/baz085 Database 2019;2019:article ID baz085; <https://academic.oup.com/database/article/doi/10.1093/database/baz085/5608006>
537. Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E, Fernandez-Prado R, Kanbay M, Ortiz A. Potential dangers of serum urate-lowering therapy. *Am J Med*. 2019 Jan 3. pii: S0002-9343(19)30005-1. doi: 10.1016/j.amjmed.2018.12.010. [Epub ahead of print] PubMed PMID: 30611833
538. Fernandez-Fernandez B, D'Marco L, Górriz JL, Jacobs-Cachá C, Kanbay M, Luis-Lima S, Porrini E, Sarafidis P, Soler MJ, Ortiz A. Positive/retained SDHB immunostaining in renal cell carcinomas associated to germline SDHB-deficiency: case report. *Diagn Pathol*. 2019 May 15;14(1):42.
539. Del Puerto-Nevado L, Minguez P, Corton M, Solanes-Casado S, Prieto I, Mas S, Sanz AB, Gonzalez-Alonso P, Villaverde C, Portal-Nuñez S, Aguilera O, Gomez-Guerrero C, Esbrit P, Vivanco F, Gonzalez N, Ayuso C, Ortiz A, Rojo F, Egido J, Alvarez-Llamas G, Garcia-Foncillas J; DiabetesCancerConnect Consortium. Molecular evidence of field cancerization initiated by diabetes in colon cancer patients. *Mol Oncol*. 2019 Jan 9. doi: 10.1002/1878-0261.12438. [Epub ahead of print] PubMed PMID: 30628165.
540. Fernandez-Fernandez B, Sanchez-Niño MD, Ortiz A. Working towards novel albuminuria endpoints in chronic kidney disease. *Lancet Diabetes Endocrinol*. 2019 Jan 8. pii: S2213-8587(18)30352-8. doi: 10.1016/S2213-8587(18)30352-8. [Epub ahead of print] PubMed PMID: 30635227.
541. Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. *Nephrol Dial Transplant*. 2019 Feb 1;34(2):208-230. doi: 10.1093/ndt/gfy407. PubMed PMID: 30753708.
542. Ortiz A, Sanchez-Niño MD. Sarcopenia in CKD: a roadmap from basic pathogenetic mechanisms to clinical trials. *Clin Kidney J*. 2019 Feb;12(1):110-112. doi: 10.1093/ckj/sfz001. Epub 2019 Feb 5. PubMed PMID: 30746137; PubMed Central PMCID: PMC6366131.
543. Afsar B, Elsurer Afsar R, Kanbay A, Covic A, Ortiz A, Kanbay M. Air pollution and kidney disease: review of current evidence. *Clin Kidney J*. 2019 Feb;12(1):19-32. doi: 10.1093/ckj/sfy111. Epub 2018 Nov 12. PubMed PMID: 30746128; PubMed Central PMCID: PMC6366136.
544. Ortiz A, Vinck C. The new *Clinical Kidney Journal*, 4 years later. *Clin Kidney J*. 2019 Feb;12(1):1-5. doi: 10.1093/ckj/sfy139. Epub 2019 Feb 5. PubMed PMID: 30746126; PubMed Central PMCID: PMC6366135.
545. Ortiz A. Proteomics for clinical assessment of kidney disease. *Proteomics Clin Appl*. 2019 Feb 15:e1900004. doi: 10.1002/prca.201900004. [Epub ahead of print] PubMed PMID: 30768767.
546. Donate-Correa J, Tagua VG, Ferri C, Martín-Núñez E, Hernández-Carballo C, Ureña-Torres P, Ruiz-Ortega M, Ortiz A, Mora-Fernández C, Navarro-González JF. Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons. *J Clin Med*. 2019 Feb 27;8(3). pii: E287. doi: 10.3390/jcm8030287. Review. PubMed PMID: 30818852.
547. Sanchez-Niño MD, Perez-Gomez MV, Valiño-Rivas L, Torra R, Ortiz A. Podocyturia: why it may have added value in rare diseases. *Clin Kidney J*. 2018 Oct 5;12(1):49-52. doi: 10.1093/ckj/sfy081. eCollection 2019 Feb. PubMed PMID: 30863545; PubMed Central PMCID: PMC6407136.
548. Fourdinier O, Schepers E, Metzinger-Le Meuth V, Glorieux G, Liabeuf S, Verbeke F, Vanholder R, Brigant B, Pletinck A, Diouf M, Burtey S, Choukroun G, Massy ZA, Metzinger L; European Uremic Toxin Work Group-EUTox. Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients. *Sci Rep*. 2019 Mar 14;9(1):4477. doi: 10.1038/s41598-019-41101-8. PubMed PMID: 30872798.
549. Burlacu A, Genovesi S, Ortiz A, Combe C, Basile C, Schneditz D, van der Sande F, Popa GT, Morosanu C, Covic A. Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. *Nephrol Dial Transplant*. 2019 Mar 16. pii: gfg040. doi: 10.1093/ndt/gfz040. [Epub ahead of print] PubMed PMID: 30879070.
550. Valiño-Rivas L, Vaquero JJ, Sucunza D, Gutierrez S, Sanz AB, Fresno M, Ortiz A, Sanchez-Niño MD. NIK as a Druggable Mediator of Tissue Injury. *Trends Mol Med*. 2019 Mar 26. pii: S1471-4914(19)30040-1. doi: 10.1016/j.molmed.2019.02.005. [Epub ahead of print] Review. PubMed PMID: 30926358.
551. Calderón Sandubete EJ, Briones Pérez de la Blanca E, Alonso-Ortiz Del Río C, Santamaría Olmo R, López Mendoza M, Barcos Martínez M, Márquez Infante C, Marín-León I; en nombre del Grupo Guía Fabry (Ortiz A y cols). Spanish multidisciplinary clinical practice guidelines for Anderson-Fabry Disease in Adults. I. Method and recommendations. *Rev Clin Esp*. 2019 Jan 25. pii: S0014-2565(18)30293-5. doi: 10.1016/j.rce.2018.09.017. [Epub ahead of print] English, Spanish. PubMed PMID: 30691688.
552. Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E, Fernandez-Prado R, Fernandez-Fernandez B, Martin-Cleary C, Gracia-Iguacel C, Ortiz A. Clarifying the concept of chronic kidney disease for non-nephrologists. *Clin Kidney J*.

- 2019 Feb 14;12(2):258-261. doi: 10.1093/ckj/sfz007. eCollection 2019 Apr. PubMed PMID: 30976406; PubMed Central PMCID: PMC6452188.
553. Ortiz A. Burden, access and disparities in kidney disease: chronic kidney disease hotspots and progress one step at a time. *Clin Kidney J.* 2019 Apr 8;12(2):157-159. doi: 10.1093/ckj/sfz026. eCollection 2019 Apr. PubMed PMID: 30976390; PubMed Central PMCID: PMC6452190.
554. Fontecha-Barriuso M, Martín-Sánchez D, Martínez-Moreno JM, Carrasco S, Ruiz-Andrés O, Monsalve M, Sanchez-Ramos C, Gómez MJ, Ruiz-Ortega M, Sánchez-Niño MD, Cannata-Ortiz P, Cabello R, Gonzalez-Enguita C, Ortiz A, Sanz AB. PGC-1 $\alpha$  deficiency causes spontaneous kidney inflammation and increases the severity of nephrotoxic AKI. *J Pathol.* 2019 Sep;249(1):65-78. doi: 10.1002/path.5282. [Epub ahead of print] PubMed PMID: 30982966.
555. Villa-Bellosta R, Mahillo-Fernández I, Ortíz A, A EG. Questioning the Safety of Calcidiol in Hemodialysis Patients. *Nutrients.* 2019 Apr 26;11(5). pii: E959. doi: 10.3390/nu11050959. PubMed PMID: 31035488.
556. Guerrero-Hue M, García-Caballero C, Palomino-Antolín A, Rubio-Navarro A, Vázquez-Carballo C, Herencia C, Martín-Sanchez D, Farré-Alins V, Egea J, Cannata P, Praga M, Ortiz A, Egido J, Sanz AB, Moreno JA. Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death. *FASEB J.* 2019 Apr 29:fj201900077R. doi: 10.1096/fj.201900077R. [Epub ahead of print] PubMed PMID: 31034781.
557. Gracia-Iguacel C, González-Parra E, Mahillo I, Ortiz A. Criteria for classification of protein-energy wasting in dialysis patients: impact on prevalence. *Br J Nutr.* 2019 May 14:1-8. doi: 10.1017/S0007114519000400. [Epub ahead of print] PubMed PMID: 31084673.
558. Carriazo S, Ortiz A, Perez-Gomez MV. Diagnostic Utility of Exome Sequencing for Kidney Disease. *N Engl J Med.* 2019 May 23;380(21):2078. doi: 10.1056/NEJMc1903250. PubMed PMID: 31116935
559. Cuarental L, Sucunza-Sáenz D, Valiño-Rivas L, Fernandez-Fernandez B, Sanz AB, Ortiz A, Vaquero JJ, Sanchez-Niño MD. MAP3K kinases and kidney injury. *Nefrologia.* 2019 Jun 10. pii: S0211-6995(19)30078-5. doi: 10.1016/j.nefro.2019.03.004. [Epub ahead of print] Review. PubMed PMID: 31196660.
560. Fernandez-Fernandez B, Fernandez-Prado R, Górriz JL, Martínez-Castelao A, Navarro-González JF, Porrini E, Soler MJ, Ortiz A. Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan? *Clin Kidney J.* 2019 May 31;12(3):313-321. doi: 10.1093/ckj/sfz070. eCollection 2019 Jun. PubMed PMID: 31198532; PubMed Central PMCID: PMC6543971.
561. Barbieri D, Goicoechea M, Sánchez-Niño MD, Ortiz A, Verde E, Verdalles U, Pérez de José A, Delgado A, Hurtado E, Sánchez-Cámara L, Lopez-Lazareno N, García-Prieto A, Luño J. Obesity and chronic kidney disease progression-the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1. *Clin Kidney J.* 2018 Oct 11;12(3):420-426. doi: 10.1093/ckj/sfy095. eCollection 2019 Jun. PubMed PMID: 31198543; PubMed Central PMCID: PMC6543966.
562. Del Puerto-Nevado L, Santiago-Hernandez A, Solanes-Casado S, Gonzalez N, Ricote M, Corton M, Prieto I, Mas S, Sanz AB, Aguilera O, Gomez-Guerrero C, Ayuso C, Ortiz A, Rojo F, Egido J, Garcia-Foncillas J, Minguez P, Alvarez-Llamas G; DiabetesCancerConnect Consortium. Diabetes-mediated promotion of colon mucosa carcinogenesis is associated with mitochondrial dysfunction. *Mol Oncol.* 2019 Jun 14. doi: 10.1002/1878-0261.12531. [Epub ahead of print] PubMed PMID: 3119905
563. Ortiz A. ERT impact on left ventricular mass in Fabry disease. *Mol Genet Metab Rep.* 2019 Jun 15;20:100485. doi: 10.1016/j.ymgmr.2019.100485. PubMed PMID: 31245278; PubMed Central PMCID: PMC6582195.
564. Kanbay M, Ertuglu LA, Afsar B, Ozdogan E, Kucuksumer ZS, Ortiz A, Covic A, Kuwabara M, Cherney DZ, van Raalte D, de Zeeuw D. Renal hyperfiltration defined by high estimated glomerular filtration rate: a risk factor of cardiovascular disease and mortality. *Diabetes Obes Metab.* 2019 Jul 12. doi: 10.1111/dom.13831. [Epub ahead of print] PubMed PMID: 31297976
565. Carriazo S, Perez-Gomez MV, Cordido A, García-González MA, Sanz AB, Ortiz A, Sanchez-Niño MD. Dietary Care for ADPKD Patients: Current Status and Future Directions. *Nutrients.* 2019 Jul 12;11(7). pii: E1576. doi: 10.3390/nu11071576. PubMed PMID: 31336917.
566. Rubio-Navarro A, Vázquez-Carballo C, Guerrero-Hue M, García-Caballero C, Herencia C, Gutiérrez E, Yuste C, Sevillano Á, Praga M, Egea J, Cannata P, Cortegano I, de Andrés B, Gaspar ML, Cadenas S, Michalska P, León R, Ortiz A, Egido J, Moreno JA. Nrf2 Plays a Protective Role Against Intravascular Hemolysis-Mediated Acute Kidney Injury. *Front Pharmacol.* 2019 Jul 3;10:740. doi: 10.3389/fphar.2019.00740. PubMed PMID: 31333462;
567. Kanbay M, Yilmaz S, Dincer N, Ortiz A, Sag AA, Covic A, Sánchez-Lozada LG, Lanaspá MA, Cherney DZI, Johnson RJ, Afsar B. Antidiuretic hormone and serum osmolarity physiology and related outcomes: What is old, what is new and what is unknown? *J Clin Endocrinol Metab.* 2019 Jul 31. pii: jc.2019-01049. doi: 10.1210/jc.2019-01049. [Epub ahead of print] PubMed PMID: 31365096.
568. Fernandez-Prado R, Carriazo-Julio SM, Torra R, Ortiz A, Perez-Gomez MV. MYH9-related disease: it does exist,

- may be more frequent than you think and requires specific therapy. *Clin Kidney J.* 2019 Aug 1;12(4):488-493. doi: 10.1093/ckj/sfz103. PubMed PMID: 31384439; PubMed Central PMCID: PMC6671427.
569. Valdivielso JM, Rodriguez-Puyol D, Pascual J, Barrios C, Bermudez-López M, Sanchez-Niño MD, Pérez-Fernández M, Ortiz A. Atherosclerosis in Chronic Kidney Disease. *Arterioscler Thromb Vasc Biol.* 2019 Aug 15:ATVBAHA119312705. doi: 10.1161/ATVBAHA.119.312705. [Epub ahead of print] PubMed PMID: 31412740.
570. Aguilera-Correa JJ, Madrazo-Clemente P, Martínez-Cuesta MDC, Peláez C, Ortiz A, Dolores Sánchez-Niño M, Esteban J, Requena T. Lyso-Gb3 modulates the gut microbiota and decreases butyrate production. *Sci Rep.* 2019 Aug 19;9(1):12010. doi: 10.1038/s41598-019-48426-4. PubMed PMID: 31427622.
571. Valiño-Rivas L, Cuarental L, Nuñez G, Sanz AB, Ortiz A, Sanchez-Niño MD. Loss of NLRP6 expression increases the severity of acute kidney injury. *Nephrol Dial Transplant.* 2020 Apr 1;35(4):587-598.. doi: 10.1093/ndt/gfz169. [Epub ahead of print] PubMed PMID: 31504777.
572. Martín-Navarro J, Esteras R, Castillo E, Carriazo S, Fernández-Prado R, Gracia-Iguacel C, Mas Fontao S, Ortíz A, González-Parra E. Reactions to Synthetic Membranes Dialyzers: Is there an Increase in Incidence? *Kidney Blood Press Res.* 2019;44(5):907-914. doi: 10.1159/000501035. Epub 2019 Sep 10. Review. PubMed PMID: 31505506.
573. Orejudo M, Rodrigues-Diez RR, Rodrigues-Diez R, Garcia-Redondo A, Santos-Sánchez L, Rández-Garbayo J, Cannata-Ortiz P, Ramos AM, Ortiz A, Selgas R, Mezzano S, Lavoz C, Ruiz-Ortega M. Interleukin 17A Participates in Renal Inflammation Associated to Experimental and Human Hypertension. *Front Pharmacol.* 2019 Sep 13;10:1015. doi: 10.3389/fphar.2019.01015. eCollection 2019. PubMed PMID: 31572188; PubMed Central PMCID: PMC6753390.
574. Yilmaz O, Afsar B, Ortiz A, Kanbay M. The role of endothelial glycocalyx in health and disease. *Clin Kidney J.* 2019 Apr 23;12(5):611-619. doi: 10.1093/ckj/sfz042. eCollection 2019 Oct. PubMed PMID: 31583086; PubMed Central PMCID: PMC6768294.
575. Rojas-Rivera JE, Carriazo S, Ortiz A. Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal. *Clin Kidney J.* 2019 Sep 30;12(5):629-638. doi: 10.1093/ckj/sfz127. eCollection 2019 Oct. PubMed PMID: 31583088; PubMed Central PMCID: PMC6768298.
576. Ruilope LM, Rodríguez-Sánchez E, Navarro-García JA, Segura J, Órtiz A, Lucia A, Ruiz-Hurtado G. Resistant hypertension: new insights and therapeutic perspectives. *Eur Heart J Cardiovasc Pharmacother.* 2019 Oct 9. pii: pvz057. doi: 10.1093/ehjcvp/pvz057. [Epub ahead of print] PubMed PMID: 31598644.
577. Burstein R, Henry NJ, Collison ML, Marczak LB, Sligar A, Watson S, Marquez N, Abbasalizad-Farhangi M, Abbasi M, Abd-Allah F, Abdoli A, Abdollahi M, Abdollahpour I, Abdulkader RS, Abrigo MRM, Acharya D, Adebayo OM, Adekanmbi V, Adham D, Afshari M, Aghaali M, Ahmadi K, Ahmadi M, Ahmadpour E, Ahmed R, Akal CG, Akinyemi JO, Alahdab F, Alam N, Alamene GM, Alene KA, Alijanzadeh M, Alinia C, Alipour V, Aljunid SM, Almalki MJ, Al-Mekhlafi HM, Altirkawi K, Alvis-Guzman N, Amegah AK, Amini S, Amit AML, Anbari Z, Androudi S, Anjomshoa M, Ansari F, Antonio CAT, Arabloo J, Arefi Z, Aremu O, Armoon B, Arora A, Artaman A, Asadi A, Asadi-Aliabadi M, Ashraf-Ganjouei A, Assadi R, Ataeinia B, Atre SR, Quintanilla BPA, Ayanore MA, Azari S, Babae E, Babazadeh A, Badawi A, Bagheri S, Bagherzadeh M, Baheiraei N, Balouchi A, Barac A, Bassat Q, Baune BT, Bayati M, Bedi N, Beghi E, Behzadifar M, Behzadifar M, Belay YB, Bell B, Bell ML, Berbada DA, Bernstein RS, Bhattacharjee NV, Bhattarai S, Bhutta ZA, Bijani A, Bohlouli S, Breitborde NJK, Britton G, Browne AJ, Nagaraja SB, Busse R, Butt ZA, Car J, Cárdenas R, Castañeda-Orjuela CA, Cerin E, Chanie WF, Chatterjee P, Chu DT, Cooper C, Costa VM, Dalal K, Dandona L, Dandona R, Daoud F, Daryani A, Das Gupta R, Davis I, Davis Weaver N, Davitoliu DV, De Neve JW, Demeke FM, Demoz GT, Deribe K, Desai R, Deshpande A, Desyibelew HD, Dey S, Dharmaratne SD, Dhimal M, Diaz D, Doshmangir L, Duraes AR, Dwyer-Lindgren L, Earl L, Ebrahimi R, Ebrahimpour S, Effiong A, Eftekhari A, Ehsani-Chimeh E, El Sayed I, El Sayed Zaki M, El Tantawi M, El-Khatib Z, Emamian MH, Enany S, Eskandarieh S, Eyawo O, Ezalarab M, Faramarzi M, Fareed M, Faridnia R, Faro A, Fazaeli AA, Fazlzadeh M, Fentahun N, Fereshtehnejad SM, Fernandes JC, Filip I, Fischer F, Foigt NA, Foroutan M, Francis JM, Fukumoto T, Fullman N, Gallus S, Gebre DG, Gebrehiwot TT, Gebremeskel GG, Gessner BD, Geta B, Gething PW, Ghadimi R, Ghadiri K, Ghajarzadeh M, Ghashghaee A, Gill PS, Gill TK, Golding N, Gomes NGM, Gona PN, Gopalani SV, Gorini G, Goulart BNG, Graetz N, Greaves F, Green MS, Guo Y, Haj-Mirzaian A, Haj-Mirzaian A, Hall BJ, Hamidi S, Haririan H, Haro JM, Hasankhani M, Hasanpoor E, Hasanzadeh A, Hassankhani H, Hassen HY, Hegazy MI, Hendrie D, Heydarpour F, Hird TR, Hoang CL, Hollerich G, Rad EH, Hoseini-Ghahfarokhi M, Hossain N, Hosseini M, Hosseinzadeh M, Hostiuc M, Hostiuc S, Househ M, Hsairi M, Ilesanmi OS, Imani-Nasab MH, Iqbal U, Irvani SSN, Islam N, Islam SMS, Jürisson M, Balalami NJ, Jalali A, Javidnia J, Jayatilleke AU, Jenabi E, Ji JS, Jobanputra YB, Johnson K, Jonas JB, Shushtari ZJ, Jozwiak JJ, Kabir A, Kahsay A, Kalani H, Kalhor R, Karami M, Karki S, Kasaeian A, Kassebaum NJ, Keiyoro PN, Kemp GR, Khabiri R, Khader YS, Khafaie MA, Khan EA, Khan J, Khan MS, Khang YH, Khatab K, Khater A, Khater MM, Khatony A, Khazaei M, Khazaei S, Khazaei-Pool M, Khubchandani J,

- Kianipour N, Kim YJ, Kimokoti RW, Kinyoki DK, Kisa A, Kisa S, Kolola T, Kosen S, Koul PA, Koyanagi A, Kraemer MUG, Krishan K, Krohn KJ, Kugbey N, Kumar GA, Kumar M, Kumar P, Kuupiel D, Lacey B, Lad SD, Lami FH, Larsson AO, Lee PH, Leili M, Levine AJ, Li S, Lim LL, Listl S, Longbottom J, Lopez JCF, Lorkowski S, Magdeldin S, Abd El Razek HM, Abd El Razek MM, Majeed A, Maleki A, Malekzadeh R, Malta DC, Mamun AA, Manafi N, Manda AL, Mansourian M, Martins-Melo FR, Masaka A, Massenburg BB, Maulik PK, Mayala BK, Mazidi M, McKee M, Mehrotra R, Mehta KM, Meles GG, Mendoza W, Menezes RG, Meretoja A, Meretoja TJ, Mestrovic T, Miller TR, Miller-Petrie MK, Mills EJ, Milne GJ, Mini GK, Mir SM, Mirjalali H, Mirrakhimov EM, Mohamadi E, Mohammad DK, Darwesh AM, Mezerji NMG, Mohammed AS, Mohammed S, Mokdad AH, Molokhia M, Monasta L, Moodley Y, Moosazadeh M, Moradi G, Moradi M, Moradi Y, Moradi-Lakeh M, Moradinazar M, Moraga P, Morawska L, Mosapour A, Mousavi SM, Mueller UO, Muluneh AG, Mustafa G, Nabavizadeh B, Naderi M, Nagarajan AJ, Nahvijou A, Najafi F, Nangia V, Ndwandwe DE, Neamati N, Negoï I, Negoï RI, Ngunjiri JW, Thi Nguyen HL, Nguyen LH, Nguyen SH, Nielsen KR, Ningrum DNA, Nirayo YL, Nixon MR, Nnaji CA, Nojomi M, Noroozi M, Nosratnejad S, Noubiap JJ, Motlagh SM, Ofori-Asenso R, Ogbo FA, Oladimeji KE, Olagunju AT, Olfatifar M, Olum S, Olusanya BO, Oluwasanu MM, Onwujekwe OE, Oren E, Ortega-Altamirano DDV, Ortiz A, Osarenotor O, Osei FB, Osgood-Zimmerman AE, Otstavnov SS, Owolabi MO, P A M, Pagheh AS, Pakhale S, Panda-Jonas S, Pandey A, Park EK, Parsian H, Pashaei T, Patel SK, Pepito VCF, Pereira A, Perkins S, Pickering BV, Pilgrim T, Pirestani M, Pirooz B, Pirsahab M, Plana-Ripoll O, Pourjafar H, Puri P, Qorbani M, Quintana H, Rabiee M, Rabiee N, Radfar A, Rafiei A, Rahim F, Rahimi Z, Rahimi-Movaghar V, Rahimzadeh S, Rajati F, Raju SB, Ramezankhani A, Ranabhat CL, Rasella D, Rashedi V, Rawal L, Reiner RC Jr, Renzaho AMN, Rezaei S, Rezapour A, Riahi SM, Ribeiro AI, Roever L, Roro EM, Roser M, Roshandel G, Roshani D, Rostami A, Rubagotti E, Rubino S, Sabour S, Sadat N, Sadeghi E, Saeedi R, Safari Y, Safari-Faramani R, Safdarian M, Sahebkar A, Salahshoor MR, Salam N, Salamati P, Salehi F, Zahabi SS, Salimi Y, Salimzadeh H, Salomon JA, Sambala EZ, Samy AM, Santric Milicevic MM, Jose BPS, Saraswathy SYI, Sarmiento-Suárez R, Sartorius B, Sathian B, Saxena S, Sbarra AN, Schaeffer LE, Schwebel DC, Sepanlou SG, Seyedmousavi S, Shaahmadi F, Shaikh MA, Shams-Beyranvand M, Shamshirian A, Shamsizadeh M, Sharafi K, Sharif M, Sharif-Alhoseini M, Sharifi H, Sharma J, Sharma R, Sheikh A, Shields C, Shigematsu M, Shiri R, Shiue I, Shuval K, Siddiqi TJ, Silva JP, Singh JA, Sinha DN, Sisay MM, Sisay S, Sliwa K, Smith DL, Somayaji R, Soofi M, Soriano JB, Sreeramareddy CT, Sudaryanto A, Sufiyan MB, Sykes BL, Sylaja PN, Tabarés-Seisdedos R, Tabb KM, Tabuchi T, Taveira N, Temsah MH, Terkawi AS, Tessema ZT, Thankappan KR, Thirunavukkarasu S, To QG, Tovani-Palone MR, Tran BX, Tran KB, Ullah I, Usman MS, Uthman OA, Vahedian-Azimi A, Valdez PR, van Boven JFM, Vasankari TJ, Vasseghian Y, Veisani Y, Venketasubramanian N, Violante FS, Vladimirov SK, Vlassov V, Vos T, Vu GT, Vujcic IS, Waheed Y, Wakefield J, Wang H, Wang Y, Wang YP, Ward JL, Weintraub RG, Weldegewergs KG, Weldesamuel GT, Westerman R, Wiysonge CS, Wondafrash DZ, Woyczynski L, Wu AM, Xu G, Yadegar A, Yamada T, Yazdi-Feyzabadi V, Yilgwan CS, Yip P, Yonemoto N, Lebni JY, Younis MZ, Yousefifard M, Yousof HSA, Yu C, Yusefzadeh H, Zabeh E, Moghadam TZ, Bin Zaman S, Zamani M, Zandian H, Zangeneh A, Zerfu TA, Zhang Y, Ziapour A, Zodpey S, Murray CJL, Hay SI. Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. *Nature*. 2019 Oct;574(7778):353-358. doi: 10.1038/s41586-019-1545-0. Epub 2019 Oct 16. PubMed PMID: 31619795; PubMed Central PMCID: PMC6800389.
578. Fernandez-Prado R, Kanbay M, Ortiz A, Perez-Gomez MV. Expanding congenital abnormalities of the kidney and urinary tract (CAKUT) genetics: basonuclin 2 (BNC2) and lower urinary tract obstruction. *Ann Transl Med*. 2019 Sep;7(Suppl 6):S226. doi: 10.21037/atm.2019.08.73. PubMed PMID: 31656805; PubMed Central PMCID: PMC6789316.
579. Ramos AM, Fernández-Fernández B, Pérez-Gómez MV, Carriazo Julio SM, Sanchez-Niño MD, Sanz A, Ruiz-Ortega M, Ortiz A. Design and optimization strategies for the development of new drugs that treat chronic kidney disease. *Expert Opin Drug Discov*. 2019 Nov 18:1-15. doi: 10.1080/17460441.2020.1690450. [Epub ahead of print] PubMed PMID: 31736379.
580. Kanbay M, Yerlikaya A, Sag AA, Ortiz A, Kuwabara M, Covic A, Wiecek A, Stenvinkel P, Afsar B. A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease. *Clin Kidney J*. 2019 Sep 18;12(6):861-870. doi: 10.1093/ckj/sfz106. PubMed PMID: 31807301; PubMed Central PMCID: PMC6885688.
581. Castillo-Rodriguez E, Fernandez-Fernandez B, Alegre-Bellassai R, Kanbay M, Ortiz A. The chaos of hypertension guidelines for chronic kidney disease patients. *Clin Kidney J*. 2019 Sep 28;12(6):771-777. doi: 10.1093/ckj/sfz126. PubMed PMID: 31807290; PubMed Central PMCID: PMC6885687.
582. Casanova AG, Vicente-Vicente L, Hernández-Sánchez MT, Prieto M, Rihuete MI, Ramis LM, Del Barco E, Cruz JJ, Ortiz A, Cruz-González I, Martínez-Salgado C, Pescador M, López-Hernández FJ, Morales AI. Urinary transferrin pre-emptively identifies the risk of renal damage posed by subclinical tubular alterations. *Biomed Pharmacother*. 2020 Jan;121:109684. doi: 10.1016/j.biopha.2019.109684. PubMed PMID: 31810121.

583. Afsar B, Elsurer Afsar R, Sag AA, Kanbay A, Korkmaz H, Cipolla-Neto J, Covic A, Ortiz A, Kanbay M. Sweet dreams: therapeutic insights, targeting imaging and physiologic evidence linking sleep, melatonin and diabetic nephropathy. *Clin Kidney J.* 2020 Feb 6;13(4):522-530. doi: 10.1093/ckj/sfz198. PMID: 32905249; PMCID: PMC7467577.
584. Fernandez-Prado R, Gonzalez-Parra E, Ortiz A. Often forgotten, transport modality to dialysis may be life-saving. *Clin Kidney J.* 2020 Sep 2;13(4):510-512. doi: 10.1093/ckj/sfaa163. PMID: 32905336; PMCID: PMC7467588.
585. Potpara TS, Ferro C, Lip GYH, Dan GA, Lenarczyk R, Mallamaci F, Ortiz A, Sarafidis P, Ekart R, Dagnes N. Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. *Europace.* 2020 Jan 21. pii: euz358. doi: 10.1093/europace/euz358. [Epub ahead of print] PubMed PMID: 31965154.
586. Lavoz C, Rayego-Mateos S, Orejudo M, Opazo-Ríos L, Marchant V, Marquez-Exposito L, Tejera-Muñoz A, Navarro-González JF, Droguett A, Ortiz A, Egido J, Mezzano S, Rodrigues-Diez RR, Ruiz-Ortega M. Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy? *J Clin Med.* 2020 Jan 19;9(1). pii: E272. doi: 10.3390/jcm9010272. PubMed PMID: 31963845.
587. Kanbay M, Siriopol D, Ozdogan E, Afsar B, Ertuglu LA, Grigore M, Sag AA, Kuwabara M, Lanaspá MA, Ortiz A, Johnson RJ, Covic A. Serum osmolality as a potential predictor for contrast-induced nephropathy following elective coronary angiography. *Int Urol Nephrol.* 2020 Feb 1. doi: 10.1007/s11255-020-02391-4. [Epub ahead of print] PubMed PMID: 32008199.
588. Górriz JL, Navarro-González JF, Ortiz A, Vergara A, Nuñez J, Jacobs-Cachá C, Martínez-Castelao A, Soler MJ. Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. *Nephrol Dial Transplant.* 2020 Jan 1;35(Supplement\_1):i13-i23. doi: 10.1093/ndt/gfz237. PubMed PMID: 32003834.
589. Kanbay M, Afsar B, Siriopol D, Dincer N, Erden N, Yilmaz O, Sag AA, Kuwabara M, Cherney D, Rossignol P, Ortiz A, Covic A. Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies. *Angiology.* 2020 Jan 31:3319719897509. doi: 10.1177/0003319719897509. [Epub ahead of print] PubMed PMID: 32000517.
590. Córdoba-David G, Duro-Castano A, Castelo-Branco RC, González-Guerrero C, Cannata P, Sanz AB, Vicent MJ, Ortiz A, Ramos AM. Effective Nephroprotection Against Acute Kidney Injury with a Star-Shaped Polyglutamate-Curcuminoid Conjugate. *Sci Rep.* 2020 Feb 6;10(1):2056. doi: 10.1038/s41598-020-58974-9. PubMed PMID: 32029842.
591. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* 2020 Feb 13. pii: S0140-6736(20)30045-3. doi: 10.1016/S0140-6736(20)30045-3. [Epub ahead of print] PubMed PMID: 32061315.
592. Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR. Targeting the progression of chronic kidney disease. *Nat Rev Nephrol.* 2020 Feb 14. doi: 10.1038/s41581-019-0248-y. [Epub ahead of print] Review. PubMed PMID: 32060481
593. Perez-Gomez MV, Ortiz A. Aliskiren and the dual complement inhibition concept. *Clin Kidney J.* 2019 Oct 23;13(1):35-38. doi: 10.1093/ckj/sfz142. PubMed PMID: 32083617; PubMed Central PMCID: PMC7025362.
594. Sarafidis PA, Ortiz A. The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern? *Clin Kidney J.* 2019 Dec 18;13(1):24-26. doi: 10.1093/ckj/sfz170. PubMed PMID: 32082549; PubMed Central PMCID: PMC7025347.
595. Ortiz A. PDGFR- $\beta$  and kidney fibrosis. *EMBO Mol Med.* 2020 Feb 18:e11729. doi: 10.15252/emmm.201911729. [Epub ahead of print] PubMed PMID: 32072759.
596. Fontecha-Barriuso M, Martín-Sánchez D, Martínez-Moreno JM, Cardenas-Villacres D, Carrasco S, Sanchez-Niño MD, Ruiz-Ortega M, Ortiz A, Sanz AB. Molecular pathways driving omeprazole nephrotoxicity. *Redox Biol.* 2020 Feb 12;32:101464. doi: 10.1016/j.redox.2020.101464. [Epub ahead of print] PubMed PMID: 32092686.
597. Wanner C, Feldt-Rasmussen U, Jovanovic A, Linhart A, Yang M, Ponce E, Brand E, Germain DP, Hughes DA, Jefferies JL, Martins AM, Nowak A, Vujkovic B, Weidemann F, West ML, Ortiz A. Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis. *ESC Heart Fail.* 2020 Jun;7(3):825-834. doi: 10.1002/ehf2.12647. [Epub ahead of print] PubMed PMID: 32100468.
598. Fontecha-Barriuso M, Martín-Sánchez D, Martínez-Moreno JM, Monsalve M, Ramos AM, Sanchez-Niño MD, Ruiz-Ortega M, Ortiz A, Sanz AB. The Role of PGC-1 $\alpha$  and Mitochondrial Biogenesis in Kidney Diseases. *Biomolecules.* 2020 Feb 24;10(2). pii: E347. doi: 10.3390/biom10020347. Review. PubMed PMID: 32102312.
599. Paats J, Adoberg A, Arund J, Dhondt A, Fernström A, Fridolin I, Glorieux G, Leis L, Luman M, Gonzalez-Parra E, Perez-Gomez VM, Pilt K, Sanchez-Ospina D, Segelmark M, Uhlin F, Arduan Ortiz A. Serum Levels and Removal by Haemodialysis and Haemodiafiltration of Tryptophan-Derived Uremic Toxins in ESKD Patients. *Int J Mol Sci.* 2020

- Feb 23;21(4). pii: E1522. doi: 10.3390/ijms21041522. PubMed PMID: 32102247.
600. Carriazo S, Ramos AM, Sanz AB, Sanchez-Niño MD, Kanbay M, Ortiz A. Chronodisruption: A Poorly Recognized Feature of CKD. *Toxins (Basel)*. 2020 Feb 28;12(3). pii: E151. doi: 10.3390/toxins12030151. Review. PubMed PMID: 32121234.
601. Tofte N, Lindhardt M, Adamova K, Bakker SJJ, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Heerspink HJL, Kooy A, Laverman GD, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Petrie JR, Ruggenti PL, Rutters F, Rychlík I, Siwy J, Spasovski G, Speeckaert M, Trillini M, Zürlbig P, von der Leyen H, Rossing P; PRIORITY investigators. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. *Lancet Diabetes Endocrinol*. 2020 Apr;8(4):301-312.. doi: 10.1016/S2213-8587(20)30026-7. [Epub ahead of print] PubMed PMID: 32135136.
602. Soler MJ, Porrini E, Fernandez-Fernandez B, Ortiz A. SGLT2i and postglomerular vasodilation. *Kidney Int*. 2020 Apr;97(4):805-806. doi: 10.1016/j.kint.2020.01.007. PubMed PMID: 32200864.
603. Fernández-Fernández B, Valiño-Rivas L, Sánchez-Niño MD, Ortiz A. Albuminuria Downregulation of the Anti-Aging Factor Klotho: The Missing Link Potentially Explaining the Association of Pathological Albuminuria with Premature Death. *Adv Ther*. 2020 Mar 31. doi: 10.1007/s12325-019-01180-5. [Epub ahead of print] PubMed PMID: 32236874.
604. Górriz JL, Soler MJ, Navarro-González JF, García-Carro C, Puchades MJ, D'Marco L, Martínez Castela A, Fernández-Fernández B, Ortiz A, Górriz-Zambrano C, Navarro-Pérez J, Gorgojo-Martinez JJ. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. *J Clin Med*. 2020 Mar 30;9(4). pii: E947. doi: 10.3390/jcm9040947. PubMed PMID: 32235471.
605. Sanchez-Niño MD, Aguilera-Correa JJ, Politei J, Esteban J, Requena T, Ortiz A. Unraveling the drivers and consequences of gut microbiota disruption in Fabry disease: the lyso-Gb3 link. *Future Microbiol*. 2020 Mar;15:227-231. doi: 10.2217/fmb-2019-0249. PubMed PMID: 32271110.
606. Sanchez-Niño MD, Fernandez-Fernandez B, Ortiz A. Klotho, the elusive kidney-derived anti-ageing factor. *Clin Kidney J*. 2019 Sep 28;13(2):125-127. doi: 10.1093/ckj/sfz125. eCollection 2020 Apr. PubMed PMID: 32297880; PubMed Central PMCID: PMC7147303.
607. Vega A, Sanchez-Niño MD, Ortiz A, Abad S, Macías N, Aragoncillo I, Santos A, García-Prieto A, Torres E, Hernández A, Sánchez-Cámara L, Hurtado E, Valiño-Rivas L, Luño J. The new marker YKL-40, a molecule related to inflammation, is associated with cardiovascular events in stable haemodialysis patients. *Clin Kidney J*. 2019 May 20;13(2):172-178. doi: 10.1093/ckj/sfz056. eCollection 2020 Apr. PubMed PMID: 32296521; PubMed Central PMCID: PMC7147298.
608. Martinez-Moreno JM, Fontecha-Barriuso M, Martín-Sánchez D, Sánchez-Niño MD, Ruiz-Ortega M, Sanz AB, Ortiz A. The Contribution of Histone Crotonylation to Tissue Health and Disease: Focus on Kidney Health. *Front Pharmacol*. 2020 Apr 3;11:393. doi: 10.3389/fphar.2020.00393. PubMed PMID: 32308622; PubMed Central PMCID: PMC7145939.
609. LBD Double Burden of Malnutrition Collaborators (Incl. Alberto Ortiz). Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. *Nat Med*. 2020 Apr 20. doi: 10.1038/s41591-020-0807-6. [Epub ahead of print] PubMed PMID: 32313249.
610. Kanbay M, Bulbul MC, Copur S, Afsar B, Sag AA, Siriopol D, Kuwabara M, Badarau S, Covic A, Ortiz A. Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease. *J Nephrol*. 2020 May 21. doi: 10.1007/s40620-020-00751-y. Epub ahead of print. PMID: 32440840
611. Ferro CJ, Sarafidis P, Ortiz A. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. *N Engl J Med*. 2020;382(21):e65. doi:10.1056/NEJMc2004861
612. Fernandez-Fernandez B, Mahillo I, Sanchez-Rodriguez J, Carriazo S, Sanz AB, Sanchez-Niño MD, Ortiz A. Gender, Albuminuria and Chronic Kidney Disease Progression in Treated Diabetic Kidney Disease. *J Clin Med*. 2020 May 26;9(6):E1611. doi: 10.3390/jcm9061611. PMID: 32466507
613. Burlacu A, Genovesi S, Basile C, Ortiz A, Mitra S, Kirmizis D, Kanbay M, Davenport A, van der Sande F, Covic A; EUDIAL Working Group of ERA-EDTA. Coronary artery disease in dialysis patients: evidence synthesis, controversies and proposed management strategies. *J Nephrol*. 2020 May 29. doi: 10.1007/s40620-020-00758-5. Epub ahead of print. PMID: 32472526.
614. Martinez-Moreno JM, Fontecha-Barriuso M, Martin-Sanchez D, Guerrero-Mauvecin J, Goma-Garces E, Fernandez-Fernandez B, Carriazo S, Sanchez-Niño MD, Ramos AM, Ruiz-Ortega M, Ortiz A, Sanz AB. Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease. *Int J Mol Sci*. 2020;21(11):E4113. Published 2020 Jun 9. doi:10.3390/ijms21114113

615. Rodrigues-Diez RR, Tejera-Muñoz A, Marquez-Exposito L, Rayego-Mateos S, Sanchez LS, Marchant V, Santamaria LT, Ramos AM, Ortiz A, Egido J, Ruiz-Ortega M. Statins: Could an old friend help the fight against COVID-19? *Br J Pharmacol*. 2020 Jun 19. doi: 10.1111/bph.15166. Epub ahead of print. PMID: 32562276.
616. Fernandez-Fernandez B, D'Marco L, Górriz JL, Jacobs-Cachá C, Kanbay M, Luis-Lima S, Porrini E, Sarafidis P, Soler MJ, Ortiz A. Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. *J Clin Med*. 2020;9(7):E2030. Published 2020 Jun 28. doi:10.3390/jcm9072030
617. Martin-Sanchez D, Fontecha-Barriuso M, Martinez-Moreno JM, Ramos AM, Sanchez-Niño MD, Guerrero-Hue M, Moreno JA, Ortiz A, Sanz AB. Ferroptosis and kidney disease. *Nefrologia*. 2020 Jul-Aug;40(4):384-394. English, Spanish. doi: 10.1016/j.nefro.2020.03.005. Epub 2020 Jul 2. PMID: 32624210
618. Rayego-Mateos S, Morgado-Pascual JL, Valdivielso JM, Sanz AB, Bosch-Panadero E, Rodrigues-Diez RR, Egido J, Ortiz A, González-Parra E, Ruiz-Ortega M. TRAF3 Modulation: Novel Mechanism for the Anti-inflammatory Effects of the Vitamin D Receptor Agonist Paricalcitol in Renal Disease. *J Am Soc Nephrol*. 2020 Sep;31(9):2026-2042. doi: 10.1681/ASN.2019111206. Epub 2020 Jul 6. PMID: 32631974; PMCID: PMC7461676.
619. Sarafidis P, Loutradis C, Ferro CJ, Ortiz A. SGLT-2 Inhibitors to Treat Hyponatremia Associated with SIADH: A Novel Indication? [published online ahead of print, 2020 Jul 9]. *Am J Nephrol*. 2020;1-3. doi:10.1159/000509082
620. Esteras R, Fox JG, Geddes CC, Mackinnon B, Ortiz A, Moreno JA. Hematuria Is Associated with More Severe Acute Tubulointerstitial Nephritis. *J Clin Med*. 2020;9(7):E2135. Published 2020 Jul 7. doi:10.3390/jcm9072135
621. Pérez-Sáez MJ, Blasco M, Redondo-Pachón D, Ventura-Aguai P, Bada-Bosch T, Pérez-Flores I, Melilli E, Sánchez-Cámara LA, López-Oliva MO, Canal C, Shabaka A, Garra-Moncau N, Martín-Moreno PL, López V, Hernández-Gallego R, Siverio O, Galeano C, Espí-Reig J, Cabezas CJ, Rodrigo MT, Llinàs-Mallol L, Fernández-Reyes MJ, Cruzado-Vega L, Pérez-Tamajón L, Santana-Estupiñán R, Ruiz-Fuentes MC, Taberero G, Zárraga S, Ruiz JC, Gutiérrez-Dalmau A, Mazuecos A, Sánchez-Álvarez E, Crespo M, Pascual J; Spanish Society of Nephrology COVID-19 Group (Alberto Ortiz). Use of tocilizumab in kidney transplant recipients with COVID-19. *Am J Transplant*. 2020 Nov;20(11):3182-3190. doi: 10.1111/ajt.16192. Epub 2020 Aug 4. PMID: 32654422; PMCID: PMC7405397.
622. Cuarental L, Valiño-Rivas L, Mendonça L, Saleem M, Mezzano S, Sanz AB, Ortiz A, Sanchez-Niño MD. Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes. *J Clin Med*. 2020;9(7):E2178. Published 2020 Jul 10. doi:10.3390/jcm9072178
623. D'Marco L, Puchades MJ, Romero-Parra M, Gimenez-Civera E, Soler MJ, Ortiz A, Górriz JL. Coronavirus disease 2019 in chronic kidney disease. *Clin Kidney J*. 2020 Jul 16;13(3):297-306. doi: 10.1093/ckj/sfaa104. PMID: 32699615; PMCID: PMC7367105.
624. Sarafidis P, Loutradis C, Ortiz A, Ruilope LM. Blood pressure targets in patients with chronic kidney disease: MDRD and AASK now confirming SPRINT. *Clin Kidney J*. 2020;13(3):287-290. Published 2020 Feb 25. doi:10.1093/ckj/sfaa015
625. Carriazo S, Kanbay M, Ortiz A. Kidney disease and electrolytes in COVID-19: more than meets the eye. *Clin Kidney J*. 2020;13(3):274-280. Published 2020 Jul 16. doi:10.1093/ckj/sfaa112
626. Perez-Gomez MV, Sanchez-Niño MD, Ortiz A. Megalin/lipoprotein receptor-related protein 2 autoimmunity and kidney disease. *Clin Kidney J*. 2020;13(3):281-286. Published 2020 Mar 19. doi:10.1093/ckj/sfz171
627. Stock da Cunha T, Gomá-Garcés E, Avello A, Pereira-García M, Mas-Fontao S, Ortiz A, González-Parra E. The Spectrum of Clinical and Serological Features of COVID-19 in Urban Hemodialysis Patients. *J Clin Med*. 2020;9(7):2264. Published 2020 Jul 16. doi:10.3390/jcm9072264
628. GBD 2019 Universal Health Coverage Collaborators (Incl. Alberto Ortiz). Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020 Aug 27;S0140-6736(20)30750-9. doi: 10.1016/S0140-6736(20)30750-9. Epub ahead of print. PMID: 32861314.
629. Copur S, Onal EM, Afsar B, Ortiz A, van Raalte DH, Cherney DZ, Rossing P, Kanbay M. Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. *J Diabetes Complications*. 2020 Aug 13:107707. doi: 10.1016/j.jdiacomp.2020.107707. Epub ahead of print. PMID: 32861562.
630. Copur S, Siriopol D, Afsar B, Comert MC, Uzunkopru G, Sag AA, Ortiz A, Covic A, van Raalte DH, Cherney DZ, Rossing P, Kanbay M. Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker. *Acta Diabetol*. 2020 Aug 30. doi: 10.1007/s00592-020-01581-x. Epub ahead of print. PMID: 32862262.
631. Luis-Lima S, Mas-Sanmartin C, Rodríguez-Rodríguez AE, Porrini E, Ortiz A, Gaspari F, Diaz-Martin L, Åsberg A, Jenssen T, Jiménez-Sosa A, Martinez-Ros P, Gonzalez-Bulnes A. A Simplified Iohexol-Based Method to Measure Renal Function in Sheep Models of Renal Disease. *Biology (Basel)*. 2020;9(9):E259. Published 2020 Aug 31. doi:10.3390/biology9090259

632. Carriazo S, Vanessa Perez-Gomez M, Ortiz A. Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology. *Clin Kidney J.* 2020;13(4):504-509. Published 2020 Sep 2. doi:10.1093/ckj/sfaa162
633. Afsar B, Afsar RE, Copur S, Sag AA, Ortiz A, Kanbay M. The Effect of Caloric Restriction on Development and Progression of Chronic Kidney Disease: Review of the Current Evidence [published online ahead of print, 2020 Sep 14]. *Br J Nutr.* 2020;1-42. doi:10.1017/S000711452000358X
634. Kanbay M, Siritopol D, Copur S, Tapoi L, Benchea L, Kuwabara M, Rossignol P, Ortiz A, Covic A, Afsar B. Effect of Coffee Consumption on Renal Outcome: A Systematic Review and Meta-Analysis of Clinical Studies. *J Ren Nutr.* 2020 Sep 18:S1051-2276(20)30209-0. doi: 10.1053/j.jrn.2020.08.004. Epub ahead of print. PMID: 32958376
635. Marchant V, Tejera-Muñoz A, Marquez-Expósito L, Rayego-Mateos S, Rodrigues-Diez RR, Tejedor L, Santos-Sanchez L, Egido J, Ortiz A, Valdivielso JM, Fraser DJ, López-Cabrera M, Selgas R, Ruiz-Ortega M. IL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis. *Biomolecules.* 2020 Sep 24;10(10):E1361. doi: 10.3390/biom10101361. PMID: 32987705.
636. GBD 2019 Viewpoint Collaborators (Incl. Alberto Ortiz). Five insights from the Global Burden of Disease Study 2019. *Lancet.* 2020 Oct 17;396(10258):1135-1159. doi: 10.1016/S0140-6736(20)31404-5. PMID: 33069324.
637. GBD 2019 Demographics Collaborators (Incl. Alberto Ortiz). Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. *Lancet.* 2020 Oct 17;396(10258):1160-1203. doi: 10.1016/S0140-6736(20)30977-6. PMID: 33069325.
638. GBD 2019 Diseases and Injuries Collaborators (Incl. Alberto Ortiz). Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet.* 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9. PMID: 33069326.
639. GBD 2019 Risk Factors Collaborators (Incl. Alberto Ortiz).. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet.* 2020 Oct 17;396(10258):1223-1249. doi: 10.1016/S0140-6736(20)30752-2. PMID: 33069327.
640. Ortiz A. Ckj consolidation among Q1 Urology and Nephrology journals. *Clin Kidney J.* 2020 Oct 9;13(5):723-727. doi: 10.1093/ckj/sfaa197. PMID: 33123351; PMCID: PMC7577766.
641. Fernandez-Fernandez B, Sarafidis P, Kanbay M, Navarro-González JF, Soler MJ, Górriz JL, Ortiz A. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. *Clin Kidney J.* 2020 Oct 9;13(5):728-733. doi: 10.1093/ckj/sfaa198. PMID: 33123352; PMCID: PMC7577767.
642. Fernandez-Prado R, Perez-Gomez MV, Ortiz A. Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease. *Clin Kidney J.* 2020 Feb 11;13(5):753-757. doi: 10.1093/ckj/sfaa001. PMID: 33123354; PMCID: PMC7577764.
643. Ortiz A. Complement and protection from tissue injury in COVID-19. *Clin Kidney J.* 2020 Oct 4;13(5):734-738. doi: 10.1093/ckj/sfaa196. PMID: 33123353; PMCID: PMC7577760.
644. Fernandez-Prado R, Ortiz A, Perez-Gomez MV. Allopurinol and Chronic Kidney Disease. *N Engl J Med.* 2020 Oct 22;383(17):1690. doi: 10.1056/NEJMc2026125. PMID: 33085875.
645. Soler MJ, Macia Heras M, Ortiz A, Del Pino Y Pino MD, Salgueira Lazo M. Impact of the COVID-19 pandemic on Spanish Nephrology Services. *Nefrologia.* 2020 Oct 6:S0211-6995(20)30137-5. English, Spanish. doi: 10.1016/j.nefro.2020.08.002. Epub ahead of print. PMID: 33131910.
646. Gomá-Garcés E, Pérez-Gómez MV, Ortiz A. Givosiran for Acute Intermittent Porphyria. *N Engl J Med.* 2020 Nov 12;383(20):1989. doi: 10.1056/NEJMc2026458. PMID: 33176091.
647. Hopkin RJ, Feldt-Rasmussen U, Germain DP, Jovanovic A, Martins AM, Nicholls K, Ortiz A, Politei J, Ponce E, Varas C, Weidemann F, Yang M, Wilcox WR. Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype. *Mol Genet Metab Rep.* 2020 Oct 30;25:100670. doi: 10.1016/j.ymgmr.2020.100670. PMID: 33163363; PMCID: PMC7606866.
648. Gracia-Iguacel C, González-Parra E, Mahillo I, Ortiz A. Low Intracellular Water, Overhydration, and Mortality in Hemodialysis Patients. *J Clin Med.* 2020 Nov 10;9(11):E3616. doi: 10.3390/jcm9113616. PMID: 33182670.
649. Fernández-Juárez G, Rojas-Rivera J, Logt AV, Justino J, Sevillano A, Caravaca-Fontán F, Ávila A, Rabasco C, Cabello V, Varela A, Díez M, Martín-Reyes G, Diezhandino MG, Quintana LF, Agraz I, Gómez-Martino JR, Cao M, Rodríguez-Moreno A, Rivas B, Galeano C, Bonet J, Romera A, Shabaka A, Plaisier E, Espinosa M, Egido J, Segarra A, Lambeau G, Ronco P, Wetzels J, Praga M; STARMEN investigators A Ortiz). The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. *Kidney Int.* 2020 Nov 7:S0085-2538(20)31251-5. doi: 10.1016/j.kint.2020.10.014. Epub ahead of print. PMID: 33166580
650. Trimarchi H, Ortiz A, Sánchez-Niño MD. Lyso-Gb3 Increases  $\alpha v \beta 3$  Integrin Gene Expression in Cultured Human



- Podocytes in Fabry Nephropathy. *J Clin Med*. 2020 Nov 13;9(11):E3659. doi: 10.3390/jcm9113659. PMID: 33203029.
651. Bover J, Bosch R, Ureña P, Trinidad P, Jara A, Górriz JL, Furlano M, García-Trabanino RA, Gelpi R, Ortiz A, Restrepo CA, Sánchez-Baya M, Arana C, Goicoechea M, Coll V, Segura J, Gutiérrez O, Sánchez E, Ferreira A, García-Maset R. Kidneys also speak Spanish. *Nefrologia*. 2020 Dec 4:S0211-6995(20)30181-8. English, Spanish. doi: 10.1016/j.nefro.2020.11.002. Epub ahead of print. PMID: 33288346.
652. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernández-Solà J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundström J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group (Incl. Alberto Ortiz). Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. *J Am Coll Cardiol*. 2020 Dec 3:S0735-1097(20)37775-5. doi: 10.1016/j.jacc.2020.11.010. Epub ahead of print. PMID: 33309175.
653. Rudnicki M, Siwy J, Wendt R, Lipphardt M, Koziolok MJ, Maixnerova D, Peters B, Kerschbaum J, Leierer J, Neprasova M, Banasik M, Sanz AB, Perez-Gomez MV, Ortiz A, Stegmayr B, Tesar V, Mischak H, Beige J, Reich HN; PERSTIGAN working group. Urine proteomics for prediction of disease progression in patients with IgA nephropathy. *Nephrol Dial Transplant*. 2020 Dec 14:gfaa307. doi: 10.1093/ndt/gfaa307. Epub ahead of print. PMID: 33313853.
654. Quiroga B, Sanz Sainz M, Santos Sánchez-Rey B, Muñoz Ramos P, Ortiz A, Ruano P. Persistent Kidney Dysfunction after Acute Kidney Injury Predicts Short-Term Outpatient Mortality. *Intern Med J*. 2020 Dec 20. doi: 10.1111/imj.15166. Epub ahead of print. PMID: 33342021.
655. Kanbay M, Ertuglu LA, Afsar B, Ozdogan E, Siriopol D, Covic A, Basile C, Ortiz A. An update review of intradialytic hypotension: concept, risk factors, clinical implications and management. *Clin Kidney J*. 2020 Jul 8;13(6):981-993. doi: 10.1093/ckj/sfaa078. PMID: 33391741; PMCID: PMC7769545.
656. Ortiz A. The unaccomplished mission of reducing mortality in patients on kidney replacement therapy. *Clin Kidney J*. 2020 Nov 30;13(6):948-951. doi: 10.1093/ckj/sfaa235. PMID: 33391738; PMCID: PMC7769530.
657. Afsar B, Afsar RE, Ertuglu LA, Kuwabara M, Ortiz A, Covic A, Kanbay M. Renin-angiotensin system and cancer: epidemiology, cell signaling, genetics and epigenetics. *Clin Transl Oncol*. 2020 Sep 15. doi: 10.1007/s12094-020-02488-3. Epub ahead of print. PMID: 32930920.
658. Gonzalez-Martin G, Cano J, Carriazo S, Kanbay M, Perez-Gomez MV, Fernandez-Prado R, Ortiz A. The dirty little secret of urate-lowering therapy: useless to stop chronic kidney disease progression and may increase mortality. *Clin Kidney J*. 2020 Sep 16;13(6):936-947. doi: 10.1093/ckj/sfaa236. PMID: 33391737; PMCID: PMC7769546.
659. Laney DA, Germain DP, Oliveira JP, Burlina AP, Cabrera GH, Hong GR, Hopkin RJ, Niu DM, Thomas M, Trimarchi H, Wilcox WR, Politei JM, Ortiz A. Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. *Clin Kidney J*. 2020 Dec 24;13(6):913-925. doi: 10.1093/ckj/sfaa227. PMID: 33391734; PMCID: PMC7769541.
660. Guerrero-Hue M, Rayego-Mateos S, Vázquez-Carballo C, Palomino-Antolín A, García-Caballero C, Opazo-Rios L, Morgado-Pascual JL, Herencia C, Mas S, Ortiz A, Rubio-Navarro A, Egea J, Villalba JM, Egidio J, Moreno JA. Protective Role of Nrf2 in Renal Disease. *Antioxidants (Basel)*. 2020 Dec 31;10(1):E39. doi: 10.3390/antiox10010039. PMID: 33396350.
661. Alexandru S, Ortiz Arduan A, López Picasso M, García-Puente Suarez L, Pampa Saíco SE, Pizarro Sánchez MS, Cannata Ortiz P, Barba Martin R. Persistent acute renal failure in a patient infected with *Plasmodium malariae*: The importance of renal biopsy. *Nefrologia*. 2020 Sep-Oct;40(5):571-573. English, Spanish. doi: 10.1016/j.nefro.2019.10.002. Epub 2020 Jan 13. PMID: 31948826
662. ERA-EDTA Council; ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. *Nephrol Dial Transplant*. 2021 Jan 1;36(1):87-94. doi: 10.1093/ndt/gfaa314. PMID: 33340043
663. Sever MS, Ortiz A, Maggiore U, Bac-García E, Vanholder R. Mass Disasters and Burnout in Nephrology Personnel: From Earthquakes and Hurricanes to COVID-19 Pandemic. *Clin J Am Soc Nephrol*. 2021 Jan 7:CJN.08400520. doi: 10.2215/CJN.08400520. Epub ahead of print. PMID: 33414153.
664. Moreno-Martinez D, Aguiar P, Auray-Blais C, Beck M, Bichet DG, Burlina A, Cole D, Elliott P, Feldt-Rasmussen U, Feriozzi S, Fletcher J, Giugliani R, Jovanovic A, Kampmann C, Langeveld M, Lidove O, Linhart A, Mauer M,

- Moon JC, Muir A, Nowak A, Oliveira JP, Ortiz A, Pintos-Morell G, Politei J, Rozenfeld P, Schiffmann R, Svarstad E, Talbot AS, Thomas M, Tøndel C, Warnock D, West ML, Hughes DA. Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus. *Mol Genet Metab.* 2021 Apr;132(4):234-243. doi: 10.1016/j.ymgme.2021.02.001. Epub 2021 Feb 20. PMID: 33642210.
665. Favero C, Carriazo S, Cuarental L, Fernandez-Prado R, Gomá-Garcés E, Perez-Gomez MV, Ortiz A, Fernandez-Fernandez B, Sanchez-Niño MD. Phosphate, Microbiota and CKD. *Nutrients.* 2021 Apr 13;13(4):1273. doi: 10.3390/nu13041273. PMID: 33924419; PMCID: PMC8070653.
666. Esteras R, Cannata-Ortiz P, Del Palacio-Tamarit M, Guerrero-Hue M, García-Caballero C, Egido J, Gimeno J, Ortiz A, Gracia-Iguacel C, Moreno JA. Podocyte and tubular involvement in AngioJet-induced kidney injury. *Clin Kidney J.* 2019 Aug 23;14(1):424-428. doi: 10.1093/ckj/sfz104. PMID: 33564448; PMCID: PMC7857840.
667. Martin-Cleary C, Molinero-Casares LM, Ortiz A, Arce-Obieta JM. Development and internal validation of a prediction model for hospital-acquired acute kidney injury. *Clin Kidney J.* 2019 Nov 7;14(1):309-316. doi: 10.1093/ckj/sfz139. PMID: 33564433; PMCID: PMC7857831
668. Acar S, Sanli S, Oztosun C, Afsar B, Sag AA, Kuwabara M, Covic A, Ortiz A, Kanbay M. Pharmacologic and interventional paradigms of diuretic resistance in congestive heart failure: a narrative review. *Int Urol Nephrol.* 2021 Jan 3. doi: 10.1007/s11255-020-02704-7. Epub ahead of print. PMID: 33392884.
669. Kanbay M, Demiray A, Afsar B, Covic A, Tapoi L, Ureche C, Ortiz A. Role of Klotho in the Development of Essential Hypertension. *Hypertension.* 2021 Jan 11:HYPERTENSIONAHA12016635. doi: 10.1161/HYPERTENSIONAHA.120.16635. Epub ahead of print. PMID: 33423524.
670. Sarafidis P, Ortiz A, Ferro CJ, Halimi JM, Kreutz R, Mallamaci F, Mancia G, Wanner C; ‘Hypertension and the Kidney’ working group of the European Society of Hypertension (ESH) and the ‘European Renal and Cardiovascular Medicine’ (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA). Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. *J Hypertens.* 2021 Jan 11. doi: 10.1097/HJH.0000000000002776. Epub ahead of print. PMID: 33443971
671. Ortiz A, Sanchez-Niño MD. Key unsolved issues in kidney replacement therapy. *J Intern Med.* 2021 Jan 22. doi: 10.1111/joim.13255. Epub ahead of print. PMID: 33482018.
672. Gregório PC, da Cunha RS, Biagini G, Bosquetti B, Budag J, Ortiz A, Sánchez-Niño MD, Barreto FC, Stinghen AE. Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress. *Toxicol Appl Pharmacol.* 2021 Jan 20:115412. doi: 10.1016/j.taap.2021.115412. Epub ahead of print. PMID: 33484708.
673. Pizarro-Sánchez MS, Avello A, Mas-Fontao S, Stock da Cunha T, Goma-Garcés E, Pereira M, Ortíz A, González-Parra E. Clinical Features of Asymptomatic SARS-CoV-2 Infection in Hemodialysis Patients. *Kidney Blood Press Res.* 2021 Jan 27:1-9. doi: 10.1159/000512535. Epub ahead of print. PMID: 33503627.
674. Rojas-Rivera J, Ortiz A, Carriazo S. Belimumab in Lupus Nephritis. *N Engl J Med.* 2021 Jan 14;384(2):187. doi: 10.1056/NEJMc2032520. PMID: 33497557.
675. Quiroga B, Muñoz Ramos P, Giorgi M, de Santos A, Núñez A, Ortiz A, Redondo Polo C, Almería Gómez O, Marcos-Jiménez A, Esparcia Pinedo L, Barril G. Dynamic assessment of interleukin-6 during hemodialysis and mortality in COVID 19. *Ther Apher Dial.* 2021 Jan 26. doi: 10.1111/1744-9987.13626. Epub ahead of print. PMID: 33497039
676. Poveda J, Vázquez-Sánchez S, Sanz AB, Ortiz A, Ruilope LM, Ruiz-Hurtado G. TWEAK-Fn14 as a common pathway in the heart and the kidneys in cardiorenal syndrome. *J Pathol.* 2021 Jan 29. doi: 10.1002/path.5631. Epub ahead of print. PMID: 33512736.
677. Vanholder R, Rondeau E, Anders HJ, Carlson N, Fliser D, Kanbay M, António Lopes J, Murray PT, Ortiz A, Sanz AB, Selby NM, Wiecek A, Massy ZA. EDTAKI: A Nephrology and Public Policy Committee (NPPC) Platform Call for More European Involvement in AKI. *Nephrol Dial Transplant.* 2021 Feb 2:gfab018. doi: 10.1093/ndt/gfab018. Epub ahead of print. PMID: 33527142.
678. Kanbay M, Ertuglu LA, Afsar B, Ozdogan E, Siriopol D, Covic A, Basile C, Ortiz A. An update review of intradialytic hypotension: concept, risk factors, clinical implications and management. *Clin Kidney J.* 2020 Jul 8;13(6):981-993. doi: 10.1093/ckj/sfaa078. PMID: 33391741; PMCID: PMC7769545.
679. Carriazo S, Ortiz A. European East-West divide in kidney disease: the need to understand the drivers of chronic kidney disease outcomes. *Clin Kidney J.* 2020 Nov 30;14(1):1-4. doi: 10.1093/ckj/sfaa217. PMID: 33564399; PMCID: PMC7857834.
680. Martínez-Castelao A, Soler MJ, Górriz Teruel JL, Navarro-González JF, Fernandez-Fernandez B, de Alvaro Moreno F, Ortiz A. Optimizing the timing of nephrology referral for patients with diabetic kidney disease. *Clin Kidney J.* 2020 Aug 5;14(1):5-8. doi: 10.1093/ckj/sfaa125. PMID: 33564400; PMCID: PMC7857795.
681. Avello A, Fernandez-Prado R, Santos-Sanchez-Rey B, Rojas-Rivera J, Ortiz A. Slo-Mo anti-neutrophil cytoplasmic antibody-associated renal vasculitis. *Clin Kidney J.* 2020 Nov 9;14(1):18-22. doi: 10.1093/ckj/sfaa181. PMID:

33564403; PMID: PMC7857803.

682. Vlahou A, Hallinan D, Apweiler R, Argiles A, Beige J, Benigni A, Bischoff R, Black PC, Boehm F, Céraline J, Chrousos GP, Delles C, Evenepoel P, Fridolin I, Glorieux G, van Gool AJ, Heidegger I, Ioannidis JPA, Jankowski J, Jankowski V, Jeronimo C, Kamat AM, Masereeuw R, Mayer G, Mischak H, Ortiz A, Remuzzi G, Rossing P, Schanstra JP, Schmitz-Dräger BJ, Spasovski G, Staessen JA, Stamatialis D, Stenvinkel P, Wanner C, Williams SB, Zannad F, Zoccali C, Vanholder R. Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics? *Hypertension*. 2021 Feb 15;HYPERTENSIONAHA12016340. doi: 10.1161/HYPERTENSIONAHA.120.16340. Epub ahead of print. PMID: 33583200.
683. Lei Y, Sehnert B, Voll RE, Jacobs-Cachá C, Soler MJ, Sanchez-Niño MD, Ortiz A, Bülow RD, Boor P, Anders HJ. A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Faslpr mice with proliferative lupus nephritis predicts low effect size. *Kidney Int*. 2021 Jun;99(6):1331-1341. doi: 10.1016/j.kint.2021.01.024. Epub ahead of print. PMID: 33607177.
684. Vallejo-Valdivieso PA, Zambrano-Pincay G, Ortiz A. Undiagnosed cardiovascular risk factors in overweight and obese individuals: a low income country experience. *PeerJ*. 2021 Feb 2;9:e10870. doi: 10.7717/peerj.10870. PMID: 33604197; PMID: PMC7863779
685. Rodríguez-Rodríguez AE, Luis-Lima S, Donate-Correa J, Diaz-Martín L, Arnau MR, Jiménez-Sosa A, Gaspari F, Ortiz A, Porrini E. Iohexol plasma clearance simplified by Dried Blood Spot (DBS) sampling to measure renal function in conscious mice. *Sci Rep*. 2021 Feb 25;11(1):4591. doi: 10.1038/s41598-021-83934-2. PMID: 33633207
686. Fernandez-Prado R, Peña-Esparragoza JK, Santos-Sánchez-Rey B, Pereira M, Avello A, Gomá-Garcés E, González-Rivera M, González-Martin G, Gracia-Iguacel C, Mahillo I, Ortiz A, González-Parra E. Ultrafiltration rate adjusted to body weight and mortality in hemodialysis patients. *Nefrologia*. 2021 Mar 1:S0211-6995(21)00010-2. English, Spanish. doi: 10.1016/j.nefro.2020.10.007. Epub ahead of print. PMID: 33663812.
687. Cabello R, Fontecha-Barriuso M, Martin-Sanchez D, Lopez-Diaz AM, Carrasco S, Mahillo I, Gonzalez-Enguita C, Sanchez-Niño MD, Ortiz A, Sanz AB. Urinary Cyclophilin A as Marker of Tubular Cell Death and Kidney Injury. *Biomedicines*. 2021 Feb 20;9(2):217. doi: 10.3390/biomedicines9020217. PMID: 33672645.
688. Luis-Lima S, Marrero-Miranda D, González-Rinne A, Negrín-Mena N, Pérez-Tamajón L, Rodríguez A, Alvarez-González A, González-Delgado A, Ferrer-Moure C, González-Rinne F, Martín LD, Rodríguez-Rodríguez AE, Gómez-Díaz L, García-Cabrera V, Jiménez-Sosa A, Torres A, Ortiz A, Gaspari F, Porrini E. Estimated GFR Slope in Kidney Transplant Patients: When the Error Is Random. *Transplantation*. 2021 Feb 23. doi: 10.1097/TP.0000000000003719. Epub ahead of print. PMID: 33675320.
689. Afsar B, Hornum M, Afsar RE, Ertuglu LA, Ortiz A, Covic A, van Raalte DH, Cherney DZI, Kanbay M. Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications. *Mitochondrion*. 2021 Mar 4:S1567-7249(21)00032-5. doi: 10.1016/j.mito.2021.02.016. Epub ahead of print. PMID: 33677060.
690. Goicoechea M, Gomez-Preciado F, Benito S, Jorras J, Torra R, Huerta A, Restrepo A, Ugalde J, Astudillo DE, Agraz I, Lopez-Mendoza M, de Arriba G, Corchete E, Quiroga B, Gutierrez MJ, Martin-Conde ML, Lopes V, Ramos C, Mendez I, Cao M, Dominguez F, Ortiz A; Spanish Group for the Study of Glomerular Diseases (GLOSEN). Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy. *Nefrologia*. 2021 Mar 10:S0211-6995(21)00031-X. English, Spanish. doi: 10.1016/j.nefro.2021.01.002. Epub ahead of print. PMID: 33714629.
691. Pisano A, Mallamaci F, D'Arrigo G, Bolognani D, Wuerzner G, Ortiz A, Burnier M, Kanaan N, Sarafidis P, Persu A, Ferro CJ, Loutradis C, Boletis IN, London G, Halimi JM, Sautenet B, Rossignol P, Vogt L, Zoccali C. Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. *Nephrol Dial Transplant*. 2021 Mar 25;gfab076. doi: 10.1093/ndt/gfab076. Epub ahead of print. PMID: 33764450
692. Cantero-Navarro E, Fernández-Fernández B, Ramos AM, Rayego-Mateos S, Rodrigues-Diez RR, Sánchez-Niño MD, Sanz AB, Ruiz-Ortega M, Ortiz A. Renin-angiotensin system and inflammation update [published online ahead of print, 2021 Mar 30]. *Mol Cell Endocrinol*. 2021;111254. doi:10.1016/j.mce.2021.111254
693. Ortiz A, Kanters S, Hamed A, DasMahapatra P, Poggio E, Maski M, Aguiar M, Ponce E, Jansen JP, Ayers D, Goldgrub R, Desnick RJ. Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis. *Clin Kidney J*. 2020 May 22;14(4):1136-1146. doi: 10.1093/ckj/sfaa065. PMID: 33841859; PMID: PMC8023189.
694. Mas S, Ruiz-Priego A, Abaigar P, Santos J, Camarero V, Egido J, Ortiz A, Gonzalez-Parra E. Bisphenol S is a haemodialysis-associated xenobiotic that is less toxic than bisphenol A. *Clin Kidney J*. 2020 Jun 8;14(4):1147-1155. doi: 10.1093/ckj/sfaa071. PMID: 33841860; PMID: PMC8023199.
695. Quiroga B, Sánchez-Álvarez E, Ortiz A, de Sequera P; Spanish Society of Nephrology. Suboptimal personal protective equipment and SARS-CoV-2 infection in Nephrologists: a Spanish national survey. *Clin Kidney J*. 2021 Jan 18;14(4):1216-1221. doi: 10.1093/ckj/sfab009. PMID: 33841867; PMID: PMC7928998.

696. Perez-Gomez MV, Pizarro-Sanchez S, Gracia-Iguacel C, Cano S, Cannata-Ortiz P, Sanchez-Rodriguez J, Sanz AB, Sanchez-Niño MD, Ortiz A. Urinary Growth Differentiation Factor-15 (GDF15) levels as a biomarker of adverse outcomes and biopsy findings in chronic kidney disease. *J Nephrol*. 2021 Dec;34(6):1819-1832. doi: 10.1007/s40620-021-01020-2. PMID: 33847920.
697. Díez J, Navarro-González JF, Ortiz A, Santamaría R, de Sequera P. Developing the subspecialty of cardioneurology: The time has come. A position paper from the coordinating committee from the Working Group for Cardioresnal Medicine of the Spanish Society of Nephrology. *Nefrologia*. 2021 Apr 20:S0211-6995(21)00067-9. English, Spanish. doi: 10.1016/j.nefro.2021.02.003. Epub ahead of print. PMID: 33892978.
698. Ertuglu LA, Porrini E, Hornum M, Demiray A, Afsar B, Ortiz A, Covic A, Rossing P, Kanbay M. Glucagon Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Diabetes After Solid Organ Transplantation. *Transpl Int*. 2021 Apr 20. doi: 10.1111/tri.13883. Epub ahead of print. PMID: 33880815
699. Ortiz A, Ferro CJ, Balafa O, Burnier M, Ekart R, Halimi JM, Kreutz R, Mark PB, Persu A, Rossignol P, Ruilope LM, Schmieder RE, Valdivielso JM, Del Vecchio L, Zoccali C, Mallamaci F, Sarafidis P; European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association—European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and Kidney working group of the European Society of Hypertension (ESH). Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. *Nephrol Dial Transplant*. 2021 May 4:gfab167. doi: 10.1093/ndt/gfab167. Epub ahead of print. PMID: 33944938.
700. Perez-Villa F, Lafage-Proust MH, Gielen E, Ortiz A, Spasovski G, Argilés À. The renal patient seen by non-renal physicians: the kidney embedded in the 'milieu intérieur'. *Clin Kidney J*. 2020 Dec 11;14(4):1077-1087. doi: 10.1093/ckj/sfaa234. PMID: 34094517; PMCID: PMC8173597.
701. Soler MJ, Noordzij M, Abramowicz D, de Arriba G, Basile C, van Buren M, Covic A, Crespo M, Duivenvoorden R, Massy Z, Ortiz A, Sanchez E, Petridou E, Stevens K, White C, Vart P, Gansevoort R. Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure. *Clin J Am Soc Nephrol*. 2021 Jun 4:CJN.18961220. doi: 10.2215/CJN.18961220. Epub ahead of print. PMID: 34088718.
702. Bover J, Bosch R, Ureña P, Trinidad P, Jara A, Górriz JL, Furlano M, García-Trabanino RA, Gelpi R, Ortiz A, Restrepo CA, Sánchez-Baya M, Arana C, Goicoechea M, Coll V, Segura J, Gutiérrez O, Sánchez E, Ferreira A, García-Maset R. Kidneys also speak Spanish. *Nefrologia*. 2021 May 28:S2013-2514(21)00042-0. doi: 10.1016/j.nefro.2020.11.012. Epub ahead of print. PMID: 34059481.
703. Halimi JM, Ortiz A, Sarafidis PA, Mallamaci F, Wuerzner G, Pisano A, London G, Persu A, Rossignol P, Sautenet B, Ferro C, Boletis J, Kanaan N, Vogt L, Bolognani D, Burnier M, Zoccali C. Hypertension in kidney transplantation: a consensus statement of the 'hypertension and the kidney' working group of the European Society of Hypertension. *J Hypertens*. 2021 May 28. doi: 10.1097/HJH.0000000000002879. Epub ahead of print. PMID: 34054055
704. Cordido A, Nuñez-Gonzalez L, Martinez-Moreno JM, Lamas-Gonzalez O, Rodriguez-Osorio L, Perez-Gomez MV, Martin-Sanchez D, Outeda P, Chiaravalli M, Watnick T, Boletta A, Diaz C, Carracedo A, Sanz AB, Ortiz A, Garcia-Gonzalez MA. TWEAK Signaling Pathway Blockade Slows Cyst Growth and Disease Progression in Autosomal Dominant Polycystic Kidney Disease. *J Am Soc Nephrol*. 2021 Aug;32(8):1913-1932. doi: 10.1681/ASN.2020071094. Epub 2021 Jun 21. PMID: 34155062; PMCID: PMC8455272.
705. Fernandez-Prado R, Ortiz A. Verinurad/febuxostat and Nephrotoxicity. *Am J Kidney Dis*. 2021 Jun 9:S0272-6386(21)00641-7. doi: 10.1053/j.ajkd.2021.03.029. Epub ahead of print. PMID: 34126127.
706. Marquez-Exposito L, Tejedor-Santamaria L, Santos-Sanchez L, Valentijn FA, Cantero-Navarro E, Rayego-Mateos S, Rodrigues-Diez RR, Tejera-Muñoz A, Marchant V, Sanz AB, Ortiz A, Goldschmeding R, Ruiz-Ortega M. Acute Kidney Injury is Aggravated in Aged Mice by the Exacerbation of Proinflammatory Processes. *Front Pharmacol*. 2021 Jun 22;12:662020. doi: 10.3389/fphar.2021.662020. PMID: 34239439; PMCID: PMC8258347.
707. Del Vecchio L, Ekart R, Ferro CJ, Malyszko J, Mark PB, Ortiz A, Sarafidis P, Valdivielso JM, Mallamaci F; ERA-EDTA European Renal and Cardiovascular Medicine Working (EURECA-m) Group. Intravenous iron therapy and the cardiovascular system: risks and benefits. *Clin Kidney J*. 2020 Nov 26;14(4):1067-1076. doi: 10.1093/ckj/sfaa212. PMID: 34188903; PMCID: PMC8223589.
708. Díez J, Ortiz A. The need for a cardioneurology subspecialty. *Clin Kidney J*. 2021 Mar 10;14(6):1491-1494. doi: 10.1093/ckj/sfab054. PMID: 34276973; PMCID: PMC8280941.
709. Rodrigues-Diez RR, Tejera-Muñoz A, Orejudo M, Marquez-Exposito L, Santos L, Rayego-Mateos S, Cantero-Navarro E, Tejedor-Santamaria L, Marchant V, Ortiz A, Egido J, Mezzano S, Selgas R, Navarro-González JF, Valdivielso JM, Lavoz C, Ruiz-Ortega M. Interleukin-17A: Possible mediator and therapeutic target in hypertension. *Nefrologia*. 2021 Mar 25:S0211-6995(21)00022-9. English, Spanish. doi: 10.1016/j.nefro.2020.11.009. Epub ahead of print. PMID: 33775443
710. Kanbay M, Demiray A, Afsar B, Karakus KE, Ortiz A, Hornum M, Covic A, Sarafidis P, Rossing P. Sodium-glucose

- cotransporter 2 inhibitors for diabetes mellitus control after kidney transplantation: Review of the current evidence. *Nephrology (Carlton)*. 2021 Jul 14. doi: 10.1111/nep.13941. Epub ahead of print. PMID: 34263502.
711. Bover J, Bosch R, Górriz JL, Ureña P, Ortiz A, daSilva I, García-Trabanino RA, Hueso M, Trinidad P, Jara A, Furlano M, Gelpi R, Vila-Santandreu A, Restrepo CA, Sánchez-Baya M, Arana C, Goicoechea M, Coll V, Segura J, Gutiérrez O, Kalantar-Zadeh K, Sánchez E, Ferreira A, García-Maset R. Kidneys also speak Spanish: Initiatives towards standardisation of our nephrology nomenclature. *Nefrologia*. 2021 Aug 24:S0211-6995(21)00157-0. English, Spanish. doi: 10.1016/j.nefro.2021.04.011. Epub ahead of print. PMID: 34452777.
712. GBD 2019 Under-5 Mortality Collaborators. Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. *Lancet*. 2021 2021 Sep 4;398(10303):870-905. doi: 10.1016/S0140-6736(21)01207-1. Epub 2021 Aug 17. PMID: 34416195; PMCID: PMC8429803.
713. Lozano-Ojalvo D, Camara C, Lopez-Granados E, Nozal P, Del Pino-Molina L, Bravo-Gallego LY, Paz-Artal E, Pion M, Correa-Rocha R, Ortiz A, Lopez-Hoyos M, Iribarren ME, Portoles J, Rojo-Portoles MP, Ojeda G, Cervera I, Gonzalez-Perez M, Bodega-Mayor I, Montes-Casado M, Portoles P, Perez-Olmeda M, Oteo J, Sanchez- Tarjuelo R, Pothula V, Schwarz M, Brahmachary M, Tan AT, Le Bert N, Berin C, Bertoletti A, Guccione E, Ochando J. Differential effects of the second SARS- CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. *Cell Rep*. 2021 Aug 24;36(8):109570. doi: 10.1016/j.celrep.2021.109570. Epub 2021 Aug 4. PMID: 34390647; PMCID: PMC8332924.
714. Torra R, Furlano M, Ortiz A, Ars E. Genetic kidney diseases as an underrecognized cause of chronic kidney disease: the key role of international registry reports. *Clin Kidney J*. 2021 Mar 12;14(8):1879-1885. doi: 10.1093/cjk/sfab056. PMID: 34345410; PMCID: PMC8323147.
715. García-Foncillas J, Argente J, Bujanda L, Cardona V, Casanova B, Fernández-Montes A, Horcajadas JA, Iñiguez A, Ortiz A, Pablos JL, Pérez Gómez MV. Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview. *Mol Diagn Ther*. 2021 Sep;25(5):563-576. doi: 10.1007/s40291-021-00544-4. Epub 2021 Jul 30. PMID: 34331269.
716. Valdivielso JM, Balafa O, Ekart R, Ferro CJ, Mallamaci F, Mark PB, Rossignol P, Sarafidis P, Del Vecchio L, Ortiz A. Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies. *Drugs*. 2021 Jul 27. doi: 10.1007/s40265-021-01555-5. Epub ahead of print. PMID: 34313978.
717. Cantero-Navarro E, Rayego-Mateos S, Orejudo M, Tejedor-Santamaria L, Tejera-Muñoz A, Sanz AB, Marquez-Exposito L, Marchant V, Santos-Sanchez L, Egido J, Ortiz A, Bellon T, Rodrigues-Diez RR, Ruiz-Ortega M. Role of Macrophages and Related Cytokines in Kidney Disease. *Front Med (Lausanne)*. 2021 Jul 8;8:688060. doi: 10.3389/fmed.2021.688060. PMID: 34307414; PMCID: PMC8295566.
718. Imenez Silva PH, Unwin R, Hoorn EJ, Ortiz A, Trepiccione F, Nielsen R, Pesic V, Hafez G, Fouque D, Massy ZA, De Zeeuw CI, Capasso G, Wagner CA; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target). Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease. *Nephrol Dial Transplant*. 2021 Oct 31:gfab216. doi: 10.1093/ndt/gfab216. Epub ahead of print. PMID: 34718761.
719. Pépin M, Ferreira AC, Arici M, Bachman M, Barbieri M, Bumblyte IA, Carriazo S, Delgado P, Garneata L, Giannakou K, Godefroy O, Grodzicki T, Klimkowicz- Mrowiec A, Kurganaite J, Liabeuf S, Mocanu CA, Paolisso G, Spasovski G, Vazelon ES, Viggiano D, Zoccali C, Massy ZA, Więcek A; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target). Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment. *Nephrol Dial Transplant*. 2021 Oct 31:gfab262. doi: 10.1093/ndt/gfab262. Epub ahead of print. PMID: 34718757.
720. Liabeuf S, Pepin M, Franssen CFM, Viggiano D, Carriazo S, Gansevoort RT, Gesualdo L, Hafez G, Malyszko J, Mayer C, Nitsch D, Ortiz A, Pešić V, Więcek A, Massy ZA; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target). Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle? *Nephrol Dial Transplant*. 2021 Oct 31:gfab223. doi: 10.1093/ndt/gfab223. Epub ahead of print. PMID: 34718753.
721. Viggiano D, Bruchfeld A, Carriazo S, de Donato A, Endlich N, Ferreira AC, Figurek A, Fouque D, Franssen CFM, Giannakou K, Goumenos D, Hoorn EJ, Nitsch D, Ortiz A, Pešić V, Rastenytė D, Soler MJ, Rroji M, Trepiccione F, Unwin RJ, Wagner CA, Więcek A, Zaccchia M, Zoccali C, Capasso G; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target). Brain dysfunction in tubular and tubulointerstitial kidney diseases. *Nephrol Dial Transplant*. 2021 Dec 28;37(Suppl 2):ii46-ii55. doi: 10.1093/ndt/gfab276. PMID: 34792176; PMCID: PMC8713153.
722. Bikbov B, Soler MJ, Pešić V, et al. Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence? [published online ahead of print, 2021 Nov 5]. *Nephrol Dial Transplant*. 2021;gfab261. doi:10.1093/ndt/gfab261
723. Zoccali C, Ortiz A, Blumbyte IA, et al. Neuropeptide Y as a risk factor for cardiorenal disease and cognitive

- dysfunction in CKD: translational opportunities and challenges [published online ahead of print, 2021 Nov 1]. *Nephrol Dial Transplant*. 2021;gfab284. doi:10.1093/ndt/gfab284
724. Kinyoki D, Osgood-Zimmerman AE, Bhattacharjee NV; Local Burden of Disease Anaemia Collaborators, Kassebaum NJ, Hay SI. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018. *Nat Med*. 2021 Oct;27(10):1761-1782. doi: 10.1038/s41591-021-01498-0. Epub 2021 Oct 12. PMID: 34642490; PMCID: PMC8516651.
725. Ertuglu LA, Afsar B, Yildiz AB, Demiray A, Ortiz A, Covic A, Kanbay M. Substitution of Sugar-Sweetened Beverages for Other Beverages: Can It Be the Next Step Towards Healthy Aging? *Curr Nutr Rep*. 2021 Sep 30. doi: 10.1007/s13668-021-00372-2. Epub ahead of print. PMID: 34595722.
726. Rodríguez-Rodríguez AE, Donate-Correa J, Luis-Lima S, Díaz-Martín L, Rodríguez-González C, Pérez-Pérez JA, Acosta-González NG, Fumero C, Navarro-Díaz M, López-Álvarez D, Villacampa-Jiménez J, Navarro-González JA, Ortiz A, Porrini E. Obesity and metabolic syndrome induce hyperfiltration, glomerulomegaly, and albuminuria in obese ovariectomized female mice and obese male mice. *Menopause*. 2021 Sep 27. doi: 10.1097/GME.0000000000001842. Epub ahead of print. PMID: 34581293.
727. Rodríguez-Rodríguez R, Hojs R, Trevisani F, Morales E, Fernández G, Bevc S, Cases Corona CM, Cruzado JM, Quero M, Navarro Díaz M, Bettiga A, Di Marco F, López Martínez M, Moreso F, García Garro C, Khazim K, Ghanem F, Praga M, Ibernón M, Laranjinha I, Mendonça L, Bigotte Vieira M, Hornum M, Feldt-Rasmussen B, Fernández-Fernández B, Concepción PF, Negrín Mena N, Ortiz A, Porrini E; DIABESITY working group of the ERA. The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease. *Kidney Int Rep*. 2021 Jun 12;6(9):2392-2403. doi: 10.1016/j.ekir.2021.06.001. PMID: 34514200; PMCID: PMC8419124.
728. Copur S, Rossing P, Afsar B, Sag AA, Siriopol D, Kuwabara M, Ortiz A, Kanbay M. A primer on metabolic memory: why existing diabetes treatments fail. *Clin Kidney J*. 2020 Sep 2;14(3):756-767. doi: 10.1093/ckj/sfaa143. PMID: 34512957; PMCID: PMC8422888.
729. GBD 2019 Adolescent Mortality Collaborators. Global, regional, and national mortality among young people aged 10-24 years, 1950-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2021;398(10311):1593-1618. doi:10.1016/S0140-6736(21)01546-4
730. Villalvazo P, Carriazo S, Martin-Cleary C, Ortiz A. Aguascalientes: one of the hottest chronic kidney disease (CKD) hotspots in Mexico and a CKD of unknown aetiology mystery to be solved. *Clin Kidney J*. 2021 Jul 15;14(11):2285-2294. doi: 10.1093/ckj/sfab136. PMID: 34754425; PMCID: PMC8573004.
731. Quiroga B, Soler MJ, Ortiz A, et al. Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study [published online ahead of print, 2021 Nov 12]. *Nephrol Dial Transplant*. 2021;gfab313. doi:10.1093/ndt/gfab313
732. Capasso G, Wanner C; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target) . Present and future of CONNECT: a new and compelling project of modern medicine [published online ahead of print, 2021 Nov 11]. *Nephrol Dial Transplant*. 2021;gfab301. doi:10.1093/ndt/gfab301
733. Ortiz A, Fernandez-Fernandez B. Atrasentan: The Difficult Task of Integrating Endothelin A Receptor Antagonists into Current Treatment Paradigm for Diabetic Kidney Disease [published online ahead of print, 2021 Dec 1]. *Clin J Am Soc Nephrol*. 2021;CJN.13601021. doi:10.2215/CJN.13601021
734. Rojas-Rivera J, Fervenza FC, Ortiz A. Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy [published online ahead of print, 2021 Dec 21]. *Drugs*. 2021;10.1007/s40265-021-01656-1. doi:10.1007/s40265-021-01656-1
735. Fontecha-Barriuso M, Lopez-Diaz AM, Carriazo S, Ortiz A, Sanz AB. Nicotinamide and acute kidney injury. *Clin Kidney J*. 2021;14(12):2453-2462. Published 2021 Sep 23. doi:10.1093/ckj/sfab173
736. González-Alayón C, Porrini E, Luis-Lima S, Negrín-Mena N, Moreno M, Morales-Arreaez D, González-Rinne F, Díaz Martín L, Gaspari F, González-Delgado A, Ferrer-Moure C, Ortiz A, Hernandez-Guerra M. Estimated glomerular filtration rate by formulas in patients with cirrhosis: an unreliable procedure [published online ahead of print, 2021 Dec 23]. *Liver Int*. 2021;10.1111/liv.15134. doi:10.1111/liv.15134
737. Akyol M, Çevik E, Ucku D, Tanrıöver C, Afşar B, Kanbay A, Covic A, Ortiz A, Basile C, Kanbay M. Immunogenicity of SARS-CoV-2 mRNA vaccine in dialysis and kidney transplant patients: A systematic review. *Tuberk Toraks*. 2021 Dec;69(4):547-560. English. doi: 10.5578/tt.20219612. PMID: 34957748.
738. de Arriba G, Ortiz Arduán A, Rodríguez Pérez JC, Tejedor Jorge A, Santamaría Olmo R, Rodríguez Portillo M. Teaching nephrology as part of a degree in medicine. *Nefrologia (Engl Ed)*. 2021 May-Jun;41(3):284-303. English, Spanish. doi: 10.1016/j.nefro.2020.09.007. Epub 2021 Jan 5. PMID: 33413803.
739. Rojas-Rivera JE, Ortiz Arduán A. Primary membranous nephropathy in the era of autoantibodies and biological therapies. *Med Clin (Barc)*. 2021 Aug 13;157(3):121-129. English, Spanish. doi: 10.1016/j.medcli.2021.02.010. Epub 2021 Apr 5. PMID: 33832765.

740. Bowry SK, Ortiz AA, Maddux FW. Deciphering the core elements around haemodialysis therapy. *Clin Kidney J.* 2021;14(Suppl 4):i1-i4. Published 2021 Nov 11. doi:10.1093/ckj/sfab224
741. de Arriba G, Ortiz Arduán A, Rodríguez Pérez JC, Tejedor Jorge A, Santamaría Olmo R, Rodríguez Portillo M. Teaching nephrology as part of a degree in medicine. *Nefrología (Engl Ed).* 2021 May-Jun;41(3):284-303. English, Spanish. doi: 10.1016/j.nefro.2020.09.007. Epub 2021 Jan 5. PMID: 33413803.
742. Ruiz-Ortega M, Lamas S, Ortiz A. Antifibrotic Agents for the Management of CKD: A Review [published online ahead of print, 2022 Jan 6]. *Am J Kidney Dis.* 2022;S0272-6386(21)01051-9. doi:10.1053/j.ajkd.2021.11.010
743. Sánchez-Tocino ML, Miranda-Serrano B, Gracia-Iguacel C, de-Alba-Peñaranda AM, Mas-Fontao S, López-González A, Villoria-González S, Pereira-García M, Ortíz A, González-Parra E. Sarcopenia assessed by 4-step EWGSOP2 in elderly hemodialysis patients: Feasibility and limitations. *PLoS One.* 2022 Jan 13;17(1):e0261459. doi: 10.1371/journal.pone.0261459. PMID: 35025892.
744. Quiroga B, Soler MJ, Ortiz A, Bernat A, Díaz ABM, Mantecón CJJ, Pérez VOG, González CC, Cervienka M, Mazuecos A, Cazorla JM, Riso MCD, Martínez S, Diaz MO, Valverde RL, Márquez MGS, Novillo CL, Parra EG, Gracia-Iguacel C, De Tomas MTR, Cervera MCA, Giorgi M, Ramos PM, Carmona NM, Toapanta N, Guldris SC, Millán JCRS, Estupiñán RS, Crespo M, Linaza BV, Martín MIJ, Jiménez LR, Soriano S, Ferri DG, Sánchez MSP, Yugueros A, Leyva A, Rojas J, Gansevoort RT, de Sequera P, Carretero MP, Tocora DG, Rodríguez MJ, Zanón TT, Suárez ER, Santolaya AJS, Calero RC, Cobo PA, Martin-Cleary C, Sánchez-Rodríguez J, Pereira M, Ramos-Verde A, Sánchez C, Giraldo YG, Horrillo AS, Suárez PR, Perpén AF, Ramos AF, Villanueva LS, Cortiñas A, Arias PAD, Cárdenas AC, de Santos A, Núñez A, Cuadrado GB, Repollet R, Moreso F, Azancot MA, Ramos N, Bestard O, Cidraque I, Bermejo S, Agraz I, Prat O, Medina C, Pardo E, Saiz A, Vila MAM, Granados NM, Cabo MJC, Alarcón WL, Alexandru S, Suarez LGP, Saico SP, Tapia MP, Hernández RS, García-Fernández N, Moreno PLM, González NA, Ortiz AS, Iñarrea MNB, López RO, Peregrí CM, Morales MLA, Cabello MDN, Ribera AMT, Valcarce EG, Vergara EG, García T, Narváez C, Orellana C, Ganga PLQ, Carrión FV, Herrera ALG, Chamoun B, Barbosa F, Faura A, Pachón DR, Castro NB, Cendrero RMR, Hidalgo-Barquero MVM, Gallego RH, Alvarez Á, Leo EV, León JLP, García MAM, Jiménez BG, Moya JDR, Espinosa DL, Herrador AJ, Zurita MN, Álvarez LD, Martínez ÁG, Arroyo SB, Fernández RR, Vargas MJS, Casero RC, Useche G, de Miguel CS, Palacios Á, Henningsmeyer B, Calve EO, Moya JL, Sato Y, Marín MS, Torres I, Conde PD, Alfaro G, Halauko O, Rifai FEL, Martínez AD, Ávila PJ, Franco AM, Sainz MS, Martín JMB, García LDR, Canga JLP, Ochoa PMV, Pacios LM, Machado LL, Morales AQ, Cavalotti IM, Zorita IN, López SO, González SO, Montañez CS, Rubio AB, Gilsanz GDP, Gonzalez MO, Villanueva RS, Oliva MOL, Varela JC, Enríquez AG, Casas CC, Alonso PO, Tabares LG, Barreiro JML, Solla LP, Gándara A, de la Garza WN, Fleming FF, Goyanes MGR, Feijoo CC, Plaza MMM, Juan CB, Cecilio RVS, Haces CP, Kislikova M, Rodrigo E, Contreras FJP, Lara NB, Llorente EMB, Díaz LS, Bustamante AMC, Ruiz JM, Rodríguez EG, Perez VLM, Arevalo MC, Calvo JAH, Carratalá MRL, Rodríguez LMM, Salazar MS, Prieto BB, Pérez JMP, Rueda DA, Ferrero MLR, Martínez AV, Estébanez SA, Paraíso AG, Huarte E, Lanau M, Campos RA, Ubé JM, Pérez PS, Godoy IB, Aguilera ET, Alea RT, Saldaña MS DR, Salvetti ML, Valmajor MC, Sánchez MP, Barragán ML, Aunatell LR, Salgueira M, Aresté N, de Los Ángeles Rodríguez M, Collantes R, Martínez AI, Moyano MJ, Víbora EJ, Gash SC, Martínez LR, Prieto BA, Toyos C, Rio JM, Acosta AR, Zamacona AC, Ortega SB, Ruiz MIG, Rubio AH, Ledesma PG, Alvarez AG, de Briñas EPL, Cucchiari D, Monzo JB, Cabrera BE, Hernández APR, Rebollo MSG, Hernández JMR, Alonso JC, Más AM, Calvé M, Cardona MG, Balaguer VC, Pesquera JIM, Serrano AG, Simó PT, Mancilla HDR, Gómez MP, Gumpert JV, de la Fuente GA, Del Valle KP, de la Rosa EC, Santarelli DR, García AS, Martin-Caro AC, Santamaria IM, Umpierrez AM, Ruiz EH, Corbella AM, Perdomo KT, Martín YM, de la Pisa AMU, Monzon LS, Anachuri KA, García EH, Gomez VO, Amado FV, Borges PP, Vázquez RM, Beloso MD, Alonso FA, Felpete NP, Ameneiro AM, Mera MC, Casares BG, Larrondo SZ, Kareaga NM, Del Valle AISS, García ARM, Del Toro Espinosa N, Perico PE, Oliva JMS, Manrique J, Castaño I, Purroi C, Gómez N, Mansilla C, Utzurum A. Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study. *Nephrol Dial Transplant.* 2022 Jan 11:gfac007. doi: 10.1093/ndt/gfac007. Epub ahead of print. PMID: 35022757.
745. Pisano A, Mallamaci F, D'Arrigo G, et al. Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis. *Clin Kidney J.* 2021;15(1):31-42. Published 2021 Sep 23. doi:10.1093/ckj/sfab135
746. Kanbay M, Copur S, Demiray A, et al. Fatty Kidney: A Possible Future for Chronic Kidney Disease Research [published online ahead of print, 2022 Jan 18]. *Eur J Clin Invest.* 2022;e13748. doi:10.1111/eci.13748
747. Martin-Sanchez D, Guerrero-Mauvecin J, Fontecha-Barriuso M, Mendez-Barbero N, Saiz ML, Lopez-Diaz AM, Sanchez-Niño MD, Carrasco S, Cannata-Ortiz P, Ruiz-Ortega M, Ortiz A, Sanz AB. Bone Marrow-Derived RIPK3 Mediates Kidney Inflammation in Acute Kidney Injury. *J Am Soc Nephrol.* 2022 Feb;33(2):357-373. doi:10.1681/ASN.2021030383
748. Gregório PC, Biagini G, da Cunha RS, et al. Growth differentiation factor-15 (GDF-15) and syndecan-1 are potential

- biomarkers of cardiac and renal involvement in classical Fabry disease under enzyme replacement therapy [published online ahead of print, 2022 Jan 27]. *Kidney Blood Press Res.* 2022;10.1159/000521329. doi:10.1159/000521329
749. Ruilope LM, Ruiz-Hurtado G, Miranda B, Ortiz A. Use of chronic kidney disease blind spot to prevent cardiorenal outcomes. *Eur Heart J.* 2022 Jan 31;43(4):257-260. doi: 10.1093/eurheartj/ehab456. PMID: 35100341.
750. Rodrigues-Diez RR, Tejera-Muñoz A, Esteban V, Steffensen LB, Rodrigues-Diez R, Orejudo M, Rayego-Mateos S, Falke LL, Cannata-Ortiz P, Ortiz A, Egido J, Mallat Z, Briones Ana M, Bajo MA, Goldschmeding R, Ruiz-Ortega M. CCN2 (Cellular Communication Network Factor 2) Deletion Alters Vascular Integrity and Function Predisposing to Aneurysm Formation. *Hypertension.* 2022 Mar;79(3):e42-e55. doi: 10.1161/HYPERTENSIONAHA.121.18201. Epub 2021 Dec 30. PMID: 35138869.
751. Martín-Saiz L, Guerrero-Mauvecin J, Martín-Sanchez D, Fresnedo O, Gómez MJ, Carrasco S, Cannata-Ortiz P, Ortiz A, Fernandez JA, Sanz AB. Ferrostatin-1 modulates dysregulated kidney lipids in acute kidney injury. *J Pathol.* 2022 Feb 13. doi: 10.1002/path.5882. Epub ahead of print. PMID: 35152438.
752. Rayego-Mateos S, Marquez-Expósito L, Rodrigues-Diez R, Sanz AB, Guiteras R, Doladé N, Rubio-Soto I, Manonelles A, Codina S, Ortiz A, Cruzado JM, Ruiz-Ortega M, Sola A. Molecular Mechanisms of Kidney Injury and Repair. *Int J Mol Sci.* 2022 Jan 28;23(3):1542. doi: 10.3390/ijms23031542. PMID: 35163470.
753. Carriazo S, Villalvazo P, Ortiz A. More on the invisibility of chronic kidney disease... and counting. *Clin Kidney J.* 2021 Nov 27;15(3):388-392. doi: 10.1093/ckj/sfab240. PMID: 35198154; PMCID: PMC8690216.
754. Theodorakopoulou MP, Alexandrou ME, Boutou AK, Ferro CJ, Ortiz A, Sarafidis P. Renin-angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease. *Clin Kidney J.* 2021 Dec 14;15(3):397-406. doi: 10.1093/ckj/sfab272. PMID: 35198155; PMCID: PMC8754739.
755. Carriazo S, Mas-Fontao S, Seghers C, Cano J, Goma E, Avello A, Ortiz A, Gonzalez-Parra E. Increased 1-year mortality in haemodialysis patients with COVID-19: a prospective, observational study. *Clin Kidney J.* 2021 Dec 20;15(3):432-441. doi: 10.1093/ckj/sfab248. PMID: 35198156; PMCID: PMC8755355.
756. Marquez-Exposito L, Tejedor-Santamaria L, Valentijn FA, Tejera-Muñoz A, Rayego-Mateos S, Marchant V, Rodrigues-Diez RR, Rubio-Soto I, Knoppert SN, Ortiz A, Ramos AM, Goldschmeding R, Ruiz-Ortega M. Oxidative Stress and Cellular Senescence Are Involved in the Aging Kidney. *Antioxidants (Basel).* 2022 Jan 31;11(2):301. doi: 10.3390/antiox11020301. PMID: 35204184.
757. Ortiz A; Asociación Información Enfermedades Renales Genéticas (AIRG-E), European Kidney Patients' Federation (EKPF), Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón (ALCER), Fundación Renal Íñigo Álvarez de Toledo (FRIAT), Red de Investigación Renal (REDINREN), Resultados en Salud 2040 (RICORS2040), Sociedad Española de Nefrología (SENEFRO) Council, Sociedad Española de Trasplante (SET) Council, Organización Nacional de Trasplantes (ONT). RICORS2040: the need for collaborative research in chronic kidney disease. *Clin Kidney J.* 2021 Sep 23;15(3):372-387. doi: 10.1093/ckj/sfab170. PMID: 35211298; PMCID: PMC8862113.
758. Carriazo S, Ortiz A. The last pre-pandemic European Renal Association Registry report: age at start of kidney replacement therapy in Europe. *Clin Kidney J.* 2021 Dec 15;15(3):393-396. doi: 10.1093/ckj/sfab274. PMID: 35211299; PMCID: PMC8862042.
759. Boenink R, Astley ME, Huijben JA, Stel VS, Kerschbaum J, Ots-Rosenberg M, Åsberg AA, Lopot F, Golan E, Castro de la Nuez P, Rodríguez Cambor M, Trujillo-Alemán S, Ruiz San Millan JC, Ucio Mingo P, Díaz JM, Bouzas-Caamaño ME, Artamendi M, Aparicio Madre MI, Santiuste de Pablos C, Slon Roblero MF, Zurriaga O, Stendahl ME, Bell S, Idrizi A, Ioannou K, Debska-Slizien A, Galvão AA, De Meester JM, Resić H, Hommel K, Radunovic D, Pálsson R, Lassalle M, Finne P, De Los Ángeles-García Bazaga M, Gjorgjievski N, Seyahi N, Bonthuis M, Ortiz A, Jager KJ, Kramer A. The ERA Registry Annual Report 2019: summary and age comparisons. *Clin Kidney J.* 2021 Dec 15;15(3):452-472. doi: 10.1093/ckj/sfab273. PMID: 35211303; PMCID: PMC8862051.
760. Tejedor-Santamaria L, Morgado-Pascual JL, Marquez-Exposito L, Suarez-Alvarez B, Rodrigues-Diez RR, Tejera-Muñoz A, Marchant V, Mezzano S, Lopez-Larrea C, Sola A, Fernandez-Juarez GM, Ortiz A, Rayego-Mateos S, Ruiz-Ortega M. Epigenetic Modulation of Gremlin-1/NOTCH Pathway in Experimental Crescentic Immune-Mediated Glomerulonephritis. *Pharmaceuticals (Basel).* 2022 Jan 20;15(2):121. doi: 10.3390/ph15020121. PMID: 35215234.
761. AIRG-E, EKPF, ALCER, FRIAT, REDINREN, RICORS2040, SENEFRO; SET, ONT (Correspondencia: A Ortiz). CKD: The burden of disease invisible to research funders. *Nefrologia.* 2022;42(1):65-84. doi:10.1016/j.nefro.2021.09.004
762. Charalampous P, Gorasso V, Plass D, Pires SM, von der Lippe E, Mereke A, Idavain J, Kissimova-Skarbek K, Morgado JN, Ngwa CH, Noguer I, Padron-Monedero A, Santi-Cano MJ, Sarmiento R, Devleesschauwer B, Haagsma JA; COST Action CA18218 participants (A Ortiz). Burden of non-communicable disease studies in Europe: a systematic review of data sources and methodological choices. *Eur J Public Health.* 2022 Jan 7;ckab218. doi: 10.1093/eurpub/ckab218. Epub ahead of print. PMID: 35015851.



763. GBD 2019 Diabetes Mortality Collaborators. Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019. *Lancet Diabetes Endocrinol.* 2022;10(3):177-192. doi:10.1016/S2213-8587(21)00349-1
764. Kanbay M, Yildiz AB, Yavuz F, Covic A, Ortiz A, Siritopol D. The role of body mass index on IgA nephropathy prognosis: a systematic review and meta-analysis. *Int Urol Nephrol.* 2022 Mar 12. doi: 10.1007/s11255-022-03160-1. Epub ahead of print. PMID: 35278147.
765. Valiño-Rivas L, Cuarental L, Ceballos MI, Pintor-Chocano A, Perez-Gomez MV, Sanz AB, Ortiz A, Sanchez-Niño MD. Growth differentiation factor-15 preserves Klotho expression in acute kidney injury and kidney fibrosis. *Kidney Int.* 2022 Mar 22:S0085-2538(22)00210-1. doi: 10.1016/j.kint.2022.02.028. Epub ahead of print. PMID: 35337892.
766. Armocida B, Monasta L, Sawyer S, Bustreo F, Segafredo G, Castelpietra G, Ronfani L, Pasovic M, Hay S; GBD 2019 Europe NCDs in Adolescents Collaborators, Perel P, Beran D. Burden of non-communicable diseases among adolescents aged 10-24 years in the EU, 1990-2019: a systematic analysis of the Global Burden of Diseases Study 2019 [published online ahead of print, 2022 Mar 24]. *Lancet Child Adolesc Health.* 2022;S2352-4642(22)00073-6. doi:10.1016/S2352-4642(22)00073-6
767. Rodríguez RM, Luis-Lima S, Fernandez JM, Gómez MVP, Toledo BG, Cobo M, Delgado-Mallén P, Escamilla B, Marco CO, Estupiñán S, Perera CC, Mena NN, Martín LD, Reyes SP, González IH, González-Rinne F, González-Delgado A, Ferrer-Moure C, Zulueta BL, Torres A, Pérez JCR, Gaspari F, Ortiz A, Porrini E. Estimated GFR in autosomal dominant polycystic kidney disease: errors of an unpredictable method. *J Nephrol.* 2022 Mar 31. doi: 10.1007/s40620-022-01286-0. Epub ahead of print. PMID: 35357684.
768. Ortiz A, Vinck C. Farewell from the CKJ Editor-in-Chief: key kidney topics from 2014 to 2021. *Clin Kidney J.* 2022 Mar 31;15(4):593-602. doi: 10.1093/ckj/sfac023. PMID: 35371456; PMCID: PMC8967536.
769. Waldman M, Soler MJ, García-Carro C, Lightstone L, Turner-Stokes T, Griffith M, Torras J, Martinez Valenzuela L, Bestard O, Geddes C, Flossmann O, Budge KL, Cantarelli C, Fiaccadori E, Delsante M, Morales E, Gutierrez E, Niño-Cruz JA, Martinez-Rueda AJ, Comai G, Bini C, La Manna G, Slon MF, Manrique J, Avello A, Fernandez-Prado R, Ortiz A, Marinaki S, Martin Varas CR, Rabasco Ruiz C, Sierra-Carpio M, García-Agudo R, Fernández Juárez G, Hamilton AJ, Bruchfeld A, Chrysochou C, Howard L, Sinha S, Leach T, Agraz Pamplona I, Maggiore U, Cravedi P. COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry. *Kidney360.* 2021 Dec 3;3(2):293-306. doi: 10.34067/KID.0006612021. PMID: 35373130; PMCID: PMC8967646.
770. ERA Council and ERA Headquarters. From WEDA to EDTA to ERA: 60 years of supporting European Nephrology and counting [published online ahead of print, 2022 Apr 7]. *Nephrol Dial Transplant.* 2022;gfac145. doi:10.1093/ndt/gfac145
771. Gonzalez-Perez M, Montes-Casado M, Conde P, Cervera I, Baranda J, Berges-Buxeda MJ, Perez-Olmeda M, Sanchez-Tarjuelo R, Utrero-Rico A, Lozano-Ojalvo D, Torre D, Schwarz M, Guccione E, Camara C, Llópez-Carratalá MR, Gonzalez-Parra E, Portoles P, Ortiz A, Portoles J, Ochando J. Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination. *Front Immunol.* 2022 Mar 23;13:845882. doi: 10.3389/fimmu.2022.845882. PMID: 35401504; PMCID: PMC8983822.
772. Kosanović M, Milutinovic B, Glamočlija S, Morlans IM, Ortiz A, Bozic M. Extracellular Vesicles and Acute Kidney Injury: Potential Therapeutic Avenue for Renal Repair and Regeneration. *Int J Mol Sci.* 2022;23(7):3792. Published 2022 Mar 30. doi:10.3390/ijms23073792
773. Ortiz A, Sarafidis P, Ferro CJ. Cardiovascular Events with Finerenone in CKD and Diabetes. *N Engl J Med.* 2022;386(16):e43. doi:10.1056/NEJMc2200202
774. Ertuglu LA, Demiray A, Afsar B, Ortiz A, Kanbay M. The Use of Healthy Eating Index 2015 and Healthy Beverage Index for Predicting and Modifying Cardiovascular and Renal Outcomes. *Curr Nutr Rep.* 2022 Apr 27. doi: 10.1007/s13668-022-00415-2. Epub ahead of print. PMID: 35476188.
775. Carriazo S, Sarafidis P, Ferro CJ, Ortiz A. Blood pressure targets in CKD 2021: the never-ending guidelines debacle. *Clin Kidney J.* 2022 Feb 11;15(5):845-851. doi: 10.1093/ckj/sfac014. PMID: 35498896; PMCID: PMC9050556.
776. Ortiz A, Navarro-González JF, Núñez J, de la Espriella R, Cobo M, Santamaría R, de Sequera P, Díez J. The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure: Position paper from the Cardiorenal Working Groups of the Spanish Society of Nephrology and the Spanish Society of Cardiology. *Clin Kidney J.* 2021 Dec 23;15(5):865-872. doi: 10.1093/ckj/sfab290. PMID: 35498889; PMCID: PMC9050562.
777. Rinne AG, Sorensen CA, Lima SL, Gil MG, Mena NN, Martín LD, Ramírez A, Morales A, Vega N, Gallego E, Izquierdo EM, Cabello E, Rodríguez AER, González JP, Escamilla B, Cruz C, Tamajón LP, Ramírez AT, Gaspari F, Ortiz A, Porrini E. Early glomerular filtration rate changes in living kidney donors and recipients: an example of renal plasticity. *Clin Kidney J.* 2022 Jan 31;15(5):885-894. doi: 10.1093/ckj/sfab220. PMID: 35498883; PMCID: PMC9050540.
778. Quiroga B, Ortiz A, Sánchez-Álvarez E, Goicoechea M, de Sequera P; Spanish Society of Nephrology Council.

- SARS-CoV-2 infection evolution among nephrologists during the pandemic: clinical features and impact of vaccination. *Kidney Int Rep.* 2022 May 5. doi: 10.1016/j.ekir.2022.04.093. Epub ahead of print. PMID: 35529248; PMCID: PMC9069975.
779. Quiroga B, Soler MJ, Ortiz A, Orero E, Tejedor S, Mantecón CJJ, Gómez Pérez VO, Marín Franco AJ, Alfaro Sánchez C, Puerta Carretero M, Jaldo Rodríguez MT, Carnerero Di Riso MA, Martínez S, González CC, Cervienka M, Macías Carmona N, Arroyo D, Pérez Del Valle KM, de Arriba G, Mazuecos A, Cazorla JM, Pereira M, González Parra E, Sánchez Márquez MG, Lancho Novillo C, Toyos Ruiz C, Aguilar Cervera MC, Muñoz Ramos P, Sánchez Horrillo A, Jimeno Martín I, Toapanta N, Cigarrán Guldris S, Folgueiras López M, Valero San Cecilio R, Villacorta Linaza B, Minguela Pesquera I, Santana Estupiñán R, Zamora R, Soriano S, Muñoz de Bustillo E, Pizarro Sánchez MS, Martínez Puerto AI, Yugueros A, Muñiz Pacios L, Leyva A, Rojas J, Gansevoort RT, de Sequera P; SENCOVAC collaborative network. Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum. *Clin J Am Soc Nephrol.* 2022 May 12:CJN.01770222. doi: 10.2215/CJN.01770222. Epub ahead of print. PMID: 35551070.
780. Schwarz M, Torre D, Lozano-Ojalvo D, Tan AT, Tabaglio T, Mzoughi S, Sanchez-Tarjuelo R, Le Bert N, Lim JME, Hatem S, Tuballes K, Camara C, Lopez-Granados E, Paz-Artal E, Correa-Rocha R, Ortiz A, Lopez-Hoyos M, Portoles J, Cervera I, Gonzalez-Perez M, Bodega-Mayor I, Conde P, Oteo-Iglesias J, Borobia AM, Carcas AJ, Frías J, Belda-Iniesta C, Ho JSY, Nunez K, Hekmaty S, Mohammed K, Marsiglia WM, Carreño JM, Dar AC, Berin C, Nicoletti G, Della Noce I, Colombo L, Lapucci C, Santoro G, Ferrari M, Nie K, Patel M, Barcessat V, Gnjatich S, Harris J, Sebra R, Merad M, Krammer F, Kim-Schulze S, Marazzi I, Bertoletti A, Ochando J, Guccione E. Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole- blood PCR. *Nat Biotechnol.* 2022 Jun 13. doi: 10.1038/s41587-022-01347-6. Epub ahead of print. PMID: 35697804.
781. Perez-Gomez MV, Sanchez-Ospina D, Tejedor A, Ortiz A. The mysterious death of the beer drinking champ: potential role for hyperacute water loading and acute hyponatremia. *Clin Kidney J.* 2022 Mar 16;15(6):1196-1201. doi: 10.1093/ckj/sfac072. PMID: 35664275; PMCID: PMC9155218.
782. Carriazo S, Ortiz A. Stopping kidney protection in the elderly following acute kidney injury: think mortality. *Clin Kidney J.* 2022 Feb 2;15(6):1037-1040. doi: 10.1093/ckj/sfac024. PMID: 35664273; PMCID: PMC9155224.
783. GBD 2019 Diabetes and Air Pollution Collaborators. Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM<sub>2.5</sub> air pollution, 1990-2019: an analysis of data from the Global Burden of Disease Study 2019. *Lancet Planet Health.* 2022 Jul;6(7):e586-e600. doi:10.1016/S2542-5196(22)00122-X. PMID: 35809588.
784. Ortiz A, Mattace-Raso F, Soler MJ, Fouque D. Ageing meets kidney disease. *Age Ageing.* 2022 Jun 30:afac157. doi: 10.1093/ageing/afac157. Epub ahead of print. PMID: 35768070.
785. Ortiz A, Mattace-Raso F, Soler MJ, Fouque D. Ageing meets kidney disease. *Nephrol Dial Transplant.* 2022 Jun 30:gfac199. doi: 10.1093/ndt/gfac199. Epub ahead of print. PMID: 35768068.
786. Villalvazo P, Carriazo S, Martin-Cleary C, Sanchez-Niño MD, Ortiz A. Solving the riddle of Aguascalientes nephropathy: nephron number, environmental toxins and family clustering. *Clin Kidney J.* 2022 Feb 10;15(7):1226-1230. doi: 10.1093/ckj/sfac042. PMID: 35756744; PMCID: PMC9217524.
787. Ortiz A. Benchmarking CKD: incidence of CKD in a European country with low prevalence of CKD and kidney replacement therapy. *Clin Kidney J.* 2022 Mar 11;15(7):1221-1225. doi: 10.1093/ckj/sfac074. PMID: 35756737; PMCID: PMC9217648.
788. Afsar B, Afsar RE, Demiray A, Altay S, Korkmaz H, Yildiz A, Covic A, Ortiz A, Kanbay M. Sodium-glucose cotransporter inhibition in polycystic kidney disease: fact or fiction. *Clin Kidney J.* 2022 Jan 31;15(7):1275-1283. doi: 10.1093/ckj/sfac029. PMID: 35756735; PMCID: PMC9217633.
789. Luis-Lima S, Ortiz A. Assessment of the glomerular filtration rate. *Med Clin (Barc).* 2022 Aug 6:S0025-7753(22)00380-3. English, Spanish. doi: 10.1016/j.medcli.2022.06.013. Epub ahead of print. PMID: 35945055.
790. Carriazo S, Aparicio-Madre MI, Tornero-Molina F, Fernández-Lucas M, Paraiso-Cuevas V, González-Parra E, Del Río-Gallegos F, Marques-Vidas M, Alcázar-Arroyo R, Martins-Muñoz J, Sánchez-Villanueva R, Gil-Casares B, Gutiérrez-Martínez E, Martínez-Rubio MP, Ortiz A; REMER. Impact of different COVID-19 waves on kidney replacement therapy epidemiology and mortality: REMER 2020. *Nephrol Dial Transplant.* 2022 Aug 4:gfac234. doi: 10.1093/ndt/gfac234. Epub ahead of print. PMID: 35927791.
791. Germain DP, Altarescu G, Barriales-Villa R, Mignani R, Pawlaczyk K, Pieruzzi F, Terryn W, Vujkovic B, Ortiz A. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. *Mol Genet Metab.* 2022 Jul 26;137(1-2):49-61. doi: 10.1016/j.ymgme.2022.07.010. Epub ahead of print. PMID: 35926321.
792. Ortiz A. Childhood Risk Factors and Adult Cardiovascular Events. *N Engl J Med.* 2022 Aug 4;387(5):472. doi: 10.1056/NEJMc2208135. PMID: 35921461.
793. Ortiz A, Sanz AB. A pathway of osmotic stress-induced necroptosis. *Nat Rev Nephrol.* 2022 Aug 1. doi: 10.1038/s41581-022-00607-7. Epub ahead of print. PMID: 35915240.
794. Carriazo S, Ortiz A. Wasp stings and plasma exchange. *Clin Kidney J.* 2022 Feb 26;15(8):1455-1458. doi:

- 10.1093/ckj/sfac055. PMID: 35892025; PMCID: PMC9308096.
795. Sánchez-Tocino ML, González-Parra E, Miranda Serrano B, Gracia-Iguacel C, de-Alba-Peñaranda AM, López-González A, García Olegario M, Ortíz A, Mas-Fontao S. Evaluation of the impact of an intradialytic exercise programme on sarcopaenia in very elderly haemodialysis patients. *Clin Kidney J.* 2022 Feb 15;15(8):1514-1523. doi: 10.1093/ckj/sfac046. PMID: 35892024; PMCID: PMC9308088.
796. Fontecha-Barriuso M, Lopez-Diaz AM, Guerrero-Mauvecin J, Miguel V, Ramos AM, Sanchez-Niño MD, Ruiz-Ortega M, Ortiz A, Sanz AB. Tubular Mitochondrial Dysfunction, Oxidative Stress, and Progression of Chronic Kidney Disease. *Antioxidants (Basel).* 2022 Jul 12;11(7):1356. doi: 10.3390/antiox11071356. PMID: 35883847; PMCID: PMC9311633.
797. Sarafidis P, Ferro CJ, Ortiz A. Hypernatremia and subclinical chronic kidney disease. *Eur Heart J.* 2022 Jul 23;ehac367. doi: 10.1093/eurheartj/ehac367. Epub ahead of print. PMID: 35869834.
798. Quiroga B, Muñoz Ramos P, Sánchez Horrillo A, Ortiz A, Valdivieso JM, Carrero JJ. Triglycerides-glucose index and the risk of cardiovascular events in persons with non-diabetic chronic kidney disease. *Clin Kidney J.* 2022 Mar 10;15(9):1705-1712. doi: 10.1093/ckj/sfac073. PMID: 36003671; PMCID: PMC9394724.
799. Quiroga B, Ortiz A, Cabezas-Reina CJ, Ruiz Fuentes MC, Jiménez VL, Larrondo SZ, Toapanta N, Gómez MM, de Sequera P, Sánchez-Álvarez E; Spanish COVID-19 KRT Registry collaborative group. Evolving spectrum but persistent high mortality of COVID-19 among patients on kidney replacement therapy in the vaccine era: the Spanish COVID-19 KRT Registry. *Clin Kidney J.* 2022 Jun 3;15(9):1685-1697. doi: 10.1093/ckj/sfac135. PMID: 35999961; PMCID: PMC9214101.
800. Ortiz A, Wanner C, Gansevoort R; ERA Council. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association. *Eur J Prev Cardiol.* 2022 Aug 23;zwac186. doi: 10.1093/eurjpc/zwac186. Epub ahead of print. PMID: 35997796.
801. Huijben JA, Kramer A, Kerschbaum J, de Meester J, Collart F, Arévalo OLR, Helve J, Lassalle M, Palsson R, Ten Dam M, Casula A, Methven S, Ortiz A, Ferraro PM, Segelmark M, Mingo PU, Arici M, Reisæter AV, Stendahl M, Stel VS, Jager KJ. Increasing numbers and improved overall survival of patients on kidney replacement therapy over the last decade in Europe: an ERA Registry study. *Nephrol Dial Transplant.* 2022 Aug 17;gfac165. doi: 10.1093/ndt/gfac165. Epub ahead of print. PMID: 35974693.
802. Donate-Correa J, Matos-Perdomo E, González-Luis A, Martín-Olivera A, Ortiz A, Mora-Fernández C, Navarro-González JF. The Value of Klotho in Kidney Transplantation. *Transplantation.* 2022 Oct 18. doi: 10.1097/TP.0000000000004331. Epub ahead of print. PMID: 36253904.
803. Ortiz A, Wanner C, Gansevoort R; ERA Council. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association. *Nephrol Dial Transplant.* 2022 Oct 11;gfac257. doi: 10.1093/ndt/gfac257. Epub ahead of print. PMID: 36216362.
804. Bover J, Bosch R, Luis Górriz J, Ureña P, Ortiz A, daSilva I, García-Trabanino RA, Hueso M, Trinidad P, Jara A, Furlano M, Gelpi R, Vila-Santandreu A, Restrepo CA, Sánchez-Baya M, Arana C, Goicoechea M, Coll V, Segura J, Gutiérrez O, Kalantar-Zadeh K, Sánchez E, Ferreira A, García-Maset R. Kidneys also speak Spanish: Initiatives towards standardisation of our nephrology nomenclature. *Nefrologia (Engl Ed).* 2022 May-Jun;42(3):223-232. doi:10.1016/j.nefro.2022.09.003. Epub 2022 Sep 24. PMID: 36167667.
805. Goicoechea M, Gomez-Preciado F, Benito S, Torras J, Huerta A, Restrepo A, Ugalde J, Astudillo DE, Agraz I, Lopez-Mendoza M, de Arriba G, Corchete E, Quiroga B, Gutierrez MJ, Martin-Conde ML, Lopes V, Ramos C, Mendez I, Cao M, Dominguez F, Ortiz A; Spanish Group for the Study of Glomerular Diseases (GLOSEN). Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy. *Nefrologia (Engl Ed).* 2021 Nov-Dec;41(6):652-660. doi: 10.1016/j.nefro.2022.01.003. PMID: 36165155.
806. Ortiz A, Mattace-Raso F, Soler MJ, Fouque D. Ageing meets kidney disease. *Clin Kidney J.* 2022 Jun 30;15(10):1793-1796. doi: 10.1093/ckj/sfac151. PMID: 36158151; PMCID: PMC9494535.
807. Marques M, López-Sánchez P, Tornero F, Gargantilla P, Maroto A, Ortiz A, Portolés J. The hidden diabetic kidney disease in a university hospital-based population: a real-world data analysis. *Clin Kidney J.* 2022 Apr 14;15(10):1865-1871. doi: 10.1093/ckj/sfac100. PMID: 36158147; PMCID: PMC9494513.
808. Quiroga B, Soler MJ, Ortiz A, Jaravaca Mantecón CJ, Nava Pérez N, Serra Martín M, Sato Y, Marin Franco AJ, Pazmiño Zambrano DF, Lucena Valverde R, Ortega Diaz M, Calderón González C, Cazorla López JM, Pereira M, González Parra E, Sánchez Horrillo A, Sánchez González C, Toapanta N, Cigarrán Guldris S, Sánchez Hernández R, Pizarro Sánchez S, Muñoz Rincón M, García-Fernández N, Blanco Castro N, Collantes Mateo R, Quiroz Morales MA, Escamilla-Cabrera B, Berdud Godoy I, Gil-Casares Casanova B, Leyva A, Rojas J, Gansevoort RT, de Sequera P; SENCOVAC collaborative network. Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study. *Clin Kidney J.* 2022 Jul 26;15(10):1856-1864. doi: 10.1093/ckj/sfac169. PMID: 36147708; PMCID: PMC9384616.

809. Favero C, Giordano L, Mihaila SM, Masereeuw R, Ortiz A, Sanchez-Niño MD. Postbiotics and Kidney Disease. *Toxins* (Basel). 2022 Sep 6;14(9):623. doi: 10.3390/toxins14090623. PMID: 36136562; PMCID: PMC9501217.
810. Wanner C, Feldt-Rasmussen U, Ortiz A. Plain language summary of a study looking at heart muscle thickness and kidney function in women with Fabry disease who received agalsidase beta treatment. *Future Cardiol*. 2022 Sep 8. doi: 10.2217/fca-2022-0047. Epub ahead of print. PMID: 36073247.
811. Gansevoort RT, Anders HJ, Cozzolino M, Fliser D, Fouque D, Ortiz A, Soler MJ, Wanner C. What should European nephrology do with the new CKD-EPI equation? *Nephrol Dial Transplant*. 2022 Sep 7;gfac254. doi: 10.1093/ndt/gfac254. Epub ahead of print. PMID: 36069913.
812. Quiroga B, Muñoz Ramos P, Sánchez Horrillo A, Ortiz A, Valdivieso JM, Carrero JJ. Triglycerides-glucose index and the risk of cardiovascular events in persons with non-diabetic chronic kidney disease. *Clin Kidney J*. 2022 Mar 10;15(9):1705-1712. doi: 10.1093/ckj/sfac073. PMID: 36003671; PMCID: PMC9394724.
813. Quiroga B, Ortiz A, Cabezas-Reina CJ, Ruiz Fuentes MC, López Jiménez V, Zárrega Larrondo S, Toapanta N, Molina Gómez M, de Sequera P, Sánchez-Álvarez E; Spanish COVID-19 KRT Registry collaborative group. Evolving spectrum but persistent high mortality of COVID-19 among patients on kidney replacement therapy in the vaccine era: the Spanish COVID-19 KRT Registry. *Clin Kidney J*. 2022 Jun 3;15(9):1685-1697. doi: 10.1093/ckj/sfac135. PMID: 35999961; PMCID: PMC9214101.
814. Ars E, Bernis C, Fraga G, Furlano M, Martínez V, Martins J, Ortiz A, Pérez- Gómez MV, Rodríguez-Pérez JC, Sans L, Torra R; en nombre del grupo de trabajo de Enfermedades Renales Hereditarias de la Sociedad Española de Nefrología. Consensus document on autosomal dominant polycystic kidney disease from the Spanish Working Group on Inherited Kidney Diseases. Review 2020. *Nefrologia* (En l Ed). 2022 Nov 17;S2013-2514(22)00121-3. doi: 10.1016/j.nefro.2022.11.011. Epub ahead of print. PMID: 36404270.
815. Córdoba-David G, García-Giménez J, Cardoso Castelo-Branco R, Carrasco S, Cannata P, Ortiz A, Ramos AM. Crosstalk between TBK1/IKK $\epsilon$  and the type I interferon pathway contributes to tubulointerstitial inflammation and kidney tubular injury. *Front Pharmacol*. 2022 Sep 23;13:987979. doi: 10.3389/fphar.2022.987979. PMID: 36386242; PMCID: PMC9647636.
816. Vart P, Duivenvoorden R, Franssen CFM, Hemmelder MH, Jager KJ, Hilbrands LB, Noordzij M, Abramowicz D, Basile C, Covic A, Crespo M, Massy ZA, Ortiz A, Emilio Sanchez J, Petridou E, White C, Gansevoort RT. Preparing European Nephrology for the next pandemic: lessons from the ERACODA collaboration. *Nephrol Dial Transplant*. 2022 Nov 16;gfac306. doi: 10.1093/ndt/gfac306. Epub ahead of print. PMID: 36385300.
817. Villalvazo P, Fernandez-Prado R, Niño MDS, Carriazo S, Fernández-Fernández B, Ortiz A, Perez-Gomez MV. Who killed Bruce Lee? The hyponatraemia hypothesis. *Clin Kidney J*. 2022 Mar 10;15(12):2169-2176. doi: 10.1093/ckj/sfac071. PMID: 36381374; PMCID: PMC9664576.
818. Horrillo AS, Villanueva LS, Cárdenas AC, Ramos PM, Ortiz A, Quiroga B. Infectious consequences of the AKI-to-CKD transition. *Clin Kidney J*. 2022 Jul 30;15(12):2237-2244. doi: 10.1093/ckj/sfac178. PMID: 36381366; PMCID: PMC9664570.
819. Donate-Correa J, Sanchez-Niño MD, González-Luis A, Ferri C, Martín-Olivera A, Martín-Núñez E, Fernandez-Fernandez B, Tagua VG, Mora-Fernández C, Ortiz A, Navarro-González JF. Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease. *Clin Kidney J*. 2022 May 19;15(12):2200-2213. doi: 10.1093/ckj/sfac143. PMID: 36381364; PMCID: PMC9664582.
820. Vergara A, Jacobs-Cacha C, Llorens-Cebria C, Ortiz A, Martinez-Diaz I, Martos N, Dominguez-Báez P, Van den Bosch MM, Bermejo S, Pieper MP, Benito B, Soler MJ. Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice. *Int J Mol Sci*. 2022 Oct 24;23(21):12823. doi: 10.3390/ijms232112823. PMID: 36361612; PMCID: PMC9656616.
821. Gaipov A, Makhmajanov Z, Dauey Z, Markhametova Z, Mussina K, Nogaibayeva A, Kozina L, Auganova D, Tarlykov P, Bukasov R, Utegulov Z, Turebekov D, Soler MJ, Ortiz A, Kanbay M. Urinary Protein Profiling for Potential Biomarkers of Chronic Kidney Disease: A Pilot Study. *Diagnostics* (Basel). 2022 Oct 25;12(11):2583. doi: 10.3390/diagnostics12112583. PMID: 36359427.
822. Piedrafita A, Siwy J, Klein J, Akkari A, Amaya-Garrido A, Mebazaa A, Sanz AB, Breuil B, Montero Herrero L, Marcheix B, Depret F, Fernandez L, Tardif E, Minville V, Alves M, Metzger J; Kidney Attack Study Group, Grossac J, Mischak H, Ortiz A, Gazut S, Schanstra JP, Faguer S, Mayeur N, Casemayou A, Labaste F. A universal predictive and mechanistic urinary peptide signature in acute kidney injury. *Crit Care*. 2022 Nov 7;26(1):344. doi: 10.1186/s13054-022-04193-9. PMID: 36345008; PMCID: PMC9640896.
823. Favero C, Ortiz A, Sanchez-Niño MD. Probiotics for kidney disease. *Clin Kidney J*. 2022 Feb 28;15(11):1981-1986. doi: 10.1093/ckj/sfac056. PMID: 36325000; PMCID: PMC9613434.
824. Villalvazo P, Carriazo S, Rojas-Rivera J, Ramos AM, Ortiz A, Perez-Gomez MV. Gain-of-function TLR7 and loss-of-function A20 gene variants identify a novel pathway for Mendelian lupus and lupus nephritis. *Clin Kidney J*. 2022

- Jun 9;15(11):1973-1980. doi: 10.1093/ckj/sfac152. PMID: 36324999; PMCID: PMC9613427.
825. Rayego-Mateos S, Rodrigues-Diez R, Fernandez-Fernandez B, Mora-Fernández C, Marchant V, Donate-Correa J, Navarro-González JF, Ortiz A, Ruiz-Ortega M. Targeting inflammation to treat diabetic kidney disease: the road to 2030. *Kidney Int.* 2022 Dec 2;S0085-2538(22)01017-1. doi: 10.1016/j.kint.2022.10.030. Epub ahead of print. PMID: 36470394.
826. Gambaro G, Tzelvels L, Skolarikos A, Kanbay M, Ortiz A, Cozzolino M. The New Guidelines of the European Association of Urology on Urolithiasis: The Urology- Nephrology Intersection. *Nephrol Dial Transplant.* 2022 Nov 28;gfac309. doi: 10.1093/ndt/gfac309. Epub ahead of print. PMID: 36441014.
827. Quiroga B, Soler MJ, Ortiz A, Jarava Mantecón CJ, Gomes Pérez VO, Bordils A, Lacueva J, Marin Franco AJ, Delgado Conde P, Muñoz Ramos P, Calderón González C, Cazorla López JM, Sanchez-Rodríguez J, Sánchez Horrillo A, Monzón Vázquez TR, Leyva A, Rojas J, Gansevoort RT, de Sequera P; SENCOVAC collaborative network, Rodríguez MTJ, Valverde RL, Carretero MP, Díaz MO, Tocora DG, Suárez ER, Santolaya AJS, Cobo PA, Talavan T, Calero RC, Gracia-Iguacel C, González-Parra E, Pereira M, Martin-Cleary C, Ramos-Verde A, Giorgi M, Sánchez C, Giraldo YG, Horrillo AS, Suárez PR, Perpén AF, Ramos AF, Villanueva LS, Cortiñas A, Arias PAD, Cárdenas AC, de Santos A, Núñez A, Cuadrado GB, de Gante LM, Repollet R, Polo CR, Moreso F, Azancot MA, Ramos N, Toapanta OBN, Cidraque I, Bermejo S, Agraz I, Prat O, Medina C, Pardo E, Prat O, Saiz A, Vila MAM, Guldris SC, Granados NM, Cabo MJC, Alarcón WL, Sánchez SP, Alexandru S, Suarez LGP, Saico SP, Tapia MP, Zamora R, Hernández RS, Osorio LR, García-Fernández N, Moreno PLM, González NA, Ortiz AS, Iñárrrea MNB, Cabrera SS, López RO, Peregrí CM, Morales MLA, Cabello MDN, Mazuecos A, García T, Narváez C, Orellana C, Márquez MGS, Novillo CL, Ganga PLQ, Carrión FV, Herrera ALG, Castro NB, Cendrero RMR, Hidalgo-Barquero MVM, Gallego RH, Alvarez Á, Leo EV, León JLP, García MAM, Jiménez BG, Pérez VOG, de Dios Ramiro Moya J, Espinosa DL, Herrador AJ, Zurita MN, Álvarez LD, Martínez ÁG, Arroyo SB, Fernández RR, Vargas MJS, Casero RC, Useche G, García AB, Díaz ABM, de Miguel CS, Palacios Á, Henningsmeyer B, Calve EO, Moya JL, Sato Y, Marín MS, Tejedor S, Vaquera SM, di Riso MC, Torres I, Alfaro G, Halauko O, Rifai FEL, Martínez AD, Ávila PJ, Sánchez CA, Sainz MS, Martín JMB, Del Río García L, Canga JLP, Ochoa PMV, Pacios LM, Machado LL, Morales AQ, Cavalotti IM, Zorita IN, López SO, González SO, Montañez CS, Rubio AB, Del Peso Gilsanz G, Gonzalez MO, Villanueva RS, Oliva MOL, Varela JC, Enríquez AG, Casas CC, Alonso PO, Tabares LG, Barreiro JML, Solla LP, Gándara A, de la Garza WN, Fleming FF, Goyanes MGR, Feijoo CC, Plaza MMM, Juan CB, de la Fuente GA, Del Valle KP, Contreras FJP, Lara NB, Ferri DG, de Bustillo Llorente EM, Rodríguez EG, De La Manzanara Perez VL, Arealo MC, Calvo JAH, Carratalá MRL, Rodríguez LMM, Salazar MS, Prieto BB, Pérez JMP, Paraíso AG, Huarte E, Lanau M, Campos RA, Ubé JM, Godoy IB, Aguilera ET, Alea RT, Del Rosario Saldaña MS, Salgueira M, Aresté N, de Los Ángeles Rodríguez M, Collantes R, Martínez AI, Moyano MJ, Víbora EJ, Gash SC, Martínez LR, Cervera MCA, De Tomas MTR, Prieto BA, Toyos C, Del Rio JM, Acosta AR, Zamacona AC, Martin MIJ, Ortega SB, Ruiz MIG, Rubio AH, Ledesma PG, Alvarez AG, Poch E, Cucchiari D, Monzo JB, Cabrera BE, Hernández APR, Rebollo MSG, Hernández JMR, González AY, Alonso JC, Más AM, Calvé M, Cardona MG, Balaguer VC, Pesquera JIM, de la Rosa EC, Santarelli DR, Garcia AS, Martin-Caro AC, Santamaria IM, Cervienka M, de la Pisa AMU, Monzon LS, Anachuri KA, Garcia EH, Gomez VO, Estupiñán RS, Amado FV, Borges PP, Beloso MD, Alonso FA, Felpete NP, Ameneiro AM, Mera MC, Casares BG, Larrondo SZ, Kareaga NM, Del Valle AISS, García ARM, Linaza BV, Del Toro Espinosa N, Perico PE, Oliva JMS, Manrique J, Castaño I, Purroi C, Gómez N, Mansilla C, Utzurum A, de Arellano Serna MR, Perich LG, Rincón MM, De La Manzanara Perez VL, Arealo MC, Calvo JAH, Villoria JG, De Salinas APM. Humoral response after the fourth dose of the SARS-CoV-2 vaccine in the CKD spectrum: a prespecified analysis of the SENCOVAC study. *Nephrol Dial Transplant.* 2022 Nov 24;gfac307. doi: 10.1093/ndt/gfac307. Epub ahead of print. PMID: 36423334.
828. Sánchez-Tocino ML, Miranda-Serrano B, López-González A, Villoria-González S, Pereira-García M, Gracia-Iguacel C, González-Ibarguren I, Ortíz-Ardúan A, Mas- Fontao S, González-Parra E. Sarcopenia and Mortality in Older Hemodialysis Patients. *Nutrients.* 2022 Jun 5;14(11):2354. doi: 10.3390/nu14112354. PMID: 35684154; PMCID: PMC9182960.
829. González-Alayón C, Porrini E, Luis-Lima S, Negrín-Mena N, Moreno M, Morales-Arráez D, González-Rinne F, Díaz-Martín L, Gaspari F, González-Delgado A, Ferrer-Moure C, Ortiz-Ardúan A, Hernandez-Guerra M. Estimated glomerular filtration rate by formulas in patients with cirrhosis: An unreliable procedure. *Liver Int.* 2022 Apr;42(4):884-895. doi: 10.1111/liv.15134. Epub 2022 Jan 17. PMID: 34951102.
830. Ruilope LM, Ortiz A, Lucia A, Miranda B, Alvarez-Llamas G, Barderas MG, Volpe M, Ruiz-Hurtado G, Pitt B. Prevention of cardiorenal damage: importance of albuminuria. *Eur Heart J.* 2022 Dec 7;ehac683. doi: 10.1093/eurheartj/ehac683. Epub ahead of print. PMID: 36477861.
831. Lazarus JV, Ortiz A, Tyrovolas S, Fernández E, Guy D, White TM, Ma R, Hay SI, Naghavi M, Soriano JB; GBD 2019 Spain Collaborators. A GBD 2019 study of health and Sustainable Development Goal gains and forecasts to

- 2030 in Spain. *Sci Rep.* 2022 Dec 7;12(1):21154. doi: 10.1038/s41598-022-24719-z. PMID: 36477107.
832. Barbieri D, Goicoechea M, Verde E, García-Prieto A, Verdalles Ú, Pérez de José A, Delgado A, Sánchez-Niño MD, Ortiz A. Obesity, chronic kidney disease progression and the role of the adipokine C1q/TNF related protein-3. *Nefrologia (Engl Ed).* 2022 Dec 12:S2013-2514(22)00164-X. doi: 10.1016/j.nefro.2022.02.009. Epub ahead of print. PMID: 36517365.
833. Quiroga B, Soler MJ, Ortiz A, Sequera P; SENCOVAC collaborative network. Lessons from SENCOVAC: a prospective study evaluating the response to SARS-CoV-2 vaccination in the CKD spectrum. *Nefrologia.* 2022 Dec 16. Spanish. doi: 10.1016/j.nefro.2022.12.006. Epub ahead of print. PMID: 36540904; PMCID: PMC9756643.
834. Cuarental L, Ribagorda M, Ceballos MI, Pintor-Chocano A, Carriazo SM, Dopazo A, Vazquez E, Suarez-Alvarez B, Cannata-Ortiz P, Sanz AB, Ortiz A, Sanchez-Niño MD. The transcription factor Fos11 preserves Klotho expression and protects from acute kidney injury. *Kidney Int.* 2022 Dec 21:S0085-2538(22)01087-0. doi: 10.1016/j.kint.2022.11.023. Epub ahead of print. PMID: 36565807.
835. Rojas-Rivera J, Carriazo S, Ortiz A. Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. *N Engl J Med.* 2022;387(26):2481-2482. doi:10.1056/NEJMc2208182 PMID: 36577110
836. Boenink R, Kramer A, Vanholder RC, Mahillo B, Massy ZA, Bušić M, Ortiz A, Stel VS, Jager KJ; Survey Collaborators. Factors influencing kidney transplantation rates: a study from the ERA Registry. *Nephrol Dial Transplant.* 2023 Jan 10:gfad001. doi: 10.1093/ndt/gfad001. Epub ahead of print. PMID:36626928.
837. Morgado-Pascual JL, Suarez-Alvarez B, Marchant V, Basantes P, Tharaux PL, Ortiz A, Lopez-Larrea C, Ruiz-Ortega M, Rayego-Mateos S. Type IV Collagen and SOX9 Are Molecular Targets of BET Inhibition in Experimental Glomerulosclerosis. *Int J Mol Sci.* 2022 Dec 28;24(1):486. doi: 10.3390/ijms24010486. PMID: 36613933; PMCID: PMC9820124.
838. Boenink R, Kramer A, Tuinhout RE, Savoye E, Åsberg A, Idrizi A, Kerschbaum J, Ziedina I, Ziginskiene E, Farrugia E, Garneata L, Zakharova EV, Bell S, Arnol M, Segelmark M, Ioannou K, Hommel K, Rosenberg-Ots M, Vazlov E, Helve J, Mihály S, Pálsson R, Nordio M, Gjorgjievski N, de Vries APJ, Seyahi N, Magadi WA, Resić H, Kalachyk A, Rahmel AO, Galvão AA, Naumovic R, Lundgren T, Arici M, de Meester JM, Ortiz A, Jager KJ, Stel VS. Trends in kidney transplantation rate across Europe: Study from the ERA Registry. *Nephrol Dial Transplant.* 2023 Jan 4:gfac333. doi: 10.1093/ndt/gfac333. Epub ahead of print. PMID: 36610723.
839. González-Juanatey JR, Górriz JL, Ortiz A, Valle A, Soler MJ, Facila L. Cardiorenal benefits of finerenone: protecting kidney and heart. *Ann Med.* 2023;55(1):502-513. doi:10.1080/07853890.2023.2171110
840. Kalay Z, Sahin OE, Copur S, Danacı S, Ortiz A, Yau K, Cherney DZI, Kanbay M. SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence. *Clin Kidney J.* 2022 Aug 24;16(1):52-60. doi: 10.1093/ckj/sfac189. PMID: 36726436; PMCID: PMC9871839.
841. Quiroga B, Ortiz A, Navarro-González JF, Santamaría R, de Sequera P, Díez J. From cardiorenal syndromes to cardioneurology: a reflection by nephrologists on renocardiac syndromes. *Clin Kidney J.* 2022 Apr 30;16(1):19-29. doi: 10.1093/ckj/sfac113. PMID: 36726435; PMCID: PMC9871856.
842. Romero-González G, Manrique J, Slon-Roblero MF, Husain-Syed F, De la Espriella R, Ferrari F, Bover J, Ortiz A, Ronco C. PoCUS in nephrology: a new tool to improve our diagnostic skills. *Clin Kidney J.* 2022 Sep 12;16(2):218-229. doi: 10.1093/ckj/sfac203. PMID: 36755847; PMCID: PMC9900589.
843. Theodorakopoulou MP, Karagiannidis AG, Ferro CJ, Ortiz A, Sarafidis PA. Renal artery stenting in the correct patients with atherosclerotic renovascular disease: time for a proper renal and cardiovascular outcome study? *Clin Kidney J.* 2022 May 12;16(2):201-204. doi: 10.1093/ckj/sfac140. PMID: 36755839; PMCID: PMC9900577.
844. Copur S, Tanriover C, Yavuz F, Soler MJ, Ortiz A, Covic A, Kanbay M. Novel strategies in nephrology: what to expect from the future? *Clin Kidney J.* 2022 Sep 20;16(2):230-244. doi: 10.1093/ckj/sfac212. PMID: 36755838; PMCID: PMC9900595.
845. Portolés J, López-Sánchez P, Martín-Rodríguez L, Serrano-Salazar ML, Valdenebro-Recio M, Ramos A, Malo RM, Zalamea F, Martín-Giner JM, Marques M, Ortiz A. Acute and chronic kidney disease and risk of hospital mortality during COVID-19 pandemic waves in the pre-vaccination era. *Clin Kidney J.* 2022 Oct 28;16(2):374-383. doi: 10.1093/ckj/sfac239. PMID: 36751624; PMCID: PMC9620382.
846. Fernandez-Prado R, Villalvazo P, Avello A, Gonzalez-de-Rivera M, Aguirre M, Carrasco-Muñoz CG, Fernandez-Fernandez B, Martín-Cleary C, Carriazo S, Sanchez-Niño MD, Perez-Gomez MV, Ortiz A. Sodium zirconium cyclosilicate and metabolic acidosis: Potential mechanisms and clinical consequences. *Biomed Pharmacother.* 2023 Feb;158:114197. doi: 10.1016/j.biopha.2022.114197. Epub 2023 Jan 4. PMID: 36916426.
847. Harskamp LR, Perez-Gomez MV, Heida JE, Engels GE, van Goor H, van den Heuvel MC, Streets AJ, Ong ACM, Ortiz A, Gansevoort RT; DIPAK Consortium. The association of urinary epidermal growth factors with ADPKD disease severity and progression. *Nephrol Dial Transplant.* 2023 Mar 13:gfad050. doi: 10.1093/ndt/gfad050. Epub ahead of print. PMID: 36914219.

848. Ortiz A, Wanner C, Gansevoort R; ERA Council. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association. *Clin Kidney J.* 2022 Oct 11;16(3):403-407. doi: 10.1093/ckj/sfac199. PMID: 36865018; PMCID: PMC9972834.
849. Anfaíha-Sanchez M, Rodrigo Calabia E, Ortiz A, Martín-Lorenzo M, Alvarez-Llamas G. Donor liquid biopsy and outcomes in kidney transplantation. *Clin Kidney J.* 2022 Oct 15;16(3):447-455. doi: 10.1093/ckj/sfac227. PMID: 36865017; PMCID: PMC9972840.
850. Rotbain Curovic V, Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Hansen TW, Havrdova T, Kooy A, Laverman GD, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Petrie JR, Ruggenti PL, Rutters F, Rychlík I, Siwy J, Spasovski G, Speeckaert M, Trillini M, Zürbig P, von der Leyen H, Rossing P; on the behalf of the PRIORITY Study Group. Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial. *J Diabetes Complications.* 2023 Feb 18;37(4):108433. doi: 10.1016/j.jdiacomp.2023.108433. Epub ahead of print. PMID: 36841085.
851. Karagiannidis AG, Theodorakopoulou MP, Ferro CJ, Ortiz A, Soler MJ, Halimi JM, Januszewicz A, Persu A, Kreutz R, Sarafidis P. Impact of public restrictive measures on hypertension during the COVID-19 pandemic: existing evidence and long-term implications. *Clin Kidney J.* 2022 Oct 28;16(4):619-634. doi: 10.1093/ckj/sfac235. PMID: 36998307; PMCID: PMC9620380.
852. Martinelli RP, Rayego-Mateos S, Alique M, Márquez-Expósito L, Tejedor-Santamaria L, Ortiz A, González-Parra E, Ruiz-Ortega M. Vitamin D, Cellular Senescence and Chronic Kidney Diseases: What Is Missing in the Equation? *Nutrients.* 2023 Mar 10;15(6):1349. doi: 10.3390/nu15061349. PMID: 36986078; PMCID: PMC10056834.
853. Trionfetti F, Marchant V, González-Mateo GT, Kawka E, Márquez-Expósito L, Ortiz A, López-Cabrera M, Ruiz-Ortega M, Strippoli R. Novel Aspects of the Immune Response Involved in the Peritoneal Damage in Chronic Kidney Disease Patients under Dialysis. *Int J Mol Sci.* 2023 Mar 17;24(6):5763. doi: 10.3390/ijms24065763. PMID: 36982834; PMCID: PMC10059714.
854. Sanz AB, Sanchez-Niño MD, Ramos AM, Ortiz A. Regulated cell death pathways in kidney disease. *Nat Rev Nephrol.* 2023 Mar 23:1–19. doi: 10.1038/s41581-023-00694-0. Epub ahead of print. PMID: 36959481; PMCID: PMC10035496.
855. Mora-Fernández C, Sánchez-Niño MD, Donate-Correa J, Martín-Núñez E, Pérez-Delgado N, Valiño-Rivas L, Fernández-Fernández B, Ortiz A, Navarro-González JF. Sodium-glucose co-transporter-2 inhibitors increase Klotho in patients with diabetic kidney disease: A clinical and experimental study. *Biomed Pharmacother.* 2022 Oct;154:113677. doi: 10.1016/j.biopha.2022.113677. Epub 2022 Sep 7. PMID: 36942605.
856. Rojas-Rivera JE, Ortiz A, Fervenza FC. Novel Treatments Paradigms: Membranous Nephropathy. *Kidney Int Rep.* 2023 Jan 2;8(3):419-431. doi: 10.1016/j.ekir.2022.12.011. PMID: 36938069; PMCID: PMC10014375.
857. Martinelli RP, Rayego-Mateos S, Alique M, Márquez-Expósito L, Tejedor-Santamaria L, Ortiz A, González-Parra E, Ruiz-Ortega M. Vitamin D, Cellular Senescence and Chronic Kidney Diseases: What Is Missing in the Equation? *Nutrients.* 2023 Mar 10;15(6):1349. doi: 10.3390/nu15061349. PMID: 36986078; PMCID: PMC10056834.
858. Karagiannidis AG, Theodorakopoulou MP, Ferro CJ, Ortiz A, Soler MJ, Halimi JM, Januszewicz A, Persu A, Kreutz R, Sarafidis P. Impact of public restrictive measures on hypertension during the COVID-19 pandemic: existing evidence and long-term implications. *Clin Kidney J.* 2022 Oct 28;16(4):619-634. doi: 10.1093/ckj/sfac235. PMID: 36998307; PMCID: PMC9620380.
859. Nangaku M, Kitching AR, Boor P, Fornoni A, Floege J, Coates PT, Himmelfarb J, Lennon R, Anders HJ, Humphreys BD, Caskey FJ, Fogo AB; TRANSFORM group. International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology. *Kidney Int.* 2023 Mar 28:S0085-2538(23)00174-6. doi: 10.1016/j.kint.2023.03.007. Epub ahead of print. PMID: 37001557.
860. Kanbay M, Copur S, Mizrak B, Ortiz A, Soler MJ. Intravenous fluid therapy in accordance with kidney injury risk: when to prescribe what volume of which solution. *Clin Kidney J.* 2022 Dec 16;16(4):684-692. doi: 10.1093/ckj/sfac270. PMID: 37007689; PMCID: PMC10061428.
861. Paats J, Adoberg A, Arund J, Dhondt A, Fernström A, Fridolin I, Glorieux G, Gonzalez-Parra E, Holmar J, Leis L, Luman M, Perez-Gomez VM, Pilt K, Sanchez- Ospina D, Segelmark M, Uhlin F, Ortiz A. Time-averaged concentration estimation of uraemic toxins with different removal kinetics: a novel approach based on intradialytic spent dialysate measurements. *Clin Kidney J.* 2022 Dec 20;16(4):735-744. doi: 10.1093/ckj/sfac273. PMID: 37007697; PMCID: PMC10061434.
862. Gonzalez-Perez M, Baranda J, Berges-Buxeda MJ, Conde P, Pérez-Olmeda M, Lozano-Ojalvo D, Cámara C, Del Rosario López-Carratalá M, Gonzalez-Parra E, Portolés P, Ortiz A, Portoles J, Ochando J. Maintenance of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients after 1273-mRNA SARS-CoV-2

- Vaccination. *Pharmaceuticals (Basel)*. 2023 Apr 11;16(4):574. doi: 10.3390/ph16040574. PMID: 37111331; PMCID: PMC10141011.
863. Carriazo S, Ortiz A, Fernandez-Fernandez B. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. *Ann Intern Med*. 2023 Apr;176(4):eL230005. doi: 10.7326/L23-0005. PMID: 37068289.
864. Sarafidis PA, Theodorakopoulou M, Ortiz A, Fernandez-Fernández B, Nistor I, Schmieder R, Arici M, Saratzis A, Van der Niepen P, Halimi JM, Kreutz R, Januszewicz A, Persu A, Cozzolino M. Atherosclerotic Renovascular Disease: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and the Working Group Hypertension and the Kidney of the European Society of Hypertension (ESH). *Nephrol Dial Transplant*. 2023 May 18:gfad095. doi: 10.1093/ndt/gfad095. Epub ahead of print. PMID:37202218.
865. Ortiz A, Alcázar Arroyo R, Casado Escribano PP, Fernández-Fernández B, Martínez Debén F, Mediavilla JD, Michan-Doña A, Soler MJ, Gorrioz JL. Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone. *Expert Rev Clin Pharmacol*. 2023 May 16. doi: 10.1080/17512433.2023.2213888. Epub ahead of print. PMID: 37190957.
866. Barbero NM, Oller J, Sanz AB, Ramos AM, Ortiz A, Ruiz-Ortega M, Rayego-Mateos S. Mitochondrial Dysfunction in the Cardio-Renal Axis. *Int J Mol Sci*. 2023 May 3;24(9):8209. doi: 10.3390/ijms24098209. PMID: 37175915; PMCID: PMC10179675.
867. Bosch C, Carriazo S, Soler MJ, Ortiz A, Fernandez-Fernandez B. Tirzepatide and prevention of chronic kidney disease. *Clin Kidney J*. 2022 Dec 23;16(5):797-808. doi: 10.1093/ckj/sfac274. PMID: 37151412; PMCID: PMC10157759.
868. Kanbay M, Copur S, Siriopol D, Yildiz AB, Berkkan M, Popa R, Hasbal NB, Ortiz A, Perazella MA. The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis. *Clin Kidney J*. 2022 Aug 31;16(5):817-826. doi: 10.1093/ckj/sfac194. PMID: 37151409; PMCID: PMC10157786.
869. Guerrero-Mauvecin J, Fontecha-Barriuso M, López-Díaz AM, Ortiz A, Sanz AB. RIPK3 and kidney disease. *Nefrologia (Engl Ed)*. 2023 May 5:S2013-2514(23)00075-5. doi: 10.1016/j.nefro.2023.04.006. Epub ahead of print. PMID: 37150671.
870. Quiroga B, Soler MJ, Ortiz A, de Sequera P; SENCOVAC collaborative network. Lessons from SENCOVAC: A prospective study evaluating the response to SARS-CoV-2 vaccination in the CKD spectrum. *Nefrologia (Engl Ed)*. 2023 May 5:S2013-2514(23)00074-3. doi: 10.1016/j.nefro.2023.04.005. Epub ahead of print. PMID: 37150670; PMCID: PMC10160849.
871. Ortiz A, Ars E, Bernis C, Fraga G, Furlano M, Martínez V, Martins J, Pérez-Gómez MV, Rodríguez-Pérez JC, Sans L, Torra R. Reply to Comments on the SENefro Consensus Document on Autosomal Dominant Polycystic Kidney Disease. *Nefrologia (Engl Ed)*. 2023 May 20:S2013-2514(23)00089-5. doi: 10.1016/j.nefro.2022.07.009. Epub ahead of print. PMID: 37217372.
872. Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators Alberto Ortiz). Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. *Lancet*. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. PMID: 37015244.
873. Mark PB, Sarafidis P, Ekart R, Ferro CJ, Balafa O, Fernandez-Fernandez B, Herrington WG, Rossignol P, Del Vecchio L, Valdivielso JM, Mallamaci F, Ortiz A, Nistor I, Cozzolino M; European Renal and Cardiovascular Medicine Working (EURECA-m) Group and European Renal Best Practice (ERBP) Guideline Group (ERBP) of the European Renal Association (ERA). SGLT2i for evidence based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA. *Nephrol Dial Transplant*. 2023 May 25:gfad112. doi: 10.1093/ndt/gfad112. Epub ahead of print. PMID: 37230946.
874. Wanner C, Ortiz A, Wilcox WR, Hopkin RJ, Johnson J, Ponce E, Ebels JT, Batista JL, Maski M, Politei JM, Martins AM, Banikazemi M, Linhart A, Mauer M, Oliveira JP, Weidemann F, Germain DP. Global reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community. *Mol Genet Metab*. 2023 Apr 29;139(3):107603. doi: 10.1016/j.jmgme.2023.107603. Epub ahead of print. PMID: 37236007.
875. Rayego-Mateos S, Basantes P, Morgado-Pascual JL, Brazal Prieto B, Suarez-Alvarez B, Ortiz A, Lopez-Larrea C, Ruiz-Ortega M. BET Protein Inhibitor JQ1 Modulates Mitochondrial Dysfunction and Oxidative Stress Induced by Chronic Kidney Disease. *Antioxidants (Basel)*. 2023 May 20;12(5):1130. doi: 10.3390/antiox12051130. PMID: 37237996; PMCID: PMC10215880.



876. Ortiz A. Natremia after fasting 12 h, kidney disease and aging. *EBioMedicine*. 2023 May 24;92:104637. doi: 10.1016/j.ebiom.2023.104637. Epub ahead of print. PMID: 37236057.
877. Wieringa F, Søndergaard H, Ortiz A. Coordinating efforts to optimize next-generation kidney replacement therapies: the European Kidney Health Alliance Work Group 'Breakthrough Innovation'. *Clin Kidney J*. 2023 Jan 27;16(6):885-890. doi: 10.1093/ckj/sfad016. PMID: 37260995; PMCID: PMC10229277.
878. Martínez V, Furlano M, Sans L, Pulido L, García R, Pérez-Gómez MV, Sánchez-Rodríguez J, Blasco M, Castro-Alonso C, Fernández-Fresnedo G, Robles NR, Valenzuela MP, Naranjo J, Martín N, Pilco M, Agraz-Pamplona I, González-Rodríguez JD, Panizo N, Fraga G, Fernández L, López MT, Dall'Anese C, Ortiz A, Torra R; participants in the REPQRAD. Autosomal dominant polycystic kidney disease in young adults. *Clin Kidney J*. 2022 Nov 29;16(6):985-995. doi:10.1093/ckj/sfac251. PMID: 37260991; PMCID: PMC10229292.
879. Vanholder R, Coppo R, Bos WJW, Damato E, Fakhouri F, Humphreys A, Nistor I, Ortiz A, Pistollato M, Scheres E, Schaefer F. A Policy Call to Address Rare Kidney Disease in Health Care Plans. *Clin J Am Soc Nephrol*. 2023 Jun 9. doi: 10.2215/CJN.000000000000220. Epub ahead of print. PMID: 37294578.
880. Peters B, Beige J, Siwy J, Rudnicki M, Wendt R, Ortiz A, Sanz AB, Mischak H, Reich HN, Nasic S, Mahmood D, Persson A, Fernström A, Weiner M, Stegmayr B; PersTIGAN working group. Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy. *Nephrol Dial Transplant*. 2023 Jun 22:gfad125. doi: 10.1093/ndt/gfad125. Epub ahead of print. PMID: 37349951.
881. Martín-Carro B, Navarro-González JF, Ortiz A, Zoccali C, Floege J, Ferreira MA, Gorriz-Teruel JL, Carrillo-López N, Panizo S, Locatelli F, Ketteler M, London GM, Naves-Díaz M, Alonso-Montes C, Cannata-Andia JB, Fernández-Martín JL. Mineral and Bone Metabolism Markers and Mortality in Diabetic Patients on Haemodialysis. *Nephrol Dial Transplant*. 2023 Jun 22:gfad122. doi: 10.1093/ndt/gfad122. Epub ahead of print. PMID: 37349949.
882. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet*. 2023 Jun 22:S0140-6736(23)01301-6. doi: 10.1016/S0140-6736(23)01301-6. Epub ahead of print. PMID: 37356446.
883. Ortiz A, Quiroga B, Díez J, Escalada San Martín FJ, Ramirez L, Pérez Maraver M, Martínez-Berganza Asensio ML, Arranz Arija JÁ, Alvarez-Ossorio Fernández JL, Córdoba R, Brotons Muntó F, Cancelo Hidalgo MJ, Carles Reverter J, Plasencia-Rodríguez C, Carretera Gómez J, Guijarro C, Freijo Guerrero MDM, de Sequera P. The Spanish Scientific Societies before the ESC 2021 guidelines on vascular disease prevention: Generalizing the measurement of albuminuria to identify vascular risk and prevent vascular disease. *Nefrologia (Engl Ed)*. 2023 Jul 3:S2013-2514(23)00104-9. doi: 10.1016/j.nefro.2023.06.005. Epub ahead of print. PMID: 37407308.
884. Quiroga B, Ortiz A, Díez J. Selective glomerular hypofiltration syndrome. *Nephrol Dial Transplant*. 2023 Jul 5:gfad145. doi: 10.1093/ndt/gfad145. Epub ahead of print. PMID: 37407284.
885. Pépin M, Klimkowicz-Mrowiec A, Godefroy O, Delgado P, Carriazo S, Ferreira AC, Golenia A, Malyszko J, Grodzicki T, Giannakou K, Paolisso G, Barbieri M, Garneata L, Mocanu CA, Liabeuf S, Spasovski G, Zoccali C, Bruchfeld A, Farinha A, Arici M, Capasso G, Wiecek A, Massy ZA; CONNECT (Cognitive Decline in Nephro-Neurology: European Cooperative Target) Action (A Ortiz). Cognitive disorders in patients with chronic kidney disease: Approaches to prevention and treatment. *Eur J Neurol*. 2023 Jun 16. doi: 10.1111/ene.15928. Epub ahead of print. PMID: 37326125.
886. Eckardt KU, Delgado C, Heerspink HJL, Pecoits-Filho R, Ricardo AC, Stengel B, Tonelli M, Cheung M, Jadoul M, Winkelmayer WC, Kramer H; Conference Participants (Alberto Ortiz). Trends and perspectives for improving quality of chronic kidney disease care: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int*. 2023 May 26:S0085-2538(23)00388-5. doi: 10.1016/j.kint.2023.05.013. Epub ahead of print. PMID: 37245565.
887. Rojas-Rivera JE, Bakkaloglu SA, Bolognani D, Nistor I, Sarafidis PA, Stoumpos S, Cozzolino MG, Ortiz A; ERA ERBP. Chronic kidney disease: the missing concept in the 2019 EULAR/ERA-EDTA recommendations for lupus nephritis. *Nephrol Dial Transplant*. 2023 Jul 11:gfad154. doi: 10.1093/ndt/gfad154. Epub ahead of print. PMID: 37433583.
888. Vazquez-Sanchez T, Sanchez-Niño MD, Ruiz-Esteban P, López V, León M, Caballero A, Ruiz-Escalera JF, Ortiz A, Torres A, Rodríguez M, Hernandez D. Time-Dependent Changes of Klotho and FGF-23 Levels after Kidney Transplantation: Role of Cold Ischemia Time, Renal Function and Graft Inflammation. *J Clin Med*. 2023 Jul 4;12(13):4486. doi: 10.3390/jcm12134486. PMID: 37445521.
889. Rayego-Mateos S, Marquez-Exposito L, Basantes P, Tejedor-Santamaria L, Sanz AB, Nguyen TQ, Goldschmeding R, Ortiz A, Ruiz-Ortega M. CCN2 Activates RIPK3, NLRP3 Inflammasome, and NRF2/Oxidative Pathways Linked to Kidney Inflammation. *Antioxidants (Basel)*. 2023 Jul 31;12(8):1541. doi: 10.3390/antiox12081541. PMID: 37627536; PMCID: PMC10451214.
890. Fernández-Fernandez B, Sarafidis P, Soler MJ, Ortiz A. EMPA-KIDNEY: expanding the range of kidney protection

- by SGLT2 inhibitors. *Clin Kidney J.* 2023 Jun 16;16(8):1187-1198. doi: 10.1093/ckj/sfad082. PMID: 37529652; PMCID: PMC10387399.
891. Astley ME, Boenink R, Abd ElHafeez S, Trujillo-Alemán S, Arribas F, Åsberg A, Beckerman P, Bell S, Bouzas-Caamaño ME, Farnés JC, Galvão AA, Gjorgjievski N, Kelmendi VG, Guidotti R, Helve J, Idrizi A, Indriðason ÓS, Ioannou K, Kerschbaum J, Komissarov K, Castro de la Nuez P, Lassalle M, Nordio M, Arévalo OLR, Santiuste C, Seyahi N, Roblero MFS, Steenkamp R, Ten Dam MAGJ, Zakharova EV, Ziginiskiene E, Bonthuis M, Stel VS, Ortiz A, Jager KJ, Kramer A. The ERA Registry Annual Report 2020: a summary. *Clin Kidney J.* 2023 Apr 21;16(8):1330-1354. doi: 10.1093/ckj/sfad087. PMID: 37529647; PMCID: PMC10387405.
892. Ortiz A, Portoles J, Pino-Pino MD, Barea J, López M, de Sequera P, Quiroga B, Echarri R, Prieto Velasco M, Díaz R, Gómez Marqués G, Sanchez Perez P, Torregrosa V, Rodriguez M; SAVANA Research Group.; SENEPRO-BD-SHPT working group. Clinical Characteristics and Management of Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: A Feasibility Analysis of Electronic Health Records Using Natural Language Processing. *Kidney Dis (Basel).* 2023 Jan 23;9(3):187-196. doi: 10.1159/000528784. PMID: 37497203; PMCID: PMC10368074.
893. Martin-Cleary C, Sanz AB, Avello A, Sanchez-Niño MD, Ortiz A. NephroCheck at 10: addressing unmet needs in AKI diagnosis and risk stratification. *Clin Kidney J.* 2023 Jun 22;16(9):1359-1366. doi: 10.1093/ckj/sfad146. PMID: 37664563; PMCID: PMC10468756.
894. García-Giménez J, Córdoba-David G, Rayego-Mateos S, Cannata-Ortiz P, Carrasco S, Ruiz-Ortega M, Fernandez-Fernandez B, Ortiz A, Ramos AM. STING1 deficiency ameliorates immune-mediated crescentic glomerulonephritis in mice. *J Pathol.* 2023 Aug 31. doi: 10.1002/path.6177. Epub ahead of print. PMID: 37650295.
895. Barrera-Baena P, Rodríguez-García M, Rodríguez-Rubio E, González-Llorente L, Ortiz A, Zoccali C, Locatelli F, Floege J, Cohen-Solal M, Ferreira MA, Ketteler M, London GM, Gorriz-Teruel JL, Sánchez-Álvarez E, Hevia-Suárez MÁ, Fernández-Gómez JM, Martín-Carro B, Gómez-Alonso C, Alonso-Montes C, Cannata-Andia JB, Fernández-Martín JL; of COSMOS. Serum phosphate is associated with increased risk of bone fragility fractures in hemodialysis patients. *Nephrol Dial Transplant.* 2023 Sep 2:gfad190. doi: 10.1093/ndt/gfad190. Epub ahead of print. PMID: 37660283.
896. Boenink R, Kramer A, Masoud S, Rodríguez-Benot A, Helve J, Bistrup C, Segelmark MM, Rodríguez Arévalo OL, Kerschbaum J, de Vries APJ, Lundgren T, Bell S, Crespo M, Sørensen SS, Ferraro PM, Arnol M, Bakkaloglu SA, Weekers L, Reisæter AV, Rebić D, Ortiz A, Jager KJ, Stel VS. International comparison and time trends of first kidney transplant recipient characteristics across Europe: an ERA Registry study. *Nephrol Dial Transplant.* 2023 Aug 31:gfad189. doi: 10.1093/ndt/gfad189. Epub ahead of print. PMID: 37653455.
897. Abasheva D, Fernandez-Fernandez B, Ortiz A. Zilebesiran for Hypertension. *N Engl J Med.* 2023 Oct 12;389(15):1438. doi: 10.1056/NEJMc2310167. PMID: 37819962.
898. Górriz JL, González-Juanatey JR, Facila L, Soler MJ, Valle A, Ortiz A. Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease. *Nefrologia (Engl Ed).* 2023 Oct 7:S2013-2514(23)00146-3. doi: 10.1016/j.nefro.2023.09.002. Epub ahead of print. PMID: 37813743.
899. Ortiz A. CKD as a risk factor for severe COVID-19: a critical look back and lessons for the future. *Nephrol Dial Transplant.* 2023 Oct 3:gfad216. doi: 10.1093/ndt/gfad216. Epub ahead of print. PMID: 37791399.
900. Jaimes Campos MA, Andújar I, Keller F, Mayer G, Rossing P, Staessen JA, Delles C, Beige J, Glorieux G, Clark AL, Mullen W, Schanstra JP, Vlahou A, Rossing K, Peter K, Ortiz A, Campbell A, Persson F, Latosinska A, Mischak H, Siwy J, Jankowski J. Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept Study. *Pharmaceuticals (Basel).* 2023 Sep 14;16(9):1298. doi: 10.3390/ph16091298. PMID: 37765106; PMCID: PMC10537115.
901. Kanbay M, Copur S, Yilmaz ZY, Tanriover C, Hasbal NB, Ortiz A, Perazella MA. A novel risk factor for malignancy: Albuminuria. *Eur J Intern Med.* 2023 Sep 22:S0953-6205(23)00330-8. doi: 10.1016/j.ejim.2023.09.010. Epub ahead of print. PMID: 37741791.
902. Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators (Ortiz A). Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. *N Engl J Med.* 2023 Nov 3. doi: 10.1056/NEJMoa2308550. Epub ahead of print. PMID: 37921461.
903. Sarafidis P, Iatridi F, Ferro C, Alexandrou ME, Fernandez-Fernandez B, Kanbay M, Mallamaci F, Nistor I, Rossignol P, Wanner C, Cozzolino M, Ortiz A. Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA). *Clin Kidney J.* 2023 Jun 24;16(11):1885-1907. doi: 10.1093/ckj/sfad139. PMID: 37915899; PMCID: PMC10616462.

904. Rovin BH, Barratt J, Heerspink HJL, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial [published online ahead of print, 2023 Nov 2](Arduan-AO). *Lancet*. 2023;S0140-6736(23)02302-4. doi:10.1016/S0140-6736(23)02302-4
905. Hafez G, Malyszko J, Golenia A, Klimkowicz-Mrowiec A, Ferreira AC, Arıcı M, Bruchfeld A, Nitsch D, Massy ZA, Pépin M, Capasso G, Mani LY, Liabeuf S; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target, Ortiz A). Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients. *Clin Kidney J*. 2023 Sep 18;16(12):2378-2392. doi: 10.1093/ckj/sfad239. PMID: 38046029; PMCID: PMC10689198.
906. Carriazo S, Ribagorda M, Pintor-Chocano A, Perez-Gomez MV, Ortiz A, Sanchez-Niño MD. Increased expression of SCARF genes favoring SARS-CoV-2 infection in key target organs in CKD. *Clin Kidney J*. 2023 Sep 5;16(12):2672-2682. doi: 10.1093/ckj/sfad220. PMID: 38046008; PMCID: PMC10689187.
907. Carriazo S, Abasheva D, Duarte D, Ortiz A, Sanchez-Niño MD. SCARF Genes in COVID-19 and Kidney Disease: A Path to Comorbidity-Specific Therapies. *Int J Mol Sci*. 2023 Nov 8;24(22):16078. doi: 10.3390/ijms242216078. PMID: 38003268; PMCID: PMC10671056.
908. Liabeuf S, Pešić V, Spasovski G, Maciulaitis R, Bobot M, Farinha A, Wagner CA, Unwin RJ, Capasso G, Bumbleyte IA, Hafez G; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target, Ortiz A). Drugs with a negative impact on cognitive function (Part 1): chronic kidney disease as a risk factor. *Clin Kidney J*. 2023 Sep 18;16(12):2365-2377. doi: 10.1093/ckj/sfad241. PMID: 38045996; PMCID: PMC10689135.
909. Sanchez-Niño MD, Ceballos MI, Carriazo S, Pintor-Chocano A, Sanz AB, Saleem MA, Ortiz A. Interaction of Fabry Disease and Diabetes Mellitus: Suboptimal Recruitment of Kidney Protective Factors. *Int J Mol Sci*. 2023 Nov 1;24(21):15853. doi: 10.3390/ijms242115853. PMID: 37958836; PMCID: PMC10650640.
910. Mensah GA, Fuster V, Murray CJL, Roth GA; Global Burden of Cardiovascular Diseases and Risks Collaborators. Global Burden of Cardiovascular Diseases and Risks, 1990-2022. *J Am Coll Cardiol*. 2023 Dec 19;82(25):2350-2473. doi: 10.1016/j.jacc.2023.11.007. PMID: 38092509.
911. Guerrero-Mauvecin J, Villar-Gómez N, Rayego-Mateos S, Ramos AM, Ruiz-Ortega M, Ortiz A, Sanz AB. Regulated necrosis role in inflammation and repair in acute kidney injury. *Front Immunol*. 2023 Nov 24;14:1324996. doi: 10.3389/fimmu.2023.1324996. PMID: 38077379; PMCID: PMC10704359.
912. Hafez G, Malyszko J, Golenia A, Klimkowicz-Mrowiec A, Ferreira AC, Arıcı M, Bruchfeld A, Nitsch D, Massy ZA, Pépin M, Capasso G, Mani LY, Liabeuf S; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target, Ortiz A). Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients. *Clin Kidney J*. 2023 Sep 18;16(12):2378-2392. doi: 10.1093/ckj/sfad239. PMID: 38046029; PMCID: PMC10689198.
913. Mensah GA, Fuster V, Murray CJL, Roth GA; Global Burden of Cardiovascular Diseases and Risks Collaborators. Global Burden of Cardiovascular Diseases and Risks, 1990-2022. *J Am Coll Cardiol*. 2023;82(25):2350-2473. doi:10.1016/j.jacc.2023.11.007
914. Marchant V, Trionfetti F, Tejedor-Santamaria L, Rayego-Mateos S, Rotili D, Bontempi G, Domenici A, Menè P, Mai A, Martín-Cleary C, Ortiz A, Ramos AM, Strippoli R, Ruiz-Ortega M. BET Protein Inhibitor JQ1 Ameliorates Experimental Peritoneal Damage by Inhibition of Inflammation and Oxidative Stress. *Antioxidants (Basel)*. 2023 Nov 29;12(12):2055. doi: 10.3390/antiox12122055. PMID: 38136175; PMCID: PMC10740563.
915. Valdivielso JM, Carriazo S, Martín M, Fernandez-Fernandez B, Bermudez-López M, Ortiz A; NEFRONA investigators. Gender-specific risk factors and outcomes of hyperkalemia in CKD patients: smoking as a driver of hyperkalemia in men. *Clin Kidney J*. 2023 Oct 9;17(1):sfad212. doi: 10.1093/ckj/sfad212. PMID: 38186899; PMCID: PMC10768768.
916. Ortiz A. Should we enlarge the indication for kidney biopsy in diabetics? The con part. *Clin Kidney J*. 2023 Oct 26;17(1):sfad267. doi: 10.1093/ckj/sfad267. PMID: 38186897; PMCID: PMC10768755.
917. Cambray S, Bermúdez-López M, Garcia-Carrasco A, Valdivielso JM; NEFRONA investigators. Matrix Gla protein polymorphism rs1800802 is associated with atheroma plaque progression and with cardiovascular events in a chronic kidney disease cohort. *Clin Kidney J*. 2023 Oct 10;17(1):sfad257. doi: 10.1093/ckj/sfad257. PMID: 38186884; PMCID: PMC10768782.
918. Ortiz A, Galán CDA, Carlos Fernández-García J, Cerezo JG, Ochoa RI, Núñez J, Gutiérrez FP, Navarro-González JF. Consensus document on the management of hyperkalemia. *Nefrologia (Engl Ed)*. 2024 Jan 1:S2013-2514(23)00178-5. doi: 10.1016/j.nefro.2023.12.002. Epub ahead of print. PMID: 38169239.
919. Karagiannidis AG, Theodorakopoulou MP, Pella E, Sarafidis PA, Ortiz A. Uromodulin biology. *Nephrol Dial Transplant*. 2024 Jan 11:gfae008. doi: 10.1093/ndt/gfae008. Epub ahead of print. PMID: 38211973.
920. Ortiz A, Del Arco Galán C, Fernández-García JC, Gómez Cerezo J, Ibán Ochoa R, Núñez J, Pita Gutiérrez F, Navarro-González JF. Reply to "Letter to the Editor -Consensus document on the management of hyperkalaemia".

Nefrologia (Engl Ed). 2024 Jan 10:S2013-2514(24)00012-9. doi: 10.1016/j.nefro.2023.09.006. Epub ahead of print. PMID: 38212173.

921. de la Espriella R, Ortiz A, Núñez J. The blood urea nitrogen to creatinine ratio in chronic heart failure: 'When the past is prologue'. Eur J Heart Fail. 2024 Jan 18. doi: 10.1002/ejhf.3146. Epub ahead of print. PMID: 38239035.